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ABSTRACT 
Introduction 
Opioid dependence is a significant health concern in New Zealand. It has 
been estimated that there are 10,000 people who are daily or almost daily 
intravenous users of opioid drugs, half of whom are receiving opioid 
substitution treatment (OST) Similar to overseas countries. It is also 
estimated that there is a growing number of people in New Zealand who are 
dependent on prescribed opioids. However how many is currently unknown 
(Adamson et al., 2012). One alternative intervention for opioid dependence 
is ibogaine treatment. Ibogaine is a hallucinogenic drug that alleviates 
opioid withdrawal symptoms for up to three months. (Alper, Lotsof, 
Frenken, Luciano, & Bastiaans, 1999). However, ibogaine's metabolites 
interfere with cardiac centres in the brain, in some cases causing heart 
arrhythmia and death (Maas & Strubelt, 2006). Ibogaine providers promote 
pre-treatment tests (bloods and electrocardiogram (ECG)) reducing this risk 
(Alper, Lotsof, & Kaplan, 2008). Anecdotal reports suggest ibogaine 
treatments can occur with support from ibogaine treatment providers, 
ranging to; ‘peer to peer’ use with unknown medical advice. The aim of this 
study was to explore the experiences of people who had used ibogaine in 
New Zealand; and to discover what, or if, any medical tests had been sought 
and/or accessed. 
Method 
A qualitative, collective case-study research design was used. Ten people 
who used ibogaine for their opioid detoxification were recruited. Face-to-
face interviews were conducted with each of the participants, in 
participants' homes or public cafes. The interviews were recorded and 
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transcribed. Common experiences were coded then grouped into themes and 
analysed. 
Findings 
Seven identified themes and their described interactions collectively related 
an ibogaine user’s experience. It began with 'not sitting comfortably on 
opioids', due to associated low moods, physical side effects, stigma and 
despair. Hope of a successful and quick opioid detoxification treatment, 
with no opioid withdrawal experience was the main motivator for people 
choosing ibogaine. All participants sought medical testing before ibogaine 
treatment but those who had the support of an ibogaine treatment provider 
(ITP) received the most appropriate medical screening and recommended 
test. People had more positive treatment experiences when medical supports 
such as nausea control, sleep management, use of ibogaine booster doses 
and psychological support after treatment were available. Ibogaine 
treatment had major positive effects on mood and anxiety reduction for the 
participants, and was the main contributing factor for seven respondents 
who remained opioid-abstinent. Respondents described seeking and 
obtaining a spiritual or deep psychological change regarding their drug use 
and attributed this to ibogaine treatment. 
Conclusions 
The collective experience of the ten participants provided implications for 
possible future practise of ibogaine treatment. Use of an ibogaine treatment 
provider (ITP) afforded safer, more positive treatment outcomes. The 
continued legality of ibogaine is supported by this study, where 
respondents, supported by an ITP, had better access and greater medical 
support when ibogaine was legal. The use of additional doses of ibogaine 
and medical management of nausea and sleep appeared to affect better 
treatment results. This case study participants sought the hallucinogenic 
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effect of ibogaine as part of the treatment and had better treatment results 
when psychedelic experiences were achieved. Best treatment results were 
described as, no opioid withdrawals, positive effects on mood and anxiety 
and ultimately, opioid abstinence.  
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GLOSSARY AND 
TERMINOLOGY 
Ibogaine: An hallucinogenic drug with anti-addictive properties (refer 
chapter two – Literature review for fuller literature) 
Ibogaine treatment providers (ITP): This term is used broadly and risks 
losing true meaning to what may be reported. The term is used to label new 
establishing services or even single person advocate ‘services’, to more 
organised medically orientated ‘clinics’ that treat opioid dependence with 
ibogaine. For the purpose of consistency for this study a single term must be 
used, however when an ibogaine treatment provider has limited capabilities, 
this may be described as an ibogaine support service or other such more 
descriptive terms. 
Opioid / Opiate: These terms describe, in order, the synthetically made and 
naturally occurring, narcotic drug; Opioids’ (Martin, 1983). This term may 
be used interchangeably however by respondents to refer to a range of both 
synthetic and natural forms of this drug. 
Opioid dependence: This is defined as per the Diagnostic Statistic Manuel 
for Psychiatric disorders (DSM-5) (American Psychiatric Association, 
2013) as amongst other features, people having physical tolerance and 
withdrawal features to opioid use or their absence. For the purpose of this 
study this term is interchanged with New Zealand literature defining opioid 
dependence as using daily or almost daily (Deering, Sellman, & Adamson, 
2014). 
People with opioid dependence: This term is used to define people with an 
opioid dependence. However the literature and interview data interchange 
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this term with opioid dependent population and opioid dependent 
individuals, groups and populations. 
OST: Opioid Substitution Treatment (OST) is the term used to define New 
Zealand AOD treatment services which use substitution opioids for long 
term replacement of illicit opioids (New Zealand National Guidelines for 
OST, 2014). Although this incorporates multiple substitution opioids such 
as buprenorphine, this term mostly describes the drug methadone and in a 
New Zealand context often refers to methadone maintenance treatments 
(MMT) and may be referenced by respondents as; methadone 
Service user: Is the definition used for people utilising the OST services. 
Throughout this study, in the literature and in the participants interviews 
this definition may be interchanged with ‘client’ or ‘patient’.  
Detoxification: The process of withdrawing off drugs that a person is 
physically dependent on. For this case study it and its abbreviation; ‘detox’ 
is often used to describe opioid detoxification 
VTA: Ventral Tegmental Area (VTA) area of the brain – refer chapter two. 
GDNF: Glial cell derived neurotrophic factor (GDNF) – refer chapter two. 
Respondents / Participants: These terms are used interchangeably 
throughout this study due to basic grammar and sentence structure. The 
terms describe the people who responded and participated for the recorded 
interviews of this study. 
General Practitioners (GPs): The New Zealand term used for medical 
doctor who treats primary care in the community 
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CHAPTER ONE: 
INTRODUCTION 
Overview of chapter 
Chapter one will introduce the background to this thesis. It starts with 
opioid dependence being a health concern for New Zealand and the 
standard treatments that are currently available for this vulnerable 
population. As one of many alternative treatments for opioid dependence, 
ibogaine will briefly be described and its context, internationally and within 
New Zealand, outlined. Ibogaine's anti-addictive properties and associated 
cardiac risks are briefly explained and the professional background of the 
researcher is declared. 
Clinical decisions in standard treatment services have caused people 
seeking alternative treatments to not receive needed medical input and 
psycho-social support. This problem will be outlined as a direct experience 
of the researcher. The research question will be introduced and explained 
along with the outline of how this thesis will be presented. 
Background 
Opioid dependence in New Zealand 
Opioid dependence is a significant health concern in New Zealand with an 
estimated 10,000 opioid dependent people in New Zealand, with half this 
number involved in OST (Adamson et al., 2012). People with opioid 
dependence are described as using daily or almost daily and are a 
‘vulnerable and hard-to-reach group’. It can be difficult to research this 
group due to the illegal nature of the substance use (Adamson et al., 2012; 
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Kemp & Aitken, 2004; Stimmel, 2005). In New Zealand people with opioid 
dependence have a high rate of intravenous drug use, along with the 
additional health risks associated with this using needles. Opioid 
dependency is associated with high crime rates, poor health and increased 
‘at risk behaviours’ (Degenhardt & Hall, 2012; Judson et al., 2010). In 
addition to the estimated number of people dependent on opioids, there is a 
largely unknown number of people in New Zealand society that 
problematically use opioid-based, prescription medications (McMinn, 
2012). There are other ‘secretive by nature’ groups which appear to use 
seasonal, opportunistic opioids such as opium plant users and poppy seed 
tea drinkers (Braye, Harwood, Inder, & Beasley, 2007). It appeared most of 
the research regarding treatment of opioid dependence was focused on those 
using illicit opioids, and mostly on injecting populations. Prior to the 1970s 
in USA and New Zealand, this group had poor treatment outcomes in terms 
of drug abstinence using traditional methods such as detoxification and 
abstinence-orientated, short-term rehabilitation programmes (Deering, 
Sellman & Adamson, 2014). OST revolutionised the ability to effectively 
treat this relapse-prone population and methadone substitution soon became 
the ‘gold standard’, with high treatment retention rates, and with most 
having improved health scores and committing less crime (Deering et al., 
2011; Degenhardt & Hall, 2012). 
Alternative treatments 
Alternative treatments now include alternative opioids for substitution such 
as buprenorphine, available in New Zealand since 2012, which for many 
offers a different experience or effect to methadone, described as less 
sedating (Bickel & Amass, 1995). Internationally other opioids have been 
trialled with similar success to the more commonly known methadone. 
These included levomethadyl acetate hydrochloride (LAAM), now no 
longer medically supported; slow release oral morphine (SROM); and even 
dia-morphine (heroin) (Drucker, 2001; Ferri, Minozzi, Bo, & Amato, 2013; 
Finn & Wilcock, 1997). Interestingly ‘heroin substitution’ services increase 
retention rates in services in countries that trial them. Away from OSTs 
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there have been other pharmacological approaches to managing opioid 
dependency. These included the antagonist (blocking neuro-receptors) 
action of naltrexone, both as oral medicine or implants under the skin, 
causing there to be no desired effect from opioid use (Carreno et al., 2003). 
Other pharmacological approaches, too numerous for the purposes of this 
background, do include interesting and possibly effective plant compounds 
trialled in Iran (Ebrahimie, Bahmani, Shirzad, Rafieian-Kopaei, & Saki, 
2015). One of many alternative pharmacotherapies is ibogaine. It entered 
the opioid scene in the 1970s as an under-ground, sub-medical, peer-led 
treatment, and even ‘cure’ for opioid dependence (Alper, 2001). 
Ibogaine 
Ibogaine is a partial hallucinogenic alkaloid drug (Strassman, 1995) 
extracted from the bark of the Tabernanthe iboga tree, originating in West 
Africa. As well as being historically used in ancient African tribal 
ceremonies, it was discovered and marketed by the French in the 1920s as a 
relief tonic to be ingested after suffering a viral illness. In the 1970s it was 
discovered by chance, and later proved through research, that its ingestion 
and psychedelic experience assisted in the withdrawal and subsequent 
cravings associated with illicit heroin (diamorphine) use (Alper, 2001). Its 
benefits to opioid and alcohol detoxification, and abstinence rates after 
ingestion, are referenced in over 80 uncontrolled and open label studies but 
are best summarised by Alper (2001) in chapter one of his alkaloids book: 
Ibogaine: A Review.  It appeared a one-off use of ibogaine interrupted the 
neurological and physical withdrawal symptoms of opioids. Rodent studies 
determine some of the anti-addictive properties relate to Glial cell-derived 
neurotrophic factor (GDNF) expression in the Ventral Tegmental Area 
(VTA) area of rats brain and has a mediating effect on dopamine expression 
in reward pathway circuitry (Mash, et al., 2003: Glick, Maisonneurve, 
Hough, Kuehne & Bandarage, 1999). The exact pharmacodynamics in 
humans remains unclear (Mash et al 2003). However Radioligand binding 
assays report ibogaine has numerous molecular interactions with mu and 
kappa opioid receptors, serotonin 5-HT2 and 5-HT3 and M1 and M2 
~ 4 ~ 
muscarinic receptors (Mash et al 2003). From anecdotal reports and 
uncontrolled studies, its use is attributed to absence or reduction in opioid-
related cravings and elimination or reduction of withdrawal symptoms for 
dependent persons. This effect, following cessation of opioid use, is 
reported to last from 48 hours to three months. The effects of ibogaine use 
for the majority of people included an initial six-eight hours of nausea and 
vomiting, then two-three days of a dream-like hallucinogenic state, often 
experienced whilst asleep, followed by one-three months of markedly 
reduced cravings to use opioid drugs. 
In New Zealand ibogaine has been legal to prescribe by medical 
practitioners since 2010 largely due to application to the Medicines 
Authority by ibogaine support networks (Patterson, 2015). As reported 
above, internationally, treatment with ibogaine began in the 1970s, mainly 
in people's homes and peer-to-peer administered. It appeared through 
overseas literature (Alper, Lotsof, & Kaplan, 2008) and through clinical 
conversations within New Zealand that this form of underground ibogaine 
treatment is continuing, without the use of pre-treatment, medical health 
tests. This is significant as there are medical reports of 15 fatalities, 
excluding one in New Zealand in 2013, associated with ibogaine use prior 
to death. These deaths appear related to cardiac arrhythmias, possibly 
related to interruption in magnesium channels in cardiac centres in the 
brain, caused by ibogaine and ibogaine’s metabolites (Maas & Strubelt, 
2006). This same group of ibogaine cases was investigated by Alper, Stajić, 
& Gill (2012) who attributed other determinates to the fatalities such as pre-
existing lung, kidney and liver disease and co-morbid drug use. Which may 
have been indicated had pre-treatment assessments been carried out. 
However pharmacological research and Emergency department case studies 
still indicate cardiac arrhythmias can occur with ibogaine use without other 
QTc prolongation causing drugs or conditions being present (Alper et al., 
2012; Schenberg, de Castro Comis, Chaves & da Silveira 2014). 
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Research problem 
Upon exploring this topic there emerged considerable variation in the nature 
of treatment provided amongst different ibogaine treatment providers 
available to New Zealanders, including providers overseas. Some treatment 
settings provided medical assessment and testing and psychological support 
throughout treatment, while other providers appeared to focus on the 
spiritual and emotional effects of the treatment, perhaps unaware of the 
medical risks. 
The research began with a clinical issue at an OST service in the South 
Island, New Zealand. Two clients prescribed methadone, chose to utilise 
ibogaine detoxification. One did not disclose this until after ibogaine 
treatment and had a negative experience with it. The other approached the 
OST service for support (travel arrangements mostly) and was declined. 
This service user utilised ibogaine regardless, reported a positive experience 
but was discharged from the OST service for not collecting prescribed 
methadone doses. This resulted in the loss of support of that person's 
established case manager. The service decision not to support this client 
was based on emergency department case study reports of death attributed 
to the use of ibogaine. There appeared to be mixed messages in the 
available literature, especially for consumers, with some medical trials 
supporting the effectiveness of ibogaine treatment where risks are 
minimised, and some medical articles stating there are major cardiac safety 
concerns and that ibogaine treatment should not be supported.  While 
ibogaine was available as a treatment option in New Zealand, the journey of 
an ibogaine user, what they encountered and perceived as facilitators and 
barriers to safe treatment, were not currently known. 
Aim/Research objectives 
The purpose of this study was to explore the experiences and practises of 
opioid-dependent individuals who have used ibogaine as an intervention for 
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opioid dependence. This included exploring each individual’s motivations 
for the treatment, their understanding of health risks, utilisation of pre-
treatment health tests and the effects of ibogaine treatment in relation to any 
subsequent opioid use. 
Research question 
The question, not answered in current literature, and relevant for New 
Zealand prescribers: 
‘What are the experiences and motivations of opioid-dependent people 
using ibogaine?’ With the sub question: ‘What safety measures and medical 
tests were ibogaine users aware of and utilised?’ 
Description of researcher 
The researcher of this paper is a registered nurse with mental health and 
addictions experience and qualifications. Working as an opioid substitution 
treatment case manager in England (London) and New Zealand 
(Christchurch) afforded many opportunities to work with people during 
their journey of opioid recovery. A psychiatric nurse initially, there has 
always been an interest in people’s mental health experience and wellbeing. 
The clinical gaze of the researcher for this study is therefore tinted with a 
mental health, bio-medical and nursing perspective. 
Thesis outline 
Chapter two comprises the literature review on five major relevant topics 
related to this study. These are: opioid dependence in New Zealand is a 
significant health problem; ibogaine has anti-addictive qualities; ibogaine 
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has cardiac concerns; medical-supported ibogaine clinics are safest; and 
lastly, people are motivated to use hallucinogenic treatments. 
Chapter three argues the case for the chosen methodology. The case study 
method sits under the umbrella of qualitative research. The philosophies and 
paradigms driving this qualitative study are selected and described. An 
argument for a naturalistic and interpretive approach is submitted, why it 
was the best fit for the type of data obtained and the conclusions that were 
derived. The method and data analysis is also outlined and the ethical 
considerations examined. 
Chapter four is the results chapter. Here the 38 codes found throughout the 
ten interviews are categorised into seven broader themes, the table for 
which is at the end of chapter four, ‘results’. The themes are: ‘not sitting 
comfortably on opioids’; ‘motivations for using ibogaine’; ‘safety conscious 
and support-seeking’; ‘the best practise’; ‘ibogaine treatment effects on 
depression and anxiety’; ‘ibogaine treatment effects on dependence’; and 
‘the spiritual effect’. 
Chapter five is the discussion. The seven themes are again outlined and 
discussed. Six of the major themes were placed into related pairs. These 
pairs were examined as to how they effected and interplayed between each 
other. The overall relationship between the themes described the experience 
of an ibogaine user in New Zealand. The strengths and limitations of the 
study are also addressed in this chapter. 
Chapter six, the conclusion. This thesis, its background, its reason, its 
participants and their contribution will be summarised. The journey and 
experience of an ibogaine user will be outlined, including what factors 
afford safest, best practise. This final chapter considers the research overall 
and raises implications for future ibogaine treatment practice and areas for 
further research.   
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Conclusion 
The origins of this research began with the fact that opioid dependence and 
misuse are health concerns for New Zealand. The legally-prescribed drug 
ibogaine has been demonstrated to alleviate opioid withdrawal symptoms 
for up to three months, and may be a successful treatment for detoxification. 
However, ibogaines metabolites have been shown to interfere with cardiac 
centres in the brain causing arrhythmia and death. Ibogaine treatment 
providers promote pre-treatment tests (bloods and ECG) to reduce this risk. 
Anecdotal reports suggested ibogaine treatments occurred in ‘supported’ 
clinics with medical input, and unsupported in people's homes, via ‘peer-to-
peer’ use, despite medical risks. This study sought to understand the 
experience of an ibogaine user, what factors motivated people to choose this 
treatment, and what factors achieved safest, best practise when using 
ibogaine. The gathered information was coded and organised logically into 
similar themes and patterns, and through the results and discussion sections, 
the study outlined the experience of an ibogaine user in New Zealand. 
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CHAPTER TWO: 
LITERATURE REVIEW 
Overview of chapter 
The following review of literature will address three primary questions: 
firstly, is ibogaine an effective and safe treatment for opioid dependence? 
Secondly, what are the motivations for its use and are there observable 
trends in ibogaine use and alternative treatments amongst New Zealand's 
opioid-dependent population? And thirdly, if motivation or drivers to use 
alternative treatments do exist within this population, can we predict the 
continued use of ibogaine in New Zealand? 
These primary questions will be addressed through consideration of the 
following five argument statements: 
1. Opioid dependence is a significant health concern for New Zealand 
(NZ). 
2. Ibogaine has beneficial effects on opioid drug withdrawal 
symptoms and cravings during opioid detoxification. 
3. Ibogaine use has cardiac concerns which are attributed to cases of 
death. 
4. Ibogaine use for detoxification of opioids is safest and most 
effective within medically-supported treatment centres with pre-
treatment testing, counselling and follow-up care. 
5. People are motivated to use ibogaine as a treatment for opioid 
dependence. 
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Literature review methodology  
Using Databases; Ovid, Embase, Science Direct, Informa Healthcare and 
Proquest, key words were entered in relation to the scope of this study. 
International articles were included with English translation and the range 
of years was kept open. This was because some topics were specialized and 
limited in article numbers. Many key words where used and entered 
interchangeably to capture all available data. Such as Prescription Drug 
Misuse, Opioid use, Opioid dependence, Opioid Substitution Treatment, 
Opioid dependence harms. When exploring ibogaine’s anti-addictive 
properties; ‘ibogaine’ alone was entered and over 80 articles where 
manually reviewed as per Cooper (1982) guidelines for integrative review 
which categorises articles determined by validity of research methods. Due 
to lack of randomized clinical trials (RCT) on the efficacy of ibogaine for 
opioid detoxification this review included open label trials. It excluded 
personal stories and reports of ibogaine use. Fourteen ibogaine open label 
trials and case studies were selected and one closed label randomised 
controlled study was found. In regards to neurological function, nine 
relevant animal studies were chosen that had particular attention to the 
cerebral actions of ibogaine to help build understanding, although severely 
limited to being only animal studies at this point. The same data bases 
where systematically searched for ‘ibogaine’, ‘cardiac’ ‘fatalities’ and 
‘arrhythmia’. All 18 articles related to this search were selected but mostly 
the human studies are reported on. When exploring ‘motivations to use 
ibogaine’ no direct results were found however information was derived 
from articles referring peoples experiences of the negative effects of opioid 
dependence treatment and from articles referring to wider hallucinogenic 
treatment experiences that allude to spiritual motivations for people seeking 
this type of alternative treatment.  
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Statement 1: Opioid dependence is a significant 
health   concern for New Zealand 
Introduction 
Opioid dependence is a significant health concern for New Zealand (NZ). 
Information from the NZ Ministry of Health's (Government) New Zealand 
Alcohol and Drug Use Survey (Ministry of Health, 2009) demonstrates the 
scale and diversity of New Zealand’s opioid use disorders are scantily 
known. More precise measuring of opioid-dependent populations are 
explored through the National Addiction Centre (Otago University) studies 
(Adamson et al., 2012; Deering et al., 2011). The NZ trends of use are 
explored and reviewed including the ‘subculture’ definitions of this opioid 
population. These findings are matched with world statistics of opioid 
dependence. The harm associated with opioid use, both towards the 
community and users, is then explored. The literature review also explores 
the hard-to-quantify data, that long-term opioid use, even prescribed for 
pain, produces lower life satisfaction scores compared to not using opioid 
drugs. Treatment of opioid dependence is explored in the literature, from a 
New Zealand perspective, to determine the influence this has on opioid-
related harm. The review exposes ‘problematic prescription opioid use’, 
with growing world and NZ statistics showing people are over-using pain 
(opioid-based) medications, and using them for longer periods than 
prescribed or medically expected.  
New Zealand opioid use trends 
Opioid drug dependence is a health problem for New Zealand, both for 
those dependent and the community affected. Effects range from crime 
against the individual, their family and society, to the cost on the health 
sector and communities (Degenhardt & Hall, 2012). Firstly let's look at 
trends of opioid use in NZ. 
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Total numbers of New Zealand’s opioid drug dependence population appear 
to be around 10,000 of the total population (a country of 4 million) with up 
to 17,000 using opioids problematically (Ministry of Health, 2009; 
Adamson et al., 2012). A government-initiated telephone survey of sample 
populations helped estimate  these figures (10-17,000 people dependent or 
problematically using) and distinguished, within the survey, types of 
opioids used, whether it be prescription painkillers or more illicit forms of 
opioids, such as street manufactured heroin (Ministry Of Health, 2009). Of 
respondents that reported using opioids, 67% had used prescription pain 
analgesia and 33% used illicit forms. A University study (Adamson et al., 
2012) provided more robust estimations of opioid dependence within the 
population, using calculations, such as, snow-balling technique to contact 
other people that use and contacting treatment centres, as opposed to 
telephone surveys alone (Adamson et al 2012). This study targeted specific 
populations through needle exchange and opioid substitution services. A 
calculated 9,142 of the total population of NZ were believed to be using 
opioids daily or almost daily, with half this number (4,537) actually in 
opioid substitution treatment (OST) (Adamson et al., 2012). However this 
study was specifically targeting one user group; opioid dependent people as 
defined by ‘using every, or almost every day’. The authors acknowledges it 
did not measure other groups of opioid users such as those who misuse 
opioid prescriptions, poppy-seed tea drinkers and other sub-culture groups. 
These pockets of users who have adopted one source and method of opioid 
use (such as smoking morphine, or drinking poppy-seed tea) are easily 
missed through specific targeting of injecting populations (Moshier et al., 
2012). 
With around 5,000 opioid-dependent people in OST, there still remained a 
further 5,000 users actively sourcing illicit opioids, with the majority 
intravenously injecting (Adamson et al., 2012; Kemp & Aitken, 2004) 
Studies suggest within the treated population there is on-going, though 
much reduced injecting of drugs and other drug-use harm (Fountain, 
Griffiths, Farrell, Gossop, & Strang, 1998; Judson et al., 2010). One study 
also reported that after a year in OST, with sufficient substitution dosing, 
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injecting behaviour and other drug use decrease significantly (Deering et 
al., 2004). 
Prescription Drug Misuse (PDM) 
PDM is briefly reviewed here from the literature, as this is a pathway to 
opioid dependence and treatment for some people. PDM is a broad 
definition incorporating all available prescribed drugs which may be abused 
(Benzodiazepines, Opioids, Methylphenidate) (Birnbaum et al., 2011). A 
general accepted definition in literature appears to be: use in larger amounts 
than prescribed, for longer periods than prescribed, or use without a 
physician's prescription (Currie, Schopflocher, & Wild, 2011). Opioid 
analgesia prescription misuse is often defined as the main sub-group of 
prescription drug misuse (PDM) with much of the literature stating PDM is 
mostly opioid prescriptions. When exploring international literature around 
opioid dependence, PDM is widely recognised as a significant concern, 
causing harm to individuals involved and the health system (Currie et al., 
2011). The manufacture of opioid analgesia has increased four-fold between 
1997 and 2002, and in this same period overdoses from prescription 
medicines doubled at emergency departments across the United States 
(Savage, Kirsh, & Passik, 2008). In 2008, an estimated 10% of 12- to 17-
year-olds used (opioid) pain medication not prescribed for them, for 
purposes other than pain relief (Wu, Pilowsky, & Patkar, 2008). New 
Zealand’s rate of prescribing opioids has increased in line, though 
fortunately not to the same degree, with the United States and some EU 
European countries (McMinn, 2012). In North America and Western 
Europe, it is estimated problematic prescription opioid misuse was four 
times greater than the number of people injecting opioids (Holmes, 2012; 
Potter et al., 2015). New Zealand data on PDM has not yet been estimated 
however, the Ministry of Health 2007 survey suggested 17,000 of the total 
population had used an opioid drug, mostly a prescribed pain analgesia, for 
recreation in the past year.  A cohort study in the USA found a PDM 
individual had an annual medical cost of US$15,884 versus US$1,830 of a 
non-PDM counterpart (Strassels, 2009). The treatment options for PDM 
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appear limited with most treatment focus being on illicit opioid use, as this 
is the more socially observable problem (Potter et al., 2015). It appears 
Opioid Substitution Therapy (OST) and gradual withdrawal and cessation 
and switching to non-opioid pain relief remains the most effective treatment 
(Potter et al., 2015). 
Sub-groups and subculture 
Opioid drug use in New Zealand culture is illegal and secretive, and society 
generally has a negative view of dependent individuals (Moshier et al., 
2012).  Medical professionals often share this view which may lead to fewer 
people seeking treatment (Sheridan & Butler, 2008), and contribute to an 
increase in subculture populations that are difficult to target and measure.  
The role of perceived 'belongingness' and even identity to a 'drug 
subculture' was explored by Mosihier et al (2012). In literature the opioid 
users' subculture is defined in four phases: alienation from social peers; 
connectedness with using peers; the shared degree of excitement in drug 
procuring; and, finally, the mastery of the trade, which includes the skills to 
efficiently use and produce a complicated narcotic. This subculture relies on 
a degree of manipulation and deceit to achieve their needs and is very 
secretive (Fountain et al., 1998). The pharmacology of opioid dependence 
means a dependent person requires very regular usage (multiple times a 
day, every day), (Savage, Kirsh, & Passik, 2008) and this drug use 
population also has the highest rate of intravenous injecting (Degenhardt & 
Hall, 2012).  Obtaining accurate estimations of populations, especially those 
not seeking treatment, is difficult, as many do not wish to participate in 
medical studies, which may expose them as users (Degenhardt & Hall, 
2012).  
Associated harm with opioid use 
The evidence of harm associated with opioid dependence and opioid 
prescription misuse is based on an overseas perspective. Internationally, the 
global opioid dependent population has been estimated at 12–21 million 
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(Degenhardt & Hall, 2012). In the same report it revealed the amount of 
drug-related deaths, mostly overdoses, had doubled in the ten years from 
1990–2000, and most of those were from opioid-based drugs. Four areas of 
harm were commonly recognised: the risks of acute intoxication; overdose 
(respiratory depression and death); effects of drug dependence; and chronic 
use associated risks, such as poor nutrition and infections. From this study 
of global statistics there also emerged individual risk factors for becoming 
opioid-dependent, including being male, having a novelty-seeking 
personality, and early oppositional and conduct disorder behaviours in 
childhood. Other risk factors included early school leaving; associating with 
an opioid drug network; and familial factors such as alcoholic or drug-
dependent parents (Degenhardt & Hall, 2012). The report acknowledged not 
all the data from all countries was equal in quality and detail, and in some 
countries opioid usage had to be estimated due to no government data. 
Nonetheless the report concluded illicit opioid use was a major cause of 
mortality and disease worldwide. 
The ‘harms’ of opioids, even substitution opioids, is well captured in a large 
Australian sample and survey of OST clients. Over 500 telephone 
interviews with OST clients on OST for over three months and more, found 
that over half respondents had sought treatment for side effects related to 
using their substitution opioid. This ranged from Dental concerns, 
constipation, sweating and 12% reporting long term headaches, and 
appeared no difference between which substitution opioid was used. 
Sedation was also listed but appeared less often for those on buprenorphine 
than those on methadone. Mood and anxiety was not listed but was not the 
focus of the study either. The study concludes nearly half OST users have 
side effects related to their OST but this is dose related with those on higher 
doses above 100 milligrams having more concerns. It discusses that this 
could be a cause of poor retention rates in OST internationally, but this was 
not directly measured (Winstock, Lea, & Sheridan, 2008). A well-designed 
study by a New Zealand university used the health survey SF-36 (Ware Jr, 
1999) to measure the health status of clients on methadone maintenance 
therapy. It used a timeline study technique and although it reported many 
~ 16 ~ 
benefits from substitution treatment of the individual, including not being 
incarcerated, it still reported health scores, including life satisfaction scores, 
lower than the general population. It also reported concurrent drug use with 
30% having used a benzodiazepine in the past four weeks, 9% had used 
alcohol and 18% had used another opioid drug (Deering et al., 2004). 
Opioid dependence treatment 
Opioid dependence treatment in New Zealand is three-tiered. Firstly, the 
needle exchange program, initially peer developed, is now government-
funded as a harm reduction method since the late 1990s (Kemp & Aitken, 
2004). Secondly, New Zealand publicly funds long- term (12-18months) 
residential, rehabilitation, abstinence-based services with some evidence of 
treatment success (Toumbourou, Hamilton, & Fallon, 1998). Thirdly, and 
with international, evidence-based knowledge, New Zealand has offered 
opioid substitution treatment since the early 1990s, mostly in response to 
blood-borne diseases prevalent within the injecting community (Deering, 
Sellman &Adamson, 2014). Methadone was the first synthetic substitution 
opioid used, in line internationally, and typically has a high retention rate 
(Deering, Sellman & Adamson, 2014). Historically, New Zealand has 
shared similar issues to other countries. These include concerns about 
overdose potential and inadequate doses provided, lack of access and long 
waiting times, lack of treatment attractiveness and stigma associated with 
methadone (Deering, Sellman & Adamson, 2014). Reluctance from opioid 
substitution services (OST) to extend the time users required to naturally 
reduce injecting and drug-taking behaviour, often caused poor retention 
outcomes (Deering et al., 2011). Perhaps these initial learning curves for 
service providers contributed to the obstacles New Zealand’s opioid 
dependent population encountered when requesting substitution treatment. 
With nearly ten thousand people opioid dependent nationally, half were 
formally engaged with the fourteen OST services across NZ (Adamson et 
al., 2012; Sheridan, Goodyear-Smith, Butler, Wheeler, & Gohns, 2008). 
Other studies promoted the effectiveness of, and perhaps preference for, 
other substitution opioids, including slow release oral morphine (SROM), 
~ 17 ~ 
buprenorphine and even, dia-morphine (heroin). From a pharmacological 
view these can have full agonist action on opioid receptors (heroin, SROM) 
or partial agonist, high receptor affinity action (buprenorphine). This, it was 
argued, may attract a wider opioid-dependent population base into 
treatment, as those who don’t like the mental sedating effect of methadone 
may be attracted to the effects of ‘clearer minded’ buprenorphine or the full 
agonist effects of heroin (Ferri, Davoli, & Perucci, 2011; Ferri, Minozzi, 
Bo, & Amato, 2013). Although buprenorphine is currently, since 2013, 
prescribed in NZ, SROM and heroin are not. Internationally, evidence 
suggests they both have equal treatment effectiveness as methadone therapy 
(Ferri et al., 2013). Although New Zealand has slightly better treatment 
retention rates than some other countries around the world, there are studies 
which suggest New Zealand’s historical perspective of long wait-lists for 
treatment, and strong enforcement of treatment regulations have played a 
part not achieving above the 50% in-treatment rate (Sheridan et al., 2008). 
These barriers to treatment are reflected in international studies (Ferri et al., 
2013). A study exploring barriers to OST treatment in NZ reported 55% of 
individuals not on OST stated they did not like the drug methadone (its 
effects), so it will be interesting to discover if the introduction of 
buprenorphine to NZ in 2013 has captured more of the dependent 
population (Deering et al., 2011). 
Statement 1: Conclusion 
 Illicit or traditional opioid-dependent populations of New Zealand have 
remained steady, with half of this population in substitution treatment. 
While literature suggests harms from drug use decrease after approximately 
a year on OST, there is an unavoidable theme around poor life satisfaction 
scores, for individuals on long-term opioid prescription as compared to the 
general population (Deering et al., 2004). Choice of opioid substitution 
medication has increased in New Zealand to include buprenorphine (in 
combination with naloxone and marketed as Suboxone). More recently 
concerns about misuse of  prescribed opioids has increased in accord with 
other countries although the nature and extent of this issue hasn’t been 
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clearly identified (Crowley, Jones, Coffman, & Greenberg, 2014; 
MacIntyre, Huxtable, Flint, & Dobbin, 2014). The harm from opioid 
dependence, not treated, is acknowledged as negatively affecting the 
individuals, their families and society, with crimes of property damage and 
theft, and increased prostitution all correlated to opioid dependence. It is 
clear opioid dependence remains a significant health concern for New 
Zealand (McMinn, 2012). 
Statement 2: Ibogaine has beneficial effects on 
opioid drug withdrawal symptoms and 
cravings during opioid detoxification. 
Introduction 
This argument will briefly address available literature on the pharmacology 
and effectiveness of ibogaine as a treatment for addiction. It will very 
briefly outline nine relevant rodent trials, which help understanding of the 
complexity and unique pharmacological function of ibogaine. It will then 
explore initial stage one human trials, which used FDA approved low does, 
assumed sub-therapeutic. These studies are followed by exploring many 
open label or non-controlled human studies from various private clinics 
around the world. As stated in the literature review methodology section 
above these data are reported on as they are the main form of available 
information around ibogaine use. This is despite the lower evidence base of 
open label studies and associated methodological issues, especially poor 
research control conditions. Lastly, around human trials, it will explore the 
one known, double blind randomised controlled nor-ibogaine trial. Further, 
other hallucinogenic drug trials and participant’s experiences, with regard to 
treatment for addiction, will be briefly reported to attempt to understand the 
complexity and limitations of undertaking hallucinogenic research. 
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Historical context 
Firstly, however, in reviewing literature on ibogaine’s anti-addictive 
properties, the historical and political context of ibogaine's discovery and 
research require understanding, as it has influenced the scope and nature of 
research. Although used by forest-dwelling tribes in Africa's Gabon region 
for ancestral ceremonies as far back as 2,000 years ago, and marketed by 
French pharmaceutical companies in the early 20th century as a post-viral 
relief tonic, its anti-addictive properties were not discovered until the mid-
1960s, by a New York film student, Howard Lotsof (De Rienzo & Beal, 
1997).  Lotsof was experimenting with many hallucinogens at the time and 
used ibogaine, by chance, with a group of friends who were heroin users.  
The effect for some of this group was to not have the desire or need to use 
heroin for a period of time afterward (De Rienzo & Beal, 1997). Howard’s 
subsequent ‘vision’ of bringing ibogaine to the world to cure addiction 
however, was thwarted by America's classification of LSD and all 
hallucinogenic drugs, including ibogaine, as ‘class A’ narcotics, citing 
potential harm to the public (Strassman, 1995). Ibogaine became embroiled 
in the hysteria surrounding hallucinogens but Howard Lotsof sought and 
gained legal patent for ibogaine as an anti-addictive drug (Lotsof, 1992). 
The claimed motive was to keep ibogaine's potential from being ‘locked 
away’ by pharmaceutical companies who are not interested in ‘one off’ 
treatments. However, another outcome of this patent was very limited 
scientific research. Money was gained through ‘imaginative’ research 
applications and in 1993 the USA, through the Food and Drug 
Administration (FDA), allowed the first animal, and then human, ibogaine 
drug trials - the rodent trials and two human clinical trials resulted. 
However, lack of money and the FDA continually declining research 
applications eventually lead to a private, user-pays, research clinic in the 
West Indies, where legal permission for trials was gained. Thus, ibogaine 
use was limited to private clinics, and research can appear somewhat 
‘unauthorised’ or otherwise discreditable. 
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From a New Zealand perspective, a group of people who had successfully 
used ibogaine in Australia and New Zealand initiated the application to 
New Zealand Medicines Authority, Medsafe in the early 2000’s for 
ibogaine to be prescribed as an anti-addictive medicine. In 2009 ibogaine 
became available on the medicines schedule as a non-approved medicine.  
A Dunedin group informally emerged as an ibogaine treatment provider 
providing their first ‘legal’ ibogaine treatment in 2010. A further ibogaine 
treatment provider emerged in the North Island, founded and operated by a 
General Practitioner around the same time. This has afforded more open 
access to studying ibogaine to include valuable information and 
participation of treatment providers (Paterson 2015). Noller, Frampton and 
Yazar-Klosinki (2017) were able to capture 12 month longitudinal data on 
14 users of ibogaine for opioid detoxification across the two New Zealand 
treatment providers. This has been perhaps a pivotal human clinical study 
internationally as the article provides participant data that was able to be 
cross- checked with the treatment providers without fear of prosecution. 
Animal studies 
The anti-addictive effects of ibogaine where first explored in rodent trails. 
In brief, ibogaine was found when administered directly into the Ventral 
Tegmental Area (VTA) of rodents’ brains to reduce alcohol, heroin and 
cocaine self-administration (He, McGough, Ravindranathan, Jeanblanc, 
Logrip, Phamluong, Janak and Ron, 2005). The effect of ibogaine on this 
region (VTA) was to increase the expression of glial cell line-derived 
neurotrophic factor (GDNF) which increases the activity of the MAPK 
pathway (Carnicella, Kharazia, Jeanblanc, Janak and Ron 2008). 
Mesolimbic dopaminergic pathways between the VTA and Nucleus 
Accumbens (NAC) usually demonstrate an increase in dopamine release 
after using drugs, and this is thought to be part of the larger reward 
pathway, which mediates drug-taking behaviour. Following use of 18-MC 
(synthesized ibogaine) with the above drugs, microdialysis showed 
decreased levels of dopamine in this pathway (Glick, Maisonneuve, Hough, 
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Kuehne and Bandarage, 1999). 18-MC also worked as an antagonist on 
alpha3 and Beta4 nicotine receptors, which are highly dense in the 
diencephalic cerebral pathways. Suppression of these nicotine receptors 
modulated the diencephalic pathway, which in turn modulated the 
mesocortico-limbic pathway, directly involved with drug-use reinforcement 
behaviour (Maisonneuve and Glick, 2003). When exploring ibogaine 
alkaloids on extra-cellular serotonin (5-HT) levels in Nucleus Accumbens 
(NAC) and striatum areas (STR) of the rodent's brain a study found that 
ibogaine had the highest affinity for serotonin transporters and produced 
large increases in extra cellular serotonin levels in the NAC (25 times 
greater, compared to base-line levels) and STR (10 times greater). 
Suggesting the long-lasting effects of serotonin re-uptake on these regions 
by ibogaine, may enhance mood (Glick, Kuehhne, Maisonneuve and Wei, 
1998). The peripheral nervous system of rats was explored and it appears 
ibogaine at 40mg/kg administered after morphine injections significantly 
decreased morphine’s pain-reducing ability, that is, the rats had a normal 
baseline pain response when their tails were burnt. Contrary to this result 
was the other conclusive outcome that  Noribogaine (metabolite of 
ibogaine) at 40mg/kg administered with morphine injections significantly 
increased pain-reducing ability by 15 – 20%, and increased four-fold the 
length of time the pain blockade occurred (from 30min to 120+min) (Bagal, 
Hough, Nalwalk and Glick, 1996). 
Ibogaine trials 
Leading the charge for medical-clinical research on the effect of ibogaine 
on heroin-dependent patients is Doctor Deborah Mash, who gained Food 
and Drug Authority (FDA) approval in 1993 for stage one human trials in 
the U.S.A., sponsored by the University of Miami. Stage three clinical trial 
approval was rejected in 1999 by the FDA and Mash has since run ibogaine 
clinical trials on heroin-dependent patients in St Kitts Hospital in the West 
Indies (Vastag, 2002; Alper 2001). The data from this clinic is not 
published directly, believed to be mired in a disagreement with ibogaine's 
patent holder, Howard Lotsof. The stage one and two trial data are reported 
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in a chapter in a book, titled, ‘Ibogaine in the Treatment of Heroin 
Withdrawal’. In this chapter, Mash, Kovera and Pablo (2001) reviewed the 
pharmacokinetics of ibogaine and its longer-lasting metabolite, noribogaine. 
Results reported from her stage one, low dose, trials in 1993, were that 
ibogaine was eliminated from blood within 25-30 hours, with noribogaine 
taking up to 72 hours (Mash Staley, Baumann, Rothman, & Hearn, 1995). 
Her stage one trials also indicated a similar response to ibogaine in all the 
same neurotransmitter systems as the rat studies. The chapter also reviewed 
other West Indies studies, concluding ibogaine is metabolised with greatest 
effectiveness by the CYP2D6 cytochrome, and patients with higher 
CYP2D6 metabolised the most ibogaine, and consequently had higher 
levels of noribogaine after dosing. 
Mash et al. (2001) and Mash et al. (2000) explored ibogaine's anti-addictive 
properties with a 14-day inpatient hospital study involving 27 heroin (n=18) 
and cocaine-dependent (n=9) persons. The trial was mainly focussed on 
medical observations of withdrawal signs, and scales of depression and 
cravings, using DSM-4 (1984) criteria for both heroin and cocaine 
dependence.  The Addiction Severity Index, heroin/cocaine craving 
questionnaires and depression self-rating tests were administered pre-
treatment, an average of eight hours since last use of heroin, on each day of 
the 14-day treatment, and at a one-month follow-up assessment. The 
participants were encouraged to attend counselling and post-treatment 
support groups such as Narcotics Anonymous. The treatment trial itself had 
limited ‘motivation counselling‘, and focussed on clinical observations and 
questionnaires on physical and mental withdrawal symptoms. A limiting 
factor of the trial could have been an inadequate dose of 10mg/kg being 
administered. Alper, Lotsoff and Kaplan (2008) argued 19-30mg/kg was the 
average ‘therapeutic’ dose of ibogaine used effectively in most ibogaine 
clinics they investigated around the world. Mash et al. (2000) study, 
however, demonstrated a significant decrease in Objective Opiate 
Withdrawal Scale (OOWS) scores. Measurements for depression and 
negative self-beliefs were also significantly reduced and still maintained 
one month following treatment. The study concluded ibogaine effectively 
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and safely helped ‘detoxify’ or withdraw heroin-dependent patients, and 
helped maintain positive behaviour patterns away from drug use because its 
pharmacological targets modulate or interrupt the drug-reward circuits.   
Stage two trials additionally ran extensive cardiac and neurological tests 
and investigations. Most study participants experienced a slower heart rate, 
a decrease of 15-20%, including one patient who became ataxic (no 
coordination).  Decreased blood pressure was observed, contrary to 
expected heroin withdrawal which increases blood pressure. No other ill-
effects were recorded.  The chapter extensively discussed cardiac studies 
with ibogaine, highlighting risk of heart arrhythmia associated with 
ibogaine sometimes prolonging electro-cardiac ‘QTc’ intervals – again this 
is discussed later. Anti-addictive results were the same for the smaller 
cocaine group, however their craving index scores were higher than the 
opiate group at one month follow-up, though lower than their pre-treatment 
score. The discussion mentioned that patients reported changes to thinking 
patterns and an increased desire to not use drugs. 
Wider ibogaine trials 
Escaping the limitations of the FDA and difficulties applying for clinical 
trials have been the world-wide independent ibogaine treatment providers 
who have provided many ibogaine treatments for opioid detoxification since 
early 1990’s. Alper, Lotsof and Kaplan (2008), in their investigation, 'The 
ibogaine medical sub-culture', tracked down a variety of ibogaine providers 
and estimated 3414 people had used ibogaine through their connected 
clinics as of February 2006. Sixty-eight percent of these providers claimed 
to have administered ibogaine for drug dependency, 53% of those 
specifically for heroin/methadone (opiate) dependence. The study found the 
average dose of ibogaine was 19mg /kg +/- 12mg/kg. Most human 
examples of ibogaine administration for opioid dependency came through 
local drug and alcohol communities operating sub-medically, drug-using 
peer groups, or in some countries, from medical clinics. Alper, Lotsof, 
Frenken, Luciano and Bastiaans (1999) further studied 33 cases of ibogaine 
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used for heroin withdrawal and dependency in an inpatient clinic over five 
days. With an average dose of 19.3mg +/- 6.9mg/kg, at the end of the five-
day, in-clinic stay, 25 of the sample of 33 reported they had no withdrawal 
symptoms and were objectively observed not to have drug-seeking 
behaviour. Four patients had drug-seeking behaviour but no withdrawal 
symptoms; two clients had withdrawal symptoms for the duration of the 
five-day treatment but maintained drug abstinence; and one participant had 
withdrawal symptoms and drug seeking behaviour. 
New Zealand research 
A ‘closed label’, and perhaps the only double blind randomized control 
study on Noribogaine was conducted in Dunedin (Glue et al. 2016). This 
study investigated both the efficacy of anti-addictive properties and the 
safety profile of this active metabolite of ibogaine. Measures included 
opioid withdrawal symptoms and time taken to resume current methadone 
treatment/use of opioid drugs and electrocardiogram (ECG) after 
administration of noribogaine doses. The 27 participants who were, mostly 
dependent on methadone were divided into four groups, a control (placebo) 
group, a group administered 60mg of noribogaine, a group administered 
120mg and a last group administered 180mg. Non placebo groups reported 
mild light sensitivity and nausea as the only symptoms likely to be 
perceived as the ‘active’ dose. The authors concluded there were non-
significant differences between control and test groups on mean time to 
return to opioid (methadone) use and withdrawal symptom scores, except 
for the 120mg group who had slightly better scores, but not statistically 
significant, for both withdrawals and return to use of methadone times. 
While the authors reported limitations related to study design they 
considered further trials where warranted as although not statistically 
significant there were differences found. Indeed the results are confusing, as 
two of one test group did not return to methadone use at end of the study (3 
months). In addition, the study provides evidence for dose related cardiac 
QTc prolongation with administration of noribogaine with mean differences 
in time of 16, 28 and 42 milliseconds in the 60, 120 and 180mg groups 
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respectively. Reports of lesser anti-addictive properties of ibogaine have 
been interpreted in subsequent literature citing Glue et al (2016) study 
concluding there should be caution for prescribers due to over-reported anti-
addictive properties of ibogaine by authors of lesser quality open- label 
designed studies (Dos Santos, Bouso, & Hallak 2016). Perhaps wider 
limitations of this trial is noribogaine being accepted and referenced as 
superior to ibogaine because of its research design compared to open-label 
non-controlled trials and case studies and other factors of treatment 
including the effects of a hallucinogenic experience not being considered.  
In a further New Zealand study Noller, Frampton and Yazar-Klosinki 
(2017) followed-up 14 people who were opioid dependent and underwent 
ibogaine treatment with two different providers  over 12 months This 
longitudal study had access to the treatment providers and participants 
before, during and after ibogaine treatments for each person using ibogaine. 
This is an important study as it afforded objective, systematic third party 
assessment of primarily the effects on drug addiction following ibogaine 
treatment using the Addiction Severity Index-Lite (ASI-Lite). The study 
also assessed opioid withdrawal symptoms using the Opioid Withdrawal 
Scale (SOWS) as well as Beck Depression Inventory-II (BDI-II). These 
measures were administered before and immediately post treatment, 
monthly up to three months, and then three monthly until the 12-month final 
assessment. Eight participants (57%) completed the 12-month assessment. 
The authors concluded there was a significant reduction in scores from base 
line to 12 months for both ASI-Lite and BDI-II, with significant drops at the 
one-month post treatment point but continuing to decrease up till 12 
months. There was a reduction in scores for those who did not complete as 
well. The limitations of the study, and although not directly studying effects 
on mood, were the limitations with the quantitative data recording of the 
BDI-II. This limits understanding if the cause of better moods was 
influenced by the absence of opioid and other drug use and better lifestyle 
prospects, by the effect of ibogaine itself, or a combination of factors. 
Kaplan & Alper (2010) reports from case-studies with St Kitts private 
ibogaine treatment provider, used qualitative interviews and discussions and 
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found participants described ibogaine itself as the mood enhancer, 
describing participants ‘knowing’ when it (ibogaine) had ‘worn off’. 
Hallucinogens used with psychotherapy for addiction 
Although ibogaine is characterised as a hallucinogen (Strassman, 1995), its 
chemical grouping doesn’t fit with the ‘classical’ three types of 
hallucinogens:  phenethylamines (e.g., mescaline); indoleaklyamines (e.g., 
psilocybin and N,N-dimethyltryptamine [DMT]); and lysergamides (e.g., 
LSD). These three chemical families represent the most ‘psychoactive’ or 
‘psychedelic’ chemicals for humans (Strassman, 1995). Other types of 
hallucinogenic drugs cause different intensity ‘psychoactive’ experiences 
and are from an ‘overlap’ of the drugs’ other actions, for example  MDMA 
and phenethylamine stimulate the serotonin pathways and cause the user to 
have 'psychedelic moments'. Ketamine and other anaesthetics, before too 
high a dose renders one unconscious, can have the same effect. It would 
appear from anecdotal reports and Strassman (1995) that ibogaine, 
combined with other chemical actions within the cerebellum, ‘overlaps’ and 
causes ’phantasticant’ or ‘psychotogen’ (dream-producing) type 
hallucinogenic experiences. Dos Santos, Bouso, & Hallak (2016) reports 
there are anti-addictive effects involved with other hallucinogenic 
substances such as LSD and Ketamine with greater evidence of efficacy 
through Randomised Controlled Trial (RCT). The authors dispute 
ibogaine’s anti-addictive properties and/or this being unique to ibogaine and 
found only one RCT trial on Noribogaine, which did not demonstrate 
significant anti-addictive effects. Therefore, wider literature is briefly 
outlined of other hallucinogenic addiction treatments. This appears relevant 
as it helps understand the nature of research involved with hallucinogenic 
treatments, often thwart with inability to operate Double Blind Randomised 
Controlled Trials because of the noticeable effect of the drugs for both 
participants and researchers (Oram 2012). Similarly, in relation to LSD, in a 
review of LSD psychotherapy research, Oram (2012) found promising 
research with LSD in the treatment of alcoholism. This author also argued 
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that a limitation of the greater focus on randomised controlled trials after 
the early 1960’s was the lack of attention paid to qualitative data and its 
contribution to understanding the experiences of participants in such 
studies. 
Thirty-one treatment studies conducted on alcohol-dependent patients using 
various hallucinogens and psychotherapies were reviewed by Strassman 
(1995), but again, the effectiveness was unable to be ascertained due to 
inconsistent study designs. Common reported benefits of this type of 
treatment included ‘religious type epiphanies’ for patients who felt the 
issues behind their drinking were instantly resolved, and a sense of being 
able to ‘work through' mental issues/depression related to alcohol use for 
those who reported long-term improvements. The review advocated the 
future use of hallucinogens in modern psychotherapy treatments for 
dependence and depression from an economic perspective, stating: 
“Economic constraints create increasing pressure for cost effective medical 
psychotherapy…high dose hallucinogen assisted sessions should be 
considered in a model combining the psychedelic and psychoanalytic 
models” (Strassman, 1995., pp 134). Simlarly, in a later review review of 
LSD psychotherapy research, Oram (2012) found promising research with 
LSD in the treatment of alcoholism.  
Spirituality and addiction treatment 
Strassman’s review (1995) and other articles cited exploring hallucinogenic 
addiction treatments all reported greater success rates than conventional 
treatments. The reported positive effects were linked with greater internal 
resolve of issues or a spiritual-like epiphany, induced by the use of a 
hallucinogenic. A general, deeper sense of understanding, or connectedness, 
during the psychotherapy sessions has been described. Purely medical-
clinical, observational human trials on ibogaine struggle to represent as data 
patients' reports of spiritual effects from the treatment. Information on 
ibogaine users from various case studies, from different countries, generally 
all described spiritual changes or awakenings, to which the subjects 
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attributed their success at avoiding further drug use. Other treatment 
philosophies such as the ‘12-step program’ developed by Alcoholics 
Anonymous (AA), also incorporated growth or development of the spiritual 
self (Mattson, 1993). Although the AA spirituality is religious-based, the 
limited success of the 12-step abstinence program promoted an internal 
sense of connectedness, which they labelled ‘inner peace’, to help resolve 
emotional issues behind the urge to use drugs.  Development of 18-
Methoxycoronaridine (18-MC) to both manoeuvre around legal patents of 
ibogaine and to eliminate the hallucinogenic ‘side effects’, risk missing the 
potential enhancement of counselling or psychotherapy, the 'spiritual' 
element (Lotsof, 1992). 
Statement 2: Conclusion 
Ibogaine affects parts of the brain, in both rodents and humans, believed to 
be involved with mood, drug-use reinforcement behaviour, and the ability to 
sense drug withdrawal and pain. It initiates the expression of glial cell line-
derived neurotrophic factor (GDNF) in the VTA region of the brain, and 
directly reduced alcohol and opioid self-administration in rats (Glick, 
Maisonneuve, & Szumlinski, 2000). GDNF increased the activity of the 
MAPK brain pathway, which also decreased self-administration of alcohol 
and opioids in rats (when the pathway was inhibited, self-administration 
continued). It appeared the effects of GDNF on the VTA, and increased 
stimulation of MAPK pathways reduced self-administration of alcohol and 
continued to do so for some time after these regions had been affected (He 
et al., 2005; Kamlet & Alper, 2010). Human clinical trials have shown 
evidence of decreased drug-using behaviour, significantly less withdrawal 
symptoms, increased mood indicators and periods of drug abstinence from 
days, to three months, after one ibogaine dose. However, while ibogaine 
research, including that conducted in New Zealand shows promising results 
on its effect on reducing withdrawal effects of opioid drugs and limiting 
return to opioid use, the methodology of many studies limits the nature of 
the evidence available. There is limited evidence of increased anti-addictive 
effects of the hallucinogenic drug treatment when enhanced with 
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psychotherapy (Alper, Lotsof, & Kaplan, 2008). Relatedly it is suggested 
that better treatment outcomes were achieved when addiction treatment 
incorporates a 'spiritual' aspect for consumers (Oram, 2012; Strassman, 
1995).  . 
Statement 3: Ibogaine use has cardiac 
concerns, which are attributed to cases 
of death. 
Introduction 
In this section, relevant literature is explored and reviewed considering the 
safety of ibogaine in the treatment of opioid withdrawal. Especially articles 
related to irregular heart rhythms, and cardiac centres of the brain being 
affected by ibogaine and its metabolites. Accounts of death associated with 
ibogaine use will be examined. Firstly, four neurological articles are 
reviewed regarding the effects of ibogaine on various centres of the brain. 
Then eight case studies from emergency departments are summarised. The 
latest research on human studies in New Zealand using noribogaine are 
reviewed. Countering these concerns, are articles examining and supporting 
the neurological safety of ibogaine, when cases of death are matched to 
other causes. Finally, literature supporting protective medical testing will be 
critiqued. 
Adverse effects  
The main adverse effects include prolonged QTc intervals and affected 
cardiac action potential, sometimes causing cardiac arrhythmia and 
potentially death (Koenig et al. 2013). The authors explored ibogaine and its 
metabolites effects on ECG and heart rate through ibogaines effect on ion 
channels within cardiac tissue (simulated by a computer for humans and 
tested on guinea pigs). The results demonstrated ibogaine affected cardiac 
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action potential, effecting QTc prolongation, and this was at lower doses 
than would be used for treatment of addiction (Koenig et al., 2013). 18-MC 
had less effect and the authors concluded this was the first avenue for future 
investigation on safely administering ibogaine as an anti-addictive 
treatment. The paper also investigated the effects of low potassium on 
hERG channels and noted that low extracellular potassium increased the 
blockade effect of ibogaine on hERG channels. This was significant when 5 
of 8 reported cases of death from ibogaine had known hypokalemia (low 
potassium) (Koenig et al., 2013; Alper 2012 ). 
Further effects on the brain 
Prior to the above study, Maas & Strubelt (2006) reviewed eight cases of 
death attributed to ibogaine ingestion, investigating toxicology reports and 
emergency department data including records of their attempts to reverse 
arrhythmia prior to death. They ‘hypothesized’ through literature searches 
and discussions with ibogaine treatment providers that ibogaine deregulated 
the autonomic nervous system by influencing neurotransmitter systems and 
the fastigial nucleus. They concluded that arrhythmia is more likely if there 
is also sympathetic (nervous system) stimulation, e.g. a fright, or a 
coincidence of parasympathetic tones and a left-sided sympathetic 
stimulation (in the brain). This coincidence could occur in circumstances of 
patient fatigue and high vagal tones (emotion-induced, fast heart rate). 
Despite being referenced by literature (Galea et al., 2011) as definitive 
proof that ibogaine is medically dangerous, the actual article referred to 
ways in which ancient Gabonian and Bwiti tribal practices mitigated these 
risks by using patient isolation and ‘trance-like states’ to promote rest 
before ibogaine use (Maas & Strubelt, 2006). 
Mortality 
With ibogaine clinics throughout the world, there is available human data, 
but access to sensitive data, such as cases of death, requires permission 
from each centre involved. One recent study (Alper et al., 2012) had access 
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to multiple, world-wide clinics through relationships already established by 
the authors. The study medically examined 19 cases of death attributed to 
ibogaine ingestion, as stated on death certificates, between 1990 and 2008. 
The subjects ranged in age from 24 to 54 years. Twelve of the 19 had pre-
existing medical complications, mostly cardiovascular but also brain 
neoplasm and liver disease. Fourteen of 19 cases (where toxicology reports 
are available) had comorbid drug use, mostly alcohol and stimulants. Four 
subjects used ibogaine for detoxification of cocaine. It appears where there 
is adequate toxicology and medical reports available, there exists some 
medical or other drug use comorbidity (Alper et al., 2012). The paper 
naturally concludes the importance of protective medical testing before 
ibogaine use. In direct contrast, the same lead author along with other 
medical practitioners, reports at a toxicology conference on the case of an 
otherwise healthy, 63yrs male, who had five-day prolongation of the QTc 
interval, and arrhythmia resistant to medical intervention post-ibogaine 
treatment. The subject had healthy ECG results prior to treatment, and was 
cleared to use ibogaine at an established treatment centre. The authors 
concluded cardiac arrhythmia can occur following ibogaine treatment 
despite medical and blood screening tests (Shawn et al., 2012). 
New Zealand perspective 
In New Zealand, although ibogaine is an unauthorized prescription (off-
license) medication, Galea et al (2011) concluded in a letter to the editor for 
a widely-distributed medical magazine that with the above evidence of 
prolongation of ECG and QTc intervals, prescribers in New Zealand 
“should be cautious in promoting or prescribing ibogaine as a treatment 
option” (pp87). They endorsed this with an agreement to this prescribing 
caution by the NZ Drug Foundation, a non-government organization 
promoting drug education in NZ. 
In 2013, New Zealand had its first fatality of an ibogaine user under 
prescription from a medical practitioner (Stewart, 2015). The 45 year old 
patient died of suspected cardiac arrhythmia two days after ingesting 1.5 
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grams of ibogaine as treatment for heroin addiction.  She had received 
medical screening, including an ECG, prior to treatment. The medical 
council's findings concluded there was insufficient aftercare/medical 
monitoring, and the patient had not been advised of the medical risks 
(Stewart, 2015). Neither the council nor the newspapers reported that this 
same patient had previously been excluded from another New Zealand 
ibogaine treatment facility, for concurrent drug use and not being 'ready for 
treatment’, raising the question of whether a true alcohol and drug 
assessment was achieved (Paterson, 2015). This case is still awaiting the 
coroner's report at time of writing. 
 
Statement 3: Conclusion 
In conclusion of this argument, there is sufficient medical and human 
evidence that ibogaine and its metabolites, at doses used for addiction 
treatment, can interrupt cardiac centres in the brain, causing cardiac 
arrhythmia, and if not medically treated, can lead to death (Koenig et al., 
2013,Glue et al., 2016, Zhang & Cuevas 2001). This appears to be the case 
despite pre-treatment medical screening tests (Alper et al., 2012). However 
medical screening prior to ibogaine treatment does appear to reduce this risk 
by advising against ibogaine treatment when people present with co-morbid 
medical and addiction conditions (Alper et al., 2012). Conditions that also 
effect the cardiac QTc wave prolongation are believed to be at higher risk of 
developing arrhythmia, from ibogaine treatment including other psychiatric 
medications and drug use (Alper et al., 2012). The inhibition effect of 
ibogaine and its metabolites directly on HeRG ion channels in the cerebral 
cardiac tissue are present at therapeutic/treatment doses of ibogaine and 
effect cardiac QTc prolongation which can lead to arrhythmias and death 
(Koenig et al., 2013). However, this effect was potentiated by hypokalaemia 
(low cerebral magnesium) which was involved with one case of death, and 
this can be screened and potentially protected from (Koenig et al., 2013). 
Outside of HeRG channels there are other autonomic dysfunction raised 
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with ibogaine use which can cause heart arrythymia (Mass & Strubelt 
2006). However, Noller et al (2017) made the important point in that the 
number of deaths associated with ibogaine use, was less than the mortality 
rate of people with opioid dependence whilst in opioid substitution 
treatment programmes. Which of course is far less than people with opioid 
dependence not in opioid substitution treatment. 
Statement 4: Ibogaine use for detoxification of 
opioids is safest and most effective 
within medically-supported treatment 
centres. 
Introduction 
1. Ibogaine use for detoxification of opioids is safest and most 
effective within medically-supported treatment centres (Alper, 
Lotsof, & Kaplan, 2008; Harrison, Mojeiko, & Jerome, 2009).  It 
should be noted that much of the available accounts of ibogaine 
treatment comprises case study reports, personal accounts and data 
from ibogaine treatment providers. However ibogaine treatment 
providers have released data which, though it may have a bias in 
favour of their own centre/service, still provides accounts and 
follow-up data for individuals who have not been successful in 
treating their addiction by other means. Treatment providers have 
generally been influenced by or directly follow the ‘Manual for 
Ibogaine Therapy’ prepared by Howard Lotsof (Lotsof & Wachtel, 
2002), in consultation with experienced, operating ibogaine 
treatment centres. Within it are chapters dedicated to the need for 
‘therapy’ to coincide with treatment.  Ibogaine treatment centres 
need to perform pre-treatment medical testing, rigorous through-
treatment monitoring, and be ready to medically intervene (Alper, 
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2014). Case studies of ibogaine users from around the world suggest 
there are improved treatment outcomes, including abstinent rates, 
when additional psychological support is provided (Harrison, 
Mojeiko, & Jerome, 2009).    
The evolution of ibogaine treatment 
Launching the argument for ibogaine therapy to be administered in 
conjunction with medical and emotional support, is Lotsof and Alexandra 
(2001) who present qualitative reports of ibogaine use in opioid-dependent 
people, in a variety of treatment settings. Following their discussions with 
people who have used ibogaine, they determined that having a ‘guide’ or 
someone trustworthy to talk through personal issues with, before, during 
and after treatment provided better drug abstinence reports. They found 
most ibogaine providers fall into one of three categories: self-help 
organisations; drug-using peer groups; and medically-supported clinics in 
countries where ibogaine is legal. As with case study methodology, people's 
experiences were captured and briefly summarised. They were all notably 
similar, describing a three-stage, 24-36 hour process from consumption of 
ibogaine. Firstly, patients often experienced nausea and vomiting, then for 
about four hours, subjects felt the greatest intensity of the experience and 
visualised dreams with their eyes closed. Dream material was as varied as 
sleeping dreams, and interestingly, the experience was interrupted if 
subjects opened their eyes. The next 8-20 hour phase consisted of cognitive 
evaluation, often involving memories and contemplation of past traumatic 
experiences or important personal relationships. Kamlet and Alper (2010) 
described this cognitive phase as clients described it: “the working-it-out 
phase”. Most subjects stated they made important life decisions in this 
phase. The third phase is the ‘residual’ effects period and can last up to 
another 36 hours in some cases. This involved lasting euphoria for some, 
determination and resolve in others, most reported an increase in self-
efficacy or self-belief that they could achieve drug abstinence. Most 
reported an improvement in overall mood. The sample presented included 
subjects that ibogaine did not work for: reasons given included further life 
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events; partners still using; nil profound effects of treatment; and residual, 
non-resolved withdrawal symptoms. The report asserted the effectiveness of 
ibogaine, citing the majority of users rated ibogaine treatment as the most 
beneficial among detailed histories of other attempted addiction treatments. 
Case studies were presented over a year since treatment began, and 
considered successful where drug abstinence and non drug-seeking 
behaviours were maintained. Some cases used up to three sessions with 
ibogaine. The case studies and excerpts highlighted the importance of 
having therapy. “..as I treated other addicts, I realized that in order to stay 
clean, most people need some kind of therapy… and to provide aftercare” 
(Lotsof & Alexander, 2001, p. 8). One may argue the evidence in support of 
psychotherapy as an adjunct to ibogaine drug therapy is solely through 
qualitative case study analysis.  
Support and discussion around treatment 
The theme was continued in a retrospective study on patients who used 
ibogaine for drug dependence in a Brazilian treatment centre, which used a 
combined approach of ibogaine and psychotherapy. Here the centre 
routinely offered and encouraged psychotherapy before and after treatment, 
and provided support and follow-up. The study measured 75 patients who 
had ibogaine treatment variously for poly-drug dependence, heroin, and 
alcohol dependence. 72% recorded drug abstinence one year following 
treatment, with the study concluding that psychotherapy was a contributing 
factor to success rates, though to what extent was unmeasurable by this 
study design (Schenberg, de Castro Comis, Chaves, & da Silveira, 2014). 
Of interest and perhaps one of the few studies to report the use of multiple 
doses of ibogaine.. These authors commented that multiple doses of 
ibogaine seemed to lead to longer abstincee rates, from 5.5 months for 
single dose compared to 8.4 months for multiple. 
In Hittner and Quello's (2004) data analysis they concluded many ibogaine 
studies referenced the ‘psychological’ impact of the drug. There seemed to 
be value in having psychological support, whether in a formal clinical 
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setting or with a friend at the beach. They went so far as to recommend 
‘potential’ types of useful therapy, including ‘cue exposure therapy’ (CET), 
to enhance treatment success, at both pre-treatment and post-treatment 
stages. Their analysis found that studies used abstinence rates for 
measurement of treatment success, but there was qualitative, descriptive 
self-reported evidence that psychological support improved patient 
outcomes, even if some returned to some form of drug use. 
Interwoven effects of treatment 
Harrison and Mojeiko (2010) embarked on an observation study of over 30 
case studies of drug-dependent clients using ibogaine and ‘associated 
therapies’, including psychology and counselling services, at the Ibogaine 
Association treatment facility in Mexico. They attempted to provide 
evidence of longer-term effectiveness with a one-year follow-up interview 
to record current drug-use with voluntary drug screens. The report does not 
establish why the Ibogaine Association include psychological intervention 
in their treatment protocol, just described what the overall 5-day ibogaine 
therapy entails. Thus, the evidence, which does support the long-term 
effectiveness of ibogaine therapy, is clouded by what aspects of the therapy 
had the effect – the drug ibogaine, the counselling, or a combination of 
both. The report did not call for control studies but rather drew on evidence 
for hallucinogen-enhanced psychotherapy in other mental health disorders 
(Strassman, 1995) to support the likely notion that it was the combination of 
both. Baastiaans (2004) also achieved a year-long, follow-up study on 21 
individuals who used ibogaine in various non-medical centres in Holland, 
though interestingly most of the clients were from the USA. This study 
concluded 67% made significant changes, maintained at one year, on the 
primary and/or secondary drug they wanted to change, mainly heroin. The 
study design again was to measure drug use, abstinence and current health 
status, compared to measurements taken before treatment. Respondents 
reported better medical health, but also better psychological health, with 
improved depression and anxiety states (although these were not formally 
measured in the study). The study did not report respondents mentioning 
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their support person during treatment, but they did mention the ‘work’ they 
still had to do, to maintain their changes. The non-medical treatment centres 
approached for respondents were not described in full, but operated by 
‘experienced’ alcohol and drug workers. 
Statement 4: Conclusion 
In conclusion, there has evolved and been maintained, a well- developed 
manual that includes reference including medical screening and testing, 
various forms of psychological therapy and follow-up support and advice, 
that goes alongside pretreatment medical screening and testing and  
ibogaine treatment in most established treatment centres. With the evidence 
from statement three around cardiac safety of ibogaine, it is fairly 
conclusive that ibogaine treatment is ‘safest’ with full medical support. 
Psychological  interventions, especially around managing cravings of other 
drugs (Kamlet & Alper, 2010), appear woven throughout the case studies 
and other data. Most cases of independent use of ibogaine, alone and 
without any support, rarely get captured in the literature, except for talk 
forums on internet sites, where there is unsubstantiated claims of 
independent use. Talking therapy and discussion of drug-use issues appears 
widely supported and has some limited evidence of effectiveness, especially 
when exploring individual case studies and testimonials. This appears to be 
in-line with reports of other forms of hallucinogenic drug treatments, such 
as with LSD, which utilise the drug as an enhancement to psychotherapy 
sessions (Strassman, 1995). This is perhaps the reverse of ibogaine, where 
the pharmacodynamics of the drug and its long-acting metabolites are the 
focus of the literature, not the seemingly peripheral psychotherapy.  Albeit, 
there are no double-blind control studies available on drug therapy verse 
drug therapy with psychotherapy, there are indications that ibogaine 
treatment is safest and most effective when provided through a medical 
centre with psycho-social components. 
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Statement 5: Opioid-dependent people are 
motivated to 




A systematic search of medical and therapy data bases through Proquest, 
Ovid, Embase and many more, and a search of unpublished material, turned 
up no results on people’s ‘motivations’ to use ibogaine as a 
dependency treatment. A wider search for studies on people’s motivations 
for using any hallucinogenic treatment also provided few results. Database 
searches on ‘negative’ experiences with current addiction treatments and 
barriers to access, were also explored, along with success rates of current 
treatments. Lastly, current data discussing ibogaine case studies is reviewed 
again, with regard to individual comments about why participants chose 
ibogaine treatment – even though this may not have been the article's point 
of discussion. 
Current trends of use 
The literature searched contains just one article that mention ibogaine use is 
continuing and even increasing as a treatment option for dependence, from 
anecdotal reports (Alper & Glick, 2001). There are no specific studies 
undertaken to determine and verify if ibogaine use is increasing. There are 
no specific studies anywhere internationally about current ibogaine use in 
any populations. Numbers of total treated, world-wide, have been estimated 
at 5000 since the 1990s (Alper et al., 2008), but this estimate was obtained 
only from known established treatment centres and the authors themselves 
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mentioned that  there is an unknown number who have used ibogaine 
independently or through unknown, word-of-mouth, treatment providers. 
Studies on motivations to use ibogaine 
To determine if ibogaine therapy is likely to continue the literature was re-
investigated, with an eye to finding what motivates addicts to specifically 
seek ibogaine treatment. The search resulted in no studies, or even findings, 
of what motivates people to choose ibogaine. 
Wider categories were searched including motivations for hallucinogenic 
treatment in general. Only one article was found that explored the concept 
of ‘redemption’, a spiritual motivation for the use of hallucinogens in 
treating addiction (de Rios, Grob, & Baker, 2002). Here the authors 
explored the historical use of hallucinogens to treat addiction by the Native 
American Church and the UDV Church in Brazil, both of which used 
Peyote and Ayahuasca, as far back as 200 years ago; up to the current use of 
ibogaine and LSD for the medical treatment of dependence. The article 
concluded there was a spiritual component to hallucinogenic treatment, and 
that people were driven from their addiction by a religious-type 
‘redemption’. They indirectly inferred the same motivation existed for 
people currently seeking treatment, but within a medical context, and 
named ‘medical redemption’. 
Barriers to mainstream treatments 
To further explore people's motivations for alternative addiction treatments, 
the literature was searched for barriers to current mainstream treatments. 
Deering et al (2011) explored barriers to opioid substitution treatment 
(OST) in New Zealand, where there is a population of 10,000 opioid 
dependents, with just under 5000 of those in OST. Two surveys were 
conducted, on both methadone clinic clients and methadone clinic staff and 
four main areas were identified as barriers to OST: waiting times (to 
commence OST treatment); a lack of flexibility in the program; poor 
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treatment by staff; and a regime of impractical take-away doses. 
Interestingly, the effectiveness of the drug methadone, compared to that of 
other opioids, was not amongst the main areas of concern; but methadone 
being the only available substitution drug was rated as the 5th-highest 
barrier. 
Barriers and motivations for methadone treatment in the USA were 
reviewed by Koester, Anderson & Hoffer (1999).  Where in a qualitative 
study, heroin-dependent persons were interviewed and directly asked what 
their motivations  for OST were when they entered programs. Abstinence 
and major drug use changes were not always the desired goals for 
respondents. The main theme seemed to be wanting a ‘time out’ from 
their addiction, usually with a short time period in mind and often with the 
intention of returning to drug use when they could better afford it or were in 
a better living situation. ‘Managing a drug habit’ appeared to be the 
other main motivator for OST treatment - a last resort to avoid prison or 
drug debts, and again with a focus to returning to drug use if ‘out of 
trouble’. Some used their first episode on methadone therapy to ‘try the 
waters’, to see if worked for them. The study recommended a wider 
tolerance of methadone therapy being used for reasons other than solely 
achieving abstinence, and different methods of measuring successful 
treatment, as patients’ goals often appeared to be risk management, not 
always abstinence. A Chinese study on barriers to OST by Lin, Wu and 
Detels (2011) found, unsurprisingly, that registration with local police 
authorities and public discrimination are the two biggest obstacles to people 
who want treatment. In Vietnam, where a methadone maintenance program 
was recently adopted, the main obstacles to treatment are the sparsity of 
clinics and available chemists, meaning long, inconvenient travel times for 
those seeking help (Nguyen, 2012). A final barrier to treatment may be 
willingness to enter a longer  term residential treatment such as Therapeutic 
Communities with demonstrated efficacy in the treatment of opioid 
dependence, particularly individuals with families and who are employed 
(Deering et al., 2004;  Sheridan et al., 2008). 
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Pharmacological effects deterring people from mainstream 
treatment 
Aside from the stigma and logistics of entering methadone programs, there 
are also the negative  effects of long-term opioid use that appear throughout 
the literature. These range from cardiac QTc prolongation (Mohamad et al., 
2013), to chronic constipation (Yuan et al., 2000) and some negative effects 
on the immune system (Neri et al., 2005). Clients can overdose while in 
substitution treatment, but incidence of this decreased the longer clients 
were in methadone therapy. Emergency department records were examined 
and revealed 57% of non-fatal opioid overdoes were unintentional and 40% 
were suicide attempts, perhaps linked back to lower mood scores associated 
with opioid use (Pfab, Eyer, Jetzinger, & Zilker, 2006;  Deering et al., 
2004). Other mortalities related to chronic opioid use were measured 
assessing the medical records of 43,000 Canadians, and showed a 17 times 
higher mortality rate for chronic opioid users (Leece et al., 2015). The 
authors found double the mortality rate amongst opioid substitution patients 
who were concurrently taking anti-psychotics and/or benzodiazepines. Lung 
disease, cardiac events and alcohol-related disorders featured as the most 
common causes of death for long-term opioid users. Sexual dysfunction in 
males on methadone therapy featured in the literature.  One study measured 
prolactin levels in clients' plasma, and found much higher levels in, firstly 
heroin users and secondly methadone users, with correlated results of sexual 
non-performance in affected clients (Trajanovska, Vujovic, Ignjatova, 
Janicevic-Ivanovska, & Cibisev, 2013). Another Canadian study found 
employment difficulties seemed to arise for people who chose methadone 
therapy over those who chose non-substitution treatments. This is 
interesting when many methadone programs use employment as a marker of 
successful treatment (Richardson, Wood, Montaner, & Kerr, 2012). 
Matched treatment styles to patients 
A Turkish study used a mixed method, but still a controlled study design, to 
explore if higher motivation for treatment correlates with better treatment 
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outcomes. They found the group rated as highly motivated for treatment 
achieved ‘significantly better treatment results’ than the group who were 
rated as having low motivation. The study concluded that using 
motivational interviewing techniques encouraged better patient outcomes 
for any treatments offered (Bilici, Tufan, Ugurlu, Tan, & Tuyluoglu, 2011). 
However, the study did not state what the various motivators for people 
were. Exploring the question, 'what motivates people for addiction 
treatment?', opens up a very broad subject that could support a literature 
review of its own. In brief, motivations for addiction treatment generally 
range from ‘threat of firing squad’ (death) in Northern Thailand (German et 
al., 2006) to social discrimination in Vietnam (Nguyen, 2012), from the 
threat of AIDS and HIV (Koester et al., 1999), to the many social, physical 
and mental effects of addiction (Adamson & Sellman, 1998; Deering et al., 
2004). A few articles argued some so-called motivations for AOD treatment 
are in fact threats, such as threat of incarceration or children being removed.  
This may encourage a 'play the game’ or ‘go through the motions’ mind-set 
towards seeking treatment where the goal as to avoid punishment, rather 
than make significant changes. Worse still, these 'motivators' may deter 
people from seeking treatment at all (Simpson, 2002). However interesting, 
Simpson's article was a speculative discussion article with no specific data 
to support the claim. 
Other Motivations 
In relation to opioid dependence and New Zealand one study collected 
information about other motivations for people seeking treatment of opioid 
dependence. As well as seeking treatment to reduce drug use (84%), 75% of 
participants had sought treatment to improve their general health, 73% for 
family/children- related reasons, 69% to reduce contact with undesirable 
associates, 68% for debt or financial reasons, 65%to reduce involvement in 
crime and 33% for employment-related reasons (Deering et al., 2004). The 
study comments that females appeared more strongly motivated to make 
changes for family and children than men. The success rate of OST is well-
documented and thus, still remains the standard treatment for opioid 
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dependence (Deering, Sellman, Adamson, 2014). It appears this is the most 
likely motivator for seeking this treatment, the success of it. Even if that 
success is only measured by the client. With the many peer reports available 
on the internet of ibogaine's success, this could be argued as a possible 
motivator for ibogaine treatment. 
As discussed with hallucinogen treatments for addiction, there were themes 
of people with addiction wanting and seeking some spiritual resolve for 
issues related to their drug use (Oram, 2012). This theme was not directly 
captured through articles related to ibogaine. 
  
Exploration of other case studies 
Lastly, ibogaine case studies were re-examined and people's statements 
sifted for themes as to why they chose ibogaine. This was far from 
conclusive as it was not the original study's purpose, however, in Lotsof's 
(2001) case study report of 16 individuals, there was twice mention of 
‘failed’ rehabilitation or treatment and twice mention of restrictions to their 
current OST. Other case studies did not publish interview transcripts. 
Statement 5: Conclusion 
In conclusion, there was no current literature on exactly what motivates 
people to choose ibogaine for opioid dependence treatment, though there 
are certainly recurrent themes. Firstly, there are barriers, restrictions, risk of 
potential exposure and some negative health related aspects associated with 
chronic opioid substitution treatment.  From specific case studies on 
ibogaine use there was mention by two people of  having tried, and been 
disappointed by, mainstream treatments. OST may still be the best and most 
effective treatment available, but it is reasonable to infer a willingness, on 
the part of users, to try something different. Secondly, the perceived success 
of a treatment may attract people wanting to make changes. Ibogaine's 
~ 44 ~ 
success, though mostly anecdotal, is very attractive, especially given that it 
is a one-off treatment, sometimes described by users as having an epiphany 
producing, almost 'miracle' effect. 
Ultimately, people are motivated to seek addiction treatment for a variety of 
reasons. From the available literature, it was not possible to conclude 
whether ibogaine use is likely to continue in New Zealand. However many 
of the themes that potentially motivate people to seek alternative treatments 
are present in New Zealand's opioid-dependent population. 
Summary of literature review 
Opioid over-use, dependence and overdoses remain significant health 
concerns for New Zealand (Ministry Of Health, 2009). There is limited 
neurological research knowledge on the pharmacodynamics of ibogaine.  Its 
anti-addictive properties have been explored using mainly rodent brain 
studies to determine how the drug and its metabolites affected opioid and 
serotonin systems. One influence appears to be with Glial cell line-derived 
neurotropic factor (GDNF) expression into the VTA, interrupting the 
complex dopaminergic pathways in the nuclease acuminous and the VTA 
areas of the  brain (Mash et al., 1998: He et al 2005). A system known to 
help reinforce drug use (Glick, Maisonneuve & Pearl, 1997). The results 
were a near 80% reduction in observable opioid withdrawal symptoms in 
opioid-dependent rats. Many human case studies and open label trials have 
reported the reduction in opioid withdrawal and cravings-to-use for an 
extended time of up to three months. Reports of a better sense of well-being 
or mood was also reported for 4-12 weeks after ibogaine treatment (Alper, 
2001: Mash et al 2001). More cardiac studies have taken place recently, in 
light of deaths around the world associated with ibogaine treatment and it is 
clear ibogaine and its metabolites at doses used for addiction treatment, 
cause and effect prolongation of the QTc cardiac interval leading to cardiac 
arrhythmia and possible death (Koenig et al., 2013).  This has occurred in 
isolation of any other co-morbidities or conditions which could be 
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medically screened for (Vlaanderen et al., 2014; Zhang & Cuevas, 2002; 
Mass & Strubelt, 2006; Apler et al., 2014 ). However, there is some clinical 
evidence that cardiac risks can be medically mitigated through rigorous 
medical history assessments, monitoring current alcohol and drug use, 
medical observation and possible intervention, during the three days of 
ibogaine treatment (Kamlet & Alper, 2010; Alper et al., 2014). This lends 
much support to the need for ibogaine to be medically supported and 
operated. Throughout the literature was the theme found through 
Qualitative research highlighted a role for psycho-social interventions and 
support and this was incorporated in a Ibogaine Treatment Manual (Lotsof 
& Alexander, 2001; Harrison et al, 2009). It was unclear, through lack of 
investigation, exactly what motivated people to try ibogaine treatment, 
except for perhaps an indication of frustration and failure with conventional 
treatments, and an attraction to the possible one-off, 'spiritual' healing with 
hallucinogenic treatments like ibogaine (Lotsof & Alexander, 2001; Oram, 
2012). In summary, it appears ibogaine was an effective treatment option 
for some people who are opioid-dependent, and was safest when medically 
supported to reduce cardiac risk (Alper et al., 2012).  
  




Chapter 3 explains the rationale behind why both qualitative and case study 
research have been selected as methodologies for this thesis. It also 
describes how the research was conducted and the parameters of the study. 
The research question and purpose are first defined, explaining that the 
nature of the phenomenon of ibogaine use is awash in social, political and 
personal influences. For the purposes of this thesis, and chapter, 
methodology is explained as identifying and defending the epistemology, or 
philosophical views on how, or even if it is possible, to obtain objective 
knowledge about the world (Travers (2001, p. 9). These various 
philosophies are explained, along with why a qualitative case study 
approach was undertaken. The method of the conducted study is also been 
outlined. 
Research topic, question and goals 
The nature and extent of ibogaine use in New Zealand is, as identified in the 
literature, intertwined with New Zealand’s prescribed and non-prescribed 
opioid problem. This opioid-dependent population, within New Zealand and 
around the world, arrived in their position through a range of social, genetic, 
political, medical, family and personal experiences (Sutherland et al., 2015). 
Throughout the literature it is also clear that ibogaine, as a treatment for 
opioid dependence, has experienced many political, funding, ethical/moral 
and perhaps most pertinent of all, safety barriers, influencing the current 
status of ibogaine treatment in New Zealand and worldwide. 
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In New Zealand, ibogaine is available to consumers through a self-funded 
medical prescription. The research began over a clinical issue at an opioid 
substitution service in the South Island, New Zealand. Two clients 
prescribed methadone chose to utilise ibogaine detoxification. One did not 
disclose until afterwards that they had had a negative experience, and the 
other approached the opioid substitution treatment [OST] service for 
support (travel arrangements mostly) and was declined. That client used 
ibogaine regardless and reported a positive experience. The decision not to 
support was based on emergency department case study reports of death 
attributed to the use of ibogaine. There appears to be mixed messages in the 
available literature, especially for consumers, with some medical trials 
supporting the effectiveness of ibogaine treatment, and some medical 
articles stating there are major cardiac safety concerns. Ibogaine is available 
as a treatment option in New Zealand, but the individual journeys of 
ibogaine users, what they encountered, and how and what they knew about 
the treatment beforehand, are not currently known. 
Research question 
This led to the question, not answered in current literature, and relevant for 
New Zealand prescribers. AOD and other practitioners and opioid 
dependent people and their families: 
‘What are the experiences and motivations of opioid-dependent people 
using ibogaine?’ With the sub question, ‘What safety measures and medical 
tests were ibogaine users aware of and which were utilised?’ 
The answer lies beneath complex social, political, medical and personal 
constructs and the interactions between them. The nature of these 
interactions between political and social influences has historically been 
best examined through qualitative, case study research (Swanborn, 2010, p. 
11). 
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The purpose of this study therefore, was to explore the experiences and 
practices of opioid-dependent individuals who have used ibogaine as an 
intervention for opioid dependence. Including individual motivations for the 
treatment, their understanding of potential health risks, utilisation of pre-
treatment health checks, and the effects of ibogaine treatment in relation to 
any subsequent opioid use. 
Areas explored in the literature have been around the significant health 
concern of opioid dependence in New Zealand, and the influence political 
and historical factors have had on the nature of drug use. The anti-addictive 
qualities of ibogaine have been scientifically explored and although results 
around detoxification of opioid dependence have been promising, they are 
limited by the nature of ibogaine use itself. Given its psychedelic nature and 
the fact that it is illegal in many countries, most attempts to substantiate 
anti-addictive reports through multiple, repeatable, peer reviewed, human 
clinical trials have been thwarted. Recent (past 10 years) reported fatalities 
involving ibogaine use in sub-medical centres, further decreased available 
funds, interest and research on ibogaine as an opioid detoxification 
treatment. However the literature clearly shows that ibogaine use continues 
worldwide and identifies on-going motivators for why opioid-dependent 
people choose this alternative treatment.   
One consideration noted in the literature is that the opioid-dependent 
population are a high-risk, vulnerable group. They inhabit a unique, 
established sub-culture within the drug-using culture of New Zealand, and 
they are over-represented in health-related harms (Moshier et al., 2012). In 
interviewing this high-risk group, and as recommended by Moshier et al. 
(2012), a specific cultural approach employing empathy and understanding 
was essential, combined with clinical drug and alcohol treatment expertise.  
To minimise the impact of research on this vulnerable population, the study 
paradigm and data collection methods needed to be fully considered. 
Existing literature related to alcohol and drug research, especially 
politically-contested alcohol and drug treatments, mostly used qualitative 
research methodologies (George & Bennett, 2005). Qualitative research 
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paradigms incorporate, allow and utilise the relationship between the 
researcher and the subject being studied. It is through this relationship that 
an understanding of wider inter-related social influences of the phenomenon 
are obtained (Yin, 2009). Therefore, a qualitative approach was decided 
upon for the purpose of this study. 
Research paradigm 
A paradigm is defined as a set of components that make up research: 
ontology, epistemology, methodology, and the method (Scotland, 2012). 
The four main paradigms are positivism, post-positivism, interpretive and 
critical. 
The purpose of choosing the correct paradigm is to obtain the most useful 
collection of data and interpret it meaningfully to answer a question. 
“Questions of method are secondary to questions of paradigm, which we 
define as the basic belief system or worldwide view that guides the 
investigator, not only in choices of method but in ontologically and 
epistemologically fundamental ways.” (Guba & Lincoln, 1994, p. 105).  
Ontology is the study of the very nature and structure of knowledge and 
defining what is existence. Epistemology looks at the relationship and 
factors between knowledge and subjective interpretation (Bloomberg & 
Volpe, 2012), as well as the nature of knowledge and how it was formed 
(Scotland, 2012). Ontology and epistemology each have their own 
philosophical backgrounds and viewpoints. The ontological viewpoint of 
positivism is that of realism, where an event exists with or without the 
researcher/observer present (Scotland, 2012). The ontological stance of 
interpretive paradigms is that of relativism. A relativism fundamental is that 
reality is subjective and different from person to person (Guba & Lincoln, 
1994). 
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The debate between quantitative and qualitative research paradigms appears 
to agree, in most recent literature, that each has an ability to answer a 
scientific question (Newman & Benz, 1998). “...we present them as 
interactive places on a methodological and philosophical continuum based 
on the philosophy of science. A researcher tests a Theory and as results 
feed-back to the original hypothesis, both inductive and deductive processes 
are operational at different points in time.”(Newman & Benz, 1998, p. xi) 
Quantitative studies often use a realist ontology (positivism) (Creswell, 
2013). The researcher is viewed as another partial instrument in a 
replicable, often-repeated experiment. It produces numbers and statistics, 
and the epistemology is that of objective observer (Creswell, 2013). 
However trialling hallucinogens requires greater human intervention and 
interpretation, including a complex understanding of individual test 
subjects. This information is more often gathered using other paradigms 
(Gillham, 2000). Attempts to examine ibogaine with a purely quantitative 
approach run into contamination from factors such as human discussion and 
support which cannot be easily quantified (Harrison & Mojeiko, 2010) 
Qualitative research 
Qualitative studies generally take the ontological position of relativity 
(Scotland, 2012). Qualitative research involves a mostly interpretive 
naturalistic approach to events in the world. “...researchers study things in 
their natural settings, attempting to make sense of, or to interpret, 
phenomena in terms of the meaning to people (Denzin & Lincoln, 2005, p. 
3). A naturalistic inquiry approach is defined by Salkind (2010) as a way of 
“understanding the social world in which the researcher observes, 
describes, and interprets the experiences and actions of specific people and 
groups in societal and cultural context”(pp 2). A naturalistic inquiry 
approach comes under and would describe the epistemology of a study. 
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The personal nature of addiction, opioid dependence and ibogaine treatment 
means each individual studied may have a different experience and a 
different interpretation of that experience. While there are definite, 
measureable objective signs and symptoms that are common for each event, 
one person's treatment success could be another person's failure, relative to 
the desired result. For example, if achieving a sense of well-being were the 
goal, it may not necessarily be achieved by simply becoming drug-free. 
Historically, research on hallucinogenic pharmaceuticals has been mostly 
qualitative, capturing people’s experiences and how it affects their disease 
(Strassman, 1995).   
Research methodology 
In reviewing quantitative and qualitative paradigms against the context of 
ibogaine use, addiction and other psychological factors relating to treatment 
success, a qualitative study approach was selected for this paper.  
Related to health, Yin (2004) revealed two qualitative case studies that 
provided data for both the establishment of a New York methadone 
programme in the 1960s, and the largest immunisation programme in U.S 
history, against swine flu. Both studies were critiqued and determined to 
have used the best methodological approach through qualitative case studies 
due to the cultural context around the two populations (New York heroin 
users, and in the swine flu case, the few deaths were localised at a U.S. 
army base during a cold winter). The first study needed to understand the 
motivations and needs of its high-risk population; the second study required 
more information, related to personal contacts and symptoms, than standard 
army medical data records could provide. Indeed George and Bennett 
(2005) stated in their book of case studies in the social sciences, that while 
over half of the political research studies in the developed world since the 
1980s have used statistical analysis,  most of the remainder used the case 
study research approach 
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Gillham (2000) states that this qualitative, case study style “gets under the 
skin of a group and explores complexities in human behaviour which are 
beyond the scope of controlled experiments” (p.11). More specifically in 
relation to case study research design and methods, Yin (2009, p. 9) states 
that utilisation of this method within a naturalistic philosophy will assist "... 
to illuminate decisions, why they were taken, how they were implemented 
and with what?" 
To answer why people used ibogaine, the study needed respondents to fully 
explain previous drug use and related harms. The study also required 
explanation of why previous conventional treatments did not suit them. 
These were sensitive topics that entailed previous trauma and feelings of 
failure, and yet shaped the decision process for people. Their important 
stories and histories require context, as each choice is often shaped by 
political and social influences related to the field of addiction. That is, a 
person’s opioid substitution treatment can be deemed unsuccessful by the 
client if the culture of the treatment service is viewed as punitive and 
restrictive to lifestyle; whereas the OST service may view the absence of 
other opioid drugs as treatment success. These complexities and 
interconnections between addiction and social politics appear best captured 
with a case study research approach. The epistemology and philosophies 
best fitted to examine a social, cultural and personal interactions is a 
naturalistic inquiry approach. Naturalistic inquiry interprets the experiences 
of people in societal and cultural context (Salkind, 2010). 
Therefore, a qualitative case study, using a naturalistic interpretive 
approach, has been selected to attempt to answer this paper's question: 
‘What are the experiences of opioid-dependent people using ibogaine’. 
Case studies can be defined very differently amongst the many experts on 
the subject. This thesis will use Robert Yin’s (2009) definition: “..an 
empirical enquiry about a contemporary phenomenon (eg: a case) set 
within the real world context, especially when the boundaries between the 
phenomenon and context are not clearly evident.” (p. 18). Yin (2009) 
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further explains that it’s the ideal methodology to examine the complex 
relationships between many influences and factors in relation to people’s 
decisions and actions. 
History of case study research 
Case studies, as a means to gain and share a deeper understanding of an 
event or phenomenon within that case, appear to have evolved alongside the 
social sciences. At the turn of the century, Sigmund Freud used case studies 
to teach students and himself about social behaviours (Swanborn, 2010). 
Law, perhaps as far back as ancient Greece, used case studies of legal 
outcomes as benchmarks for future cases (George & Bennett, 2005). As a 
research method, with its own scientific validity, it appears to have been 
born mid-20th century through sociology, with published case studies: The 
Taxi Dance Hall (Cressy, 1932) and Street Corner Society (as cited by; 
Swanborn, 2010, p. 11). Early and frequent criticism of ‘case study’ 
research was that results were not applicable to the wider population, or 
generalisations could not be made because of the ‘small sample’. The 
information was thought to be not as useful as larger (quantitative) samples 
where inference to the whole population could be drawn (Tellis, 1997). Yin 
(2004) illustrated that the world's largest and fastest immunisation 
programme (for swine flu in the USA in the 1970s), and the establishment 
of the first opioid substitution treatment in the 1960s, were both attributed 
to single case studies. Case Study research is truly evident and prominent in 
the literature from the 1980s to the present where nearly half the social 
science research in the literature involves case study methodology (George 
& Bennett, 2005). 
Interestingly, the acceptance of case studies and qualitative relative 
paradigms through the 1980s coincides with realist sciences, such as 
physics, accepting quantum physics and other theories of relativity, where 
the observer affects the outcome of the experiment (Hawking, 1996). 
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Research models of case studies 
Yin (2009) further refined case study research models, arguing they have 
four scientific applications: 
1.  To explain complex causal links in real-life interventions 
2.  To describe the real-life context in which the intervention has 
occurred 
3.  To describe the intervention itself 
4.  To explore those situations in which the intervention being 
evaluated has no clear set of outcomes. 
Explanatory, exploratory and descriptive case studies are also considered to 
be separate types of case studies. Other lead authors on case study 
methodologies include sub-categories of case studies such as intrinsic, (the 
researcher has a personal/clinical interest in the subject), instrumental 
(using a single case to explain many) and collective (groups of cases are 
examined), (Stake, 1995, as cited in Tellis, 1997). There are many other 
descriptors and subtypes of case studies by various authors on case studies 
and they vary across the different social sciences. This is another criticism 
of case study methodology:  that due to multiple and varied types of case 
study methods, studies are not replicable (Tellis, 1997). Yin (2009) 
acknowledges this perception of case study research and defends the 
position mostly through good practise. Namely, for researchers to detail 
exactly the method, the methodology and aspects to be analysed as part of 
the study. 
In reviewing Yin’s (2009) four scientific applications, it was found that they 
were applicable to three aspects of the study’s objectives: explanation of 
complex interactions; description of the treatment process; and exploration 
of motivations for use. The treatment process itself involves a long journey 
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for the client with much explanation of pharmacological and physical 
effects and much description of psychological experiences.  Case studies 
allow for the value of the subject's background and/or oral history to be 
taken into account when making overall study conclusions. Subjects have 
very different histories leading up to the point where they seek ibogaine 
treatment, and building a case file around each interviewee allows different 
opioid drugs used and combinations of drugs used, to be more fully 
interpreted.  Indeed the complexity of opioid dependence and problematic 
opioid use means, for example, negative outcomes reported by the ibogaine 
group, may not have been perceived as negative outcomes by the OST 
providers. Future researchers interpreting the reports statistically would also 
miss this nuance.  The individual case file allows for subtleties and small 
differences to be captured from other data sources such as the demographics 
and history of the participants’. Although there was personal interest from 
the researcher, the case study sub-category 'instrumental' was best fit as a 
few cases were used to explain many.  Also, multiple interviewees were 
involved, so a collective case study approach was best suited.  Other 
qualitative approaches, such as narrative analyses, were too restrictive to 
capture the complex pharmacological and political influences of the study 
subjects.  
Therefore, to clarify the paradigm and methodology chosen for this study, a 
naturalistic, qualitative, instrumental, collective case study, incorporating 
explanatory, exploratory and descriptive methods, was selected. 
Method   
Previous sections have covered the philosophies underpinning the choice of 
a case study method. This section will first lay out the advantages and 
disadvantages of case study method and look at the role of the researcher 
and the participants.  Then for purposes of transparency and replication it 
will detail the structure, framework and recommended protocols used for 
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this case study. The method section will also clarify the researcher's 
background to explain the researcher’s epistemology. 
Advantages of case study method  
Depending on the type of case study used, different authors argue different 
advantages. The common advantage with interviews and collected data is 
the ‘targeted’ information gathered, relating directly to the topic's original 
question (Tellis, 1997; Yin, 2009). The strength of data collected is related 
to case studies being able to ‘triangulate’ the data. (Tellis, 1997; George & 
Bennett, 2005). Four main types of triangulation can occur: theory 
triangulation (different investigators and view-points interpret the same 
conclusion); data source triangulation (data is the same in various contexts); 
investigator triangulation (different researchers doing ‘a’ study on the 
event); and methodological triangulation (different researchers doing the 
‘same’ study on the event), (Denzin, 1984, as cited by; Tellis, 1997). For 
the purpose of this study, it is anticipated that data will contribute to future 
‘investigator triangulation’. 
Disadvantages of case study method 
The common disadvantage throughout the literature is that of bias. 'Case 
selection bias' - choosing interviews or subjects that only support the 
researcher’s hypothesis - and 'institution bias', where respondents and 
informants choose research or people that defend a particular centre's 
practise (Tellis, 1997; George & Bennett, 2005). This is described as both 
deliberate and unintentional bias. Literature mentions interviewees’ 
eagerness to please the interviewer and give answers thought to help the 
project. Due to the very nature of case studies, there is an acknowledged 
bias in whom to examine, which can be argued as ‘targeted’ selection for a 
particular phenomenon investigated (Yin, 2009). From a statistical point of 
view, a limitation of case study information is the inherent inability to apply 
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results to broader populations (George & Bennett, 2005). This study is 
interested in the practises and experiences of ibogaine users, more than 
current estimates of use - a case study approach is not appropriate to 
extrapolate the behaviours of larger populations. To minimise the effects of 
bias on the results, an open peer review process with experienced academic 
supervisors occurred throughout the study. 
The role of the researcher and the research participant in 
case study method 
Throughout the literature on research and as reported by Yin (2009), 
perhaps the main source of data collection is interviews (although 
environmental observations and document-sourcing are also relevant). With 
interviews between two people there is a complex, psychological 
interaction. Literature around case study method indicates that interview 
experience can be more beneficial than experience with the subject matter, 
although this is of course still recommended. Experienced interviewers are 
defined by Yin (2009) as those who have received training and regular 
feedback on interviewing technique. This is crucial for avoidance of leading 
and closed questions, which sway the data. An interview protocol is 
described in the methods section, describing a set of pre-arranged and 
critiqued questions, the time and environments of interviews and the 
interviewer's level of experience. This is to identify the position of the 
interviewer and the nature of the questioning (Swanborn, 2010; Yin, 2009). 
As further discussed in the ethics part of this chapter, the interviewer is an 
experienced alcohol and drug treatment nurse with 20 years’ experience in 
the mental health field, and postgraduate qualifications in assessment. 
The role of the research participant is unique with case studies. Case study 
respondents (people eventually to be recorded) are approached first by 
informants (those known both to the respondent and researcher). A 
respondent can also be an informant, through snowballing technique, 
whereby they recruit people from within their own social circle. 
Snowballing technique also allows wider contact with people of interest, 
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such as other ibogaine treatment providers, who may then potentially 
provide further respondents (Swanborn, 2010). It has been argued that case 
study respondents may have no other motive to take part in a particular 
study, other than to respond to their peer. This is compared with other 
surveys (quantitative) and random telephone survey interviews (mixed 
method) where the respondent is agreeing because of the purpose of the 
study, and what motives they have for the study to succeed or not succeed, 
not because they know the person calling. This issue of informed consent is 
therefore an important consideration for the researcher, as he/she must be 
aware a respondent has partially agreed to the study because of their 
relationship to the informant (Travers, 2001). The criticism of this method 
of course, which concerns the statistical researchers, is sample selection 
bias. Great efforts with recruitment and snowballing allowed for a mixed 
response to this study including those for whom ibogaine had not been 
useful, and one person recruited from outside the ‘known’ Dunedin 
treatment clinic group. This was achieved through asking current 
respondents if they personally knew of other users, which lead to an 
interview with someone who had never utilised any outside assistance. 
Case study protocols 
Yin (2009), in response to the criticism of bias and undetermined structure 
to case study methods, recommended the following case study protocols 
and framework: 
1.  Design the case study protocol: 
a.  determine the required skills 
b.  develop and review the protocol 
2.  Conduct the case study: 
a.  prepare for data collection 
b.  distribute questionnaire 
c.  conduct interviews 
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3.  Analyse case study evidence: 
a.  analytic strategy 
4.  Develop conclusions:  
a.  recommendations, and implications based on the evidence 
This protocol has been selected for this study and each of the four stages of 
the protocol were peer reviewed by the researcher’s direct supervisors. 
This study interviewed ten people using ibogaine for the treatment of their 
opioid dependence. The topics explored in the interviews were: the 
individual’s motivations to use ibogaine; the user's understanding of the 
treatment risks; what if any pre-treatment health tests were completed; a 
description of the treatment setting; and the effects of ibogaine treatment on 
their opioid drug use. 
Sample and data collection 
As participants within the target population may or may not be involved 
with health services, all information was gathered directly from the 
participant. Data was not gathered from other records or patient files, as 
information sought is often not reported to health centres by users (McCoy, 
Metsch, Chitwood, Miles, 2001),  eliminating other case study research 
methods such as document and record analysis. For example, the not-for-
profit ibogaine clinic in Dunedin, mostly utilised to recruit participants, 
does not keep paper records of their clients. The study sample to be 
discussed is a small sub-group of the opioid-dependent population in New 
Zealand, defined as currently or previously opioid-dependent people who 
have used the drug ibogaine, specifically for the purpose of treating their 
dependence on opioid drugs. Ten participants comprise the study sample. 
Participants were recruited via informants at the Iboga Association 
Aotearora, one through an informant at a Christchurch OST service, and 
one in response to snowballing.  While permission was obtained to display 
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posters of the study at a local needle exchange service and an outpatient 
AOD service and Canterbury Opioid Recovery Service (CORS), no one was 
recruited via this means. 
As this form of treatment was a significant life event for an individual, there 
was no time limit on respondents, as to when their ibogaine treatment took 
place. Two participants were accepted who had treatment overseas as this is 
a current treatment option for New Zealanders. Potential participants who 
were clearly unsure as to whether their treatment was in fact ibogaine were 
excluded as were individuals who had used ibogaine for other purposes 
such as treatment of viral illness, alcohol detoxification or mental health 
disorders. One person approached the study who had used ibogaine for the 
treatment of cannabis dependence, but they were also excluded. 
Data was collected from each participant in a single interview. A brief 
questionnaire was administered to participants after the interview. This was 
to ensure standardisation of descriptive participant information. This 
included demographic information such as age group, gender, ethnicity, 
duration of opioid dependence prior to ibogaine treatment, and prior 
treatment history and opioid use following ibogaine treatment. Interviews 
were recorded, with permission, and later transcribed. As per Gillham 
(2000) interviewing brings with it many subtleties in the process, including 
different power relationships and potential interviewer bias. These potential 
data collection issues were discussed and explored with academic 
supervisors in an open, honest and transparent process. The researcher is no 
longer a clinician for opioid substitution services or addiction services 
which decreased potential power differences. 
Location of interviews 
It was proposed to respondents that the interviews could be conducted at a 
designated public location such as a café or library. Alternatively, if more 
convenient, and if the respondent agreed, then at the participant’s home. If 
in-person interviews could not be conducted, it was suggested they be 
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recorded over the phone or via social media avenues such as skype (one 
North Island respondent). Four interviews were conducted at people's 
homes (including the skype interview), two were conducted at a university, 
and four at cafes and bars. On completion of the interview, participants 
were provided with a $20 petrol voucher to acknowledge travel/time 
donated. 
Interview schedule 
The following 10 questions were designed as a standard interview schedule, 
to capture information from similar areas of interest, in the same way, with 
each case. The questions were peer reviewed prior to first interview and 
adjusted after the first interview to capture the area of previous 
hallucinogenic use, under question 1, prompt 5. 
1. Would you please tell me about your opioid use and dependence, 
as well as other drugs of use (including alcohol)? 
Prompt 1:  Age of first use and length time dependent. 
Treatments / Detoxification. 
Prompt 2:  Other drugs of use and dependence 
Prompt 3:  Approximate amounts of opioids used prior to 
ibogaine treatment 
Prompt 4:  Factors which led to wanting to make changes 
Prompt 5:  Previous hallucinogenic use and experience of 
this? 
2. Tell me about what led you to choosing ibogaine as a treatment? 
Prompt 1:  Other AOD treatments attempted 
Prompt 2:  Where did you hear/find out about ibogaine? 
3. What was your understanding of ibogaine treatment prior to using 
it. 
Prompt 1:  Any knowledge of health risks. 
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Prompt 2:  What were your expectations? 
Prompt 3:  What were your concerns? 
Prompt 4:  Any health checks (questionnaires, urine drug 
screens, electrocardiograms, blood tests, 
medications, vitamin/mineral supplements)? 
4. Tell me about the ibogaine treatment you received, the level of 
support before, during and after ibogaine treatment? 
Prompt 1:  Pre-treatment meetings and counselling 
Prompt 2:  During the experience/treatment 
Prompt 3:  After treatment and type of support 
5. Describe your experience of ibogaine treatment? 
Prompt 1:  Mood effects days 1, 2 and 3 
Prompt 2:  Physical effects days 1, 2 and 3 
Prompt 3:  Sleep, appetite and effects on smoking 
Prompt 4:  Any particular thoughts or ideas experienced, any 
other experiences 
6. What were the effects of treatment in relation to opioid usage, 
opioid withdrawals and opioid cravings at: 
A) 24 hours, B) 48hours, C) one week, D) 2 weeks E) one month 
F) three months G) presently 
Prompt 1:  Were withdrawals and cravings experienced 
less/same/more than compared to experiences of 
other opioid withdrawals. 
7. Do you know anyone else who has used ibogaine?  
8. What advice would you give someone else who was thinking about 
ibogaine treatment? 
9. Looking back would you have gone about this treatment any 
differently? 
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10. If this was illegal, would you still consider using ibogaine 
treatment? 
Ethical considerations 
The data obtained from participants in the study are related to an 
intervention that although is legal in New Zealand, is currently not 
medically supported in most regions of New Zealand. The survey and 
advertising for the study were designed to not promote the use of ibogaine, 
but to obtain information about ibogaine. Had participants disclosed adverse 
psychological side effects from previous ibogaine use, or had they been 
observed by the interviewer, a list of accessible mental health resources and 
counsellors would have been discussed and made available. The researcher 
had planned to actively support the participant in accessing health services 
should this have been necessary.  Fortunately no cases required this 
intervention 
Ethics approval was sought and gained through the University of Otago 
Human Ethics Committee, April 2015. Ethics code H15/042. Initial concern 
was expressed and clarification was asked for regarding the interviewer’s 
personal safety and safety of clients, as interviews were proposed in 
people’s homes. This issue was satisfactorily addressed with the committee 
through the provision of information on the researcher’s long-term 
experience in home visits in the role of mental health and addiction nurse.  
Also respondents’ safety was addressed in the method protocol which was 
to attempt interviews in public places first, that also ensure privacy. 
The cases or sample interviewed are people from New Zealand, from 
various cultural backgrounds, including sub-culture backgrounds of both 
addiction and opioid dependence. The interviewer was mindful of his own 
cultural background, which is a mix of ethnic influences of New Zealand 
Pakeha [Caucasian] and a career with a bio-medical focus, which could 
have influenced the researcher’s viewpoints. This cultural impact on 
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respondents, such as the researcher inappropriately reacting to cultural 
difference, was diminished through reflection and discussion with 
supervisors (George & Bennett, 2005; Stein-Parbury, 2009; Bishop, 1999). 
There was a possibility New Zealand indigenous people would be 
interviewed, however no respondents identified as Maori. 
 
Maori consultation 
Consultation was sought with the Kaitakawaenga Rangahau Māori 
(Facilitator Research Māori, University of Otago, Christchurch (refer to 
Appendix 2). Discussions focussed on informing the Canterbury District 
Health Board Mental Health Service Maori Health Workers about the 
research prior to commencement. An important decision was to involve a 
Maori research interviewer should a Maori person be recruited and a Maori 
Health Worker with many years’ experience and expertise in the area of 
addiction was very willing to participate in this role. The researcher will 
also inform the Maori Health Workers of the findings from the research. 
While no person who identified as Maori participated in the research, the 
findings remain applicable to Maori. 
The woman Maori Health Worker was also available as an interviewer for 
women participants. However, no participant took up this offer. 
Data analysis 
Consistent with, George and Bennett (2005) and Gorman and Clayton 
(2005) arguments that verbal descriptions of a subject is best converted to 
useable data through thematic analysis, this approach was selected for this 
study. Thematic analysis, or traditional qualitative analysis, was selected as 
it appeared to be the most common form of analysis used with interview 
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data in case studies (Swanborn, 2010). However, case study research 
incorporates more raw data than interviews alone and some experts on case 
studies have further developed thematic analysis into four or five sub-
categories, depending on the author (Swanborn, 2010; Yin, 2009). For the 
purpose of this study Yin’s (2009) definition of the sub-categories are 
reviewed, along with an explanation of why the sub-category ‘relying on 
theoretical propositions’ and the analytic technique of ‘explanation 
building’ have been chosen for the type of data represented in this study.   
Analytic strategies 
Yin (2009) describes four general strategies for data analysis, and then five 
specific analytic techniques. The first strategy is that of ‘relying on 
theoretical propositions’. This is defined as the author working from a 
theoretical proposition regarding a phenomenon, usually arrived at through 
clinical experience or explored literature. Due to this initial proposition, 
interview questions are selected around the idea and from the very 
beginning planning stages of the study, the hypothesis or proposition is 
foremost in the researcher's mind and shapes the direction and selection of 
data to be obtained to answer the proposition or theory. The second strategy 
of ‘developing a case description’ (Yin, 2009) involves arranging the data 
one has collected perhaps without an initial theoretical proposition. The 
researcher attempts to describe the data and the connections within the data 
and formulates chapters or divisions to capture each description made about 
phenomena. This strategy was not chosen as the researcher's clinical 
experience and reading of the literature meant some theoretical propositions 
had been made, and indeed did shape the interview questions. The third 
strategy is ‘using both qualitative and quantitative data’. Obviously, this 
strategy is beneficial when the case study involves a lot of quantitative data 
such as: number of days abstinent, or the amount of drug used. Using this 
strategy the researcher can represent numerical data through statistical 
graphs, supporting or challenging, perhaps, the themes found qualitatively 
in other data such as interviews. This was also not selected as a strategy, as 
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the focus of the research question was not aimed at measuring periods of 
abstinence, but rather the person's experience and understanding of 
treatment risks. This strategy also involves discussion with a bio-statistician 
prior to the study design, which was not required for this study. The fourth 
strategy, that of 'examining rival explanations' is defined by Yin (2009) as 
one to use alongside other strategies, or as a strategy unto itself. Here the 
questions are asked in reverse, or to ‘steal’ some quantitative terminology, 
the null-hypothesis is tested. That is, all other explanations are explored 
including asking if the phenomenon could occur without the suggested or 
theorised causations. However, exploring rival explanations also asks how 
much researcher bias has affected the outcome, or what threats to validity 
there may be. This strategy also tests other authors or experts' theories 
against the new theory formed. It may even incorporate a super-rival, where 
the researcher asks if there could be a combination of explanations, and a 
greater, yet unknown, causal effect may be at work. This strategy was 
deployed in conjunction with the first strategy (relying on theoretical 
propositions), but not in isolation or as the only strategy for this study. 
Analytic techniques 
Combined with the strategy selected, an analytic technique is chosen to 
group the data. Yin (2009) stipulates five analytic techniques specific to 
case study research. The first, and chosen, technique is ‘pattern matching’. 
Pattern matching is described by Yin (2009) as recognising similar patterns 
or themes in the data and grouping them accordingly. These patterns are 
then used to describe or explain the phenomenon. Four other techniques are 
derived from this first technique and include ‘explanation building’, ‘time 
series analysis’, 'logic models’ and ‘cross-case synthesis’. Each begins with 
matching patterns and then either arranges the patterns over a time-line, or 
attempts to build logical explanations from the patterns, or, as with the last 
technique, compares the patterns to other cases or studies. Pattern matching 
was selected as it incorporates all of the above techniques, allowing the data 
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to be moved around or played with in various ways, to validate the themes 
or patterns found.  
Coding format 
Data, which is the transcribed interviews and case description of each 
person interviewed, was read through and re-read and 22 codes were 
applied in relation to the separate areas of focus identified by the 
participants. These codes were categorised into five smaller, but related 
groups, and these groups of discovered themes are discussed as the findings 
of the study in the discussion section. Due to the small (n=10) sample, a 
computer programme such as CAQDAS or Nvivo was not required for this 
study. 
To minimise bias and the subjective interpretation of discovered themes to 
fit the researcher's hypothesis (Tellis, 1997), the researcher maintained 
discussion of themes and suggested categories with supervisors. Transcripts 
are available in full in the reference section. The coding for this thesis 
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Figure 1:  Demonstrates the adapted coding format (includes 
collaboration) 
Rigour 
Data from case studies can affect large changes politically (Yin, 2004) and 
the researcher was aware of the importance and dedication required to 
maintain validity of the data produced. A criticism of a case study approach 
is the data is not ‘testable’ through scientifically removing variables and 
running experiments to test the null hypothesis. Also selection and 
interviewer bias, and interpretation of findings are often questioned by 
statisticians (George & Bennett, 2005). However, quantitative methods for 
testing validation are not suited for qualitative studies. Graneheim and 
Lundman (2004) noted the need for trustworthiness to be woven into the 
3. Is it the same category? 
Assign a new category 
2.  Read another segment 
Assign to category 
1. Read a segment of transcript 
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study for qualitative validity. They state that credibility, dependability and 
transferability are better suited for the relative nature of qualitative research. 
Credibility is described as how well the researcher has maintained 
objectivity, usually demonstrated through clear study design and structure, 
and peer feedback (Graneheim & Lundman, 2004). For this study the 
researcher had two academic supervisors. They were involved in both the 
study design and gave feedback on identified findings and themes. The 
researcher had all work submitted and reviewed prior to the next step of the 
research. 
Dependability is detailed as the ability of the researcher to maintain the 
same questions and use the same pieces of data, despite the very changing, 
evolving nature of interviews. That is, it is common for new topics to 
emerge and be asked about on subsequent interviews and not the first. This 
is acknowledged as part of the process but must be transparent to the reader 
(Graneheim & Lundman, 2004). This did in fact occur, and one interview 
question was added to incorporate any previous use of hallucinogens by 
participants. Fortunately this information was obtained in the first interview 
and felt to be of value. The question was added after discussion with 
supervisors on how it would affect results. As the interview one respondent 
did list in conversation previous hallucinogenic experiences, it was decided 
adding the question would not skew the data represented and so was added 
to the remaining interviews. 
Transferability applies to how relevant the findings are to practise; ensuring 
the researcher is working for scientific ‘advancement’, not personal gain. 
Again, the structure of the research with two experienced supervisors, 
ensured transparent processes, discussion and feedback, examination of all 
possible biases, and that results were indeed for the purposes of increasing 
understanding and knowledge around this phenomenon. 
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Conclusion - Chapter 3 
The study paradigms for this thesis have been examined and explained in 
terms of why they have been selected for this study. The nature of ibogaine 
use within the culture of opioid-dependent individuals in New Zealand, is 
influenced by many medical, social, personal and political factors. This 
makes ibogaine use complex in nature, especially as it also appears to be 
entwined with the many influences of opioid dependence. For this reason a 
naturalistic, qualitative approach was chosen to study the nature of ibogaine 
use. The methodology selected is a naturalistic qualitative interpretative and 
collective case study, incorporating explanatory, exploratory and descriptive 
methods. The data from the interviews and case histories will be analysed 
firstly through the overall strategy of relying on theoretical propositions 
which guided the questions in the first place. Secondly, the interviews and 
cases are analysed using the technique of pattern recognition and thematic 
grouping of patterns.  The background of the interviewer is that of an opioid 
substitution nurse (addiction and mental health). The study's integrity and 
validity come from developing trustworthiness with the study process, 
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CHAPTER FOUR: 
RESULTS 
Overview of results 
This chapter will firstly briefly describe the participants of the study and 
then outline the collective findings of the 10 interviews. As per the Method 
section, using a naturalistic interpretive approach each interview segment 
was assigned to a subject area or a code. The codes were reviewed with 
study supervisors and 42 codes were collectively agreed upon. Natural 
groupings of codes formed seven themes and findings for this study. These 
groupings emerged from the data (interviews) and in turn the interview 
questions were guided by findings in the literature.  The themes are laid out 
in the order in which they were discussed in Chapter Five and in the order 
represented by Table 1.  Each theme will be described via its represented 
codes, and how strongly each code was voiced. Examples from the 
interviews highlighted the individual codes. The themes outlined are: 1) 
‘Not sitting comfortably with opioids’; 2) ‘Motivations for using ibogaine’;  
3) ‘Safety conscious and support seeking’; 4) ‘The best practise’; 5) 
‘Ibogaine treatment effects on depression and anxiety’; 6) ‘Ibogaine 
treatment effects on dependence’;  and  7) ‘The spiritual effect’. 
The themes are placed in order of the experienced journey through opioid 
dependence, ibogaine treatment and periods of opioid abstinence 
afterwards. Each theme has been methodically correlated back to the 
interview transcripts to assess how many respondents, overall, matched the 
theme. Respondents may have contributed to individual codes within the 
theme yet not have been representative of the nature of theme, so they were 
not counted as a respondent to the theme. The number of respondents for 
each theme is represented in red under the title of the theme in table 1. The 
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last theme, 'the spiritual effect' was ordered last due its low respondent 
number (four) and because it also appeared to be a described factor 
throughout people's journey with ibogaine.  
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Description of participants 
Respondents numbered ten (n=10) in total. Eight were contacted via the 
Dunedin ibogaine group or network through its main representative. One 
respondent was contacted through the Christchurch methadone programme 
(Now known as Canterbury Opioid Recovery Service (CORS)), and one 
was contacted as a result of snowballing from another respondent. Nine 
respondents used illicit opioids as part of their journey into opioid 
dependence, one respondent used opioids problematically as a result of pain 
management. Participants' ages ranged from 27 to 53 with an average of 
40.2yrs. Ages of experiencing ibogaine treatment ranged from 21 to 49yrs 
with an average age of 35.1yrs. All respondents were of New Zealand 
European ethnicity (NZ Euro). This data is captured in tables 2 – 4. 
Information about the participants provides readers with a better 
understanding of their experience and journey, however some information 
was unable to be represented in the results and discussion section of this 
study. Such as personal information which shapes each ‘case’ or person’s 
journey. Stories of abuse and trauma, mentally and physically, where shared 
and emphasised as motivations or bases for anxieties. This study focussed 
on a drug addiction treatment and its foci was not on histories and 
psychological make up of this sub-group. However these histories and 
experiences did direct some people’s decisions and are relevant. Notably 
was some observed personality traits which differed to the researchers 
experience with OST service users in New Zealand and England. The group 
studied was observed as being perhaps more motivated and each shared 
quite remarkable personal achievement’s in their lives, such as successful 
business’s, world travels and distinguished careers. All respondents are 
currently and historically employed. The respondent’s relationship with 
other drugs is also significant, with nine respondents having a strong 
relationship with cannabis before and after ibogaine treatment. As described 
by one respondent, there are opioid users who want to mask emotions and 
feelings with narcotics and other opioid users that want the psycho-active, 
~ 74 ~ 
thinking and stimulation that occurs with drugs especially cannabis and 
hallucinogens.  
….Well I know lots of people on opiates who won’t smoke 
too much pot because its slightly hallucinogenic or you 
know psycho-active. A lot of people take opiates to shut 
down their thought processes and to block out bad 
experiences from the past (respondent 001). 
Ethnically the sample group all identified as New Zealand European and 
other ethnic groups in New Zealand were not represented. This aspect is 
discussed in the studies limitations section chapter five. Over-all the group 
interviewed and that make up the cases for this study share common attributes 
of the general opioid population as described by Moshier et al (2012). That 
of belonging to a culture of and group of opioid users who share a set of 
acquired skills and experiences. They are a high risk taking population but 
also a vulnerable population over represented in health statistics physically 
and mentally (Deering et al., 2004). Respondents required much 
correspondence and discussion to reassure them of the nature and 
trustworthiness of the study and the researchers. Most respondents required 
a peer link to ‘vouch’ or speak for the study. The respondents, in line with 
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Table 1:  Themes and categories 
Categories Themes 
1. Desperation to be opioid-free 
1. Not sitting comfortably on opioids 
(Nine respondents) 
2. Multiple attempts at quitting 
3. Societal and self-stigma of addiction 
4. Physical and Mental aversion to substitution opioids 
5. Withdrawals and associated mood not tolerated 
6. Keep my methadone dose low 
7. Anti-establishment and critical of standard treatments 
8. Restricted achiever 
9. Anxiety of being dependent 
1. Hope and reports of treatment success 
2. Motivations for using ibogaine 
(Ten respondents) 
2. How ibogaine therapy was discovered 
3. Quickness of treatment 
4. Previous hallucinogenic use 
5. Use unaffected by legality 
1. Safety conscious and seeking medical input 
3. Safety conscious and support seeking 
 (Ten respondents) 
 
2. Need for preparation and guidance before treatment 
3. Need for 24/7 care during treatment 
4. Need for guidance after treatment 
5. Family/Friend/General Practitioner support 
6. AA / NA self-help group dichotomy 
7. Anxiety around ibogaine treatment 
1. Negative experience of ibogaine treatment 
4. The best practise 
 (Six respondents) 
2. Sleep disruption and management 
3. Morphine versus methadone 
4. High versus low ibogaine dose, use of boosters 
5. Control the vomit 
1. Positive effects on mood post treatment 
5. Ibogaine treatment effects on 
depression and anxiety 
 (Seven respondents) 
 
2. Anxiety management affecting abstinence 
3. How to cope without a crutch 
4. Powerful effect of hallucinogen 
5. Mental /cognitive work after treatment 
6. Acceptance of fears, vulnerability and pain 
7. Heightened senses post treatment 
1. Absence of opioid withdrawals 
6. Ibogaine treatment effects on 
dependence 
 (Seven respondents) 
2. Effects on opioid usage 
3. 3 month point after treatment 
4. Effects on other drug use 
5. Effects of treatment on pain and the physical body 
1. Long term effect of hallucinogen 
7. The spiritual effect 
 (Four respondents) 
2. Sense of epiphany during treatment 
3. The little brown man 
4. Search of the spiritual 
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Table 2: Demographics 
 
 Gender Ethnicity 
Region in  
NZ living 
Currently  




001 Female NZ / Euro Canterbury Y 26 2 
002 Male NZ / Euro Otago Y 42 7 
003 Male NZ / Euro Bulls Y 40 2 
004 Male NZ / Euro West Coast Y 53 3 
005 Male NZ / Euro Otago Y 28 7 
006 Female NZ / Euro Otago Y 42 4 
007 Female NZ / Euro Otago Y 45 8 
008 Female NZ / Euro Otago Y 42 8 
009 Female NZ / Euro Otago Y 42 4 
010 Male NZ / Euro Otago Y 42 7 
 

























Illicit 8 5 10+ 35 7+ 
003 Codeine Illicit 10 Nil OST 10+ 38 0.25(r) 




Illicit 2 2 1-2 21 7+ 
006 Morphine Illicit 12 10 1-2 38 4+ 
007 Morphine Illicit 7 2 10+ 38 8+ 
008 Morphine Illicit 5 5 10+ 35 8+ 
009 Heroin Illicit 5 7 10+ 38 4+ 
010 Morphine Illicit 5 13 10+ 35 0.5(r) 
(r) = relapsed to opioid use. (+) = remains abstinent. (PDM) = Prescription Drug Misuse 
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Table 4: Other drug use before and after ibogaine treatment 
 Alcohol Cannabis Benzodiazepine Stimulants Hallucinogens 
Use of AOD 
post Ibogaine 
001 No No No No Yes Yes (r) 
002 Yes Yes No Yes Yes Yes 
003 Yes Yes No No Yes Yes (r) 
004 No No No No Yes No 
005 Yes Yes Yes Yes Yes No 
006 Yes Yes No No Yes No 
007 Yes Yes No No Yes Yes 
008 Yes Yes No No Yes No 
009 Yes Yes No Yes Yes No 
010 Yes Yes No Yes Yes Yes (r) 
(r) = relapsed into opioid use as well 
 
Not sitting comfortably with opioids 
Theme One, 'not sitting comfortably with opioids', emerged from nine 
separate codes and captured an overall tone of discontentment, a feeling of 
‘not going anywhere’ whilst on opioids. Whether through substitution 
treatment or illicit use, there was a consistent thread of being unable to 
achieve life goals, as well as feeling both physically unwell and mentally 
depressed. It was described more in terms of an aversion to the 
pharmacological properties of opioids rather than the restrictions of OST or 
the dependence itself. 
Code 1) ‘Desperation to be opioid-free’, was consistent throughout all ten 
interviews. Mostly in response to the interview question: ‘What led you to 
choose ibogaine treatment?’ Relevant excerpts also appeared elsewhere in 
the discussions and interviews as participants described their journeys: 
002: Yeah yeah but that’s because at the time I had lots of 
money. I had met my wife and things were going to be 
very good. And the only thing that would ruin all of that 
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was drug addiction. And I didn’t want to lose her, didn’t 
want to lose my health....and I’d already lost so much to 
it, I was losing too much of my life, I mean my potential to 
it, the other things I could be doing with my life.... I could 
see that I just knew I could be so much more! You know, 
and I could just see my life being robbed day by day and it 
was quite depressing you know. 
008: Well I don’t think I would have done anything. I was 
thinking about naltrexone, if I could do naltrexone, but I 
knew someone who had done it and it hadn’t worked and 
it was hideous and it scared me... if someone said you 
could have a blood transfusion and that, you know, I 
would have said yes, sweet, I was just desperate. 
The desperation to be opioid-free flavoured many other codes such as the 
search for the spiritual, and physical and mental aversions to opioids. 
However this code captured a general and chronic feeling of frustration and 
wanting more out of life for themselves, even when it was not spurring 
some other action. It was also described as separate from low mood or the 
physical side effects captured later. 
Code 2) ‘Multiple attempts at quitting’ demonstrated the many actions 
seven out of ten of the group were willing to go through to achieve their 
goal of getting off opioids prior to, and after ibogaine treatment. 
002: Yup. And then after five years, onto the methadone 
programme. And before that I’d probably tried 10, 15, 20 
times to detox and just to no avail.. Pretty much all cold 
turkeys. You just end up having to knuckle down and try 
and get off, you know. 
009: And actually that detox was really quite difficult. He 
said that they needed to give me more naltrexone. 
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Because they knock you out to it and give you the 
naltrexone to basically speed up the process. And they 
knock you out because as you can imagine it’s so 
traumatic and hard on the body. General anaesthetic… 
Yeah it’s like 3,000 dollars. ‘We speed up the withdrawal 
process so you can go to work in a few days’… it was 
such a have… It really crippled me. 
Two of the remaining three interviewees actually used ibogaine as their first 
detoxification attempt. Both had felt uneasiness at the thought of a standard, 
gradual opioid withdrawal regime. Their data was captured in the later code 
of ‘opioid withdrawals not tolerated’. 
Code 3) ‘Societal and self-stigma of addiction’ was picked up in four of the 
interviews. The remainder of the respondents did not directly state the 
motivator for change was others' perceptions of them, but rather the clash 
and disappointment of not achieving their own expected potential. This is 
captured in code 8, ‘restricted achiever’. 
006: No… I hated being. I hated going to the chemist 
every day. I hated lining up. I hated people knowing what 
I was doing, you know. … The stigma. Massive… 
massive…. and I was working and I had a family….and 
that wasn’t cool…. I didn’t like it. I didn’t like it at. I 
never felt like I belonged on it because I thought, far out, 
I’d see everyone else line up and I would be really judge-y 
about them myself and I thought holy shit, if I’m judging 
them… you know, it’s really bad people judging me, you 
know, and no wonder they are because people are lining 
up for methadone going “agrhhhh” with no teeth and look 
like they were wasted, you know… the stigma. 
009: And I had always battled against being an addict like 
hard out. I put my body through hell. I always hated the 
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idea of being addicted. But I would do it again and again 
and again. Like I would get clean… like I know addicts 
who have never been clean. 
Again the subject of societal- and self-stigma appears well-woven through 
the other coded areas in this theme but is worth a separate code because for 
two interviewees, stigma and judgemental attitudes were the only motivator 
for change. Their motivation was not intermixed with the 4th code, 
‘physical and mental aversion to substitution opioids’, where respondents 
described not sitting comfortably on opioids due to the physical and mental 
side effects of the opioid drug. 
Code 4) ‘Physical and mental aversion to substitution opioids’ emerged as 
respondents described being on stable, non-reducing doses of substitution 
opioids.  It captured the list of side effects, both mental and physical, of 
long-term opioid use. This was a strong code, with seven people voicing it. 
004: Not good if you talk to my wife she would probably 
say a shitty bugger in the afternoons.  It really effected my 
afternoon mood. And then physically there was just this 
raft of stuff and I couldn’t really untangle it all… but my 
gut was just shot. I’d either have constipation or… and I 
pretty much had constipation all the time which I couldn’t 
control no matter what I did… yeah yeah um… in the end 
I got dependent on enemas, to go. Um… all my nerves are 
playing up really bad I was getting numbness down both 
legs, numbness in my arms... um... Headaches all the 
time…. was getting more and more unwell. I couldn’t 
make love to my wife. Physically. Yeah, so there was 
always just this sort of feeling. And I wanted to be well. 
Do you know I think that’s probably one of the major side 
effects I felt was the anxiety. 
~ 81 ~ 
009:…got really bad migraines and was real sick all the 
time. I just got real sick. I had a headache for three years 
after Z. was born. Like partial paralysis and going blind. 
Like the precursor headache never went away it was just 
nuts. The methadone? No, it was horrible. No I hated it. I 
tried swapping to Codeine… I stock piled… I got myself a 
script I never took and stock piled a 1000 of the bloody 
things and we had a whole plan of swapping to codeine 
and reducing… but then I ended up in hospital with 
problems with my bowel. And codeine just wasn’t… 
008: (laughter) because it was just... I thought I was going 
to die you know. But I didn’t feel like I had an option as I 
felt like I was going to die anyway... I was just so… I was 
just so chemical-ised… I was just so… depressed and 
traumatised and... you know? 
Respondents clearly described physical and mental side effects of opioids 
when on stable non-reducing amounts, as opposed to Code 5. 
Code 5) ‘Withdrawals and associated mood not tolerated’ emerged clearly 
in this theme. All ten respondents commented that withdrawal from opioid 
drugs was especially difficult to cope with. This included short-acting illicit 
opioids (morphine, heroin), and longer-acting substitution opioids 
(methadone).  Emotional and mental effects were listed ahead of physical 
withdrawal effects. The two respondents who had not attempted many 
opioid detoxifications described the fear of opioid withdrawal as being the 
main deterrent to trying. 
001: …yeah yeah, but I’m not very good at that ... I can’t 
do more than... two and half days then I want to shoot 
myself. Yeah. Very very scary. No I couldn’t do it, I 
couldn’t do it. No the longest I ever got was three days 
and I wanted to shoot myself. 
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008: I just wanted to get down and then I could slowly do 
it. But I was just so sick all the time. I mean I had two kids 
on my own and had other stuff going on up here which I 
didn’t know what…. and I just couldn’t afford to have 
that… Because my psych was…. Yeah… destabilise me.  
Psychologically and... you know, put me at risk of using 
other things, which is what I did, what I do.. 
Code 6) ‘Keep my methadone dose low’, seemed to position into this 
theme, with four respondents deliberately using lower doses of methadone 
to either eventually come off or to limit the reported side-effects whilst on 
maintenance doses. However the remaining six used the as expected, 
prescribed doses of substitution opioids. 
002: I think I started off at 50 and went up to 60. But, but I 
think because I could have it every day and I didn’t have 
to score or pay anything for it and it will…..be there 
waiting for you, and it was.. I was trying to get myself 
sorted so I tried to keep it reasonably low. I had heard of 
the trouble of bigger doses of people coming off, you know 
004: Ultimately looking back at it now, I probably needed 
a higher dose to control the pain better and maybe I 
would have stuck at that higher dose. 
Code 7) ‘Anti-establishment and critical of standard treatments’, was 
expressed by eight of the respondents, describing how they did not fit in 
with recommended AOD treatments and were not hopeful of treatment 
success. This was not to say respondents did not utilise standard treatments 
(demonstrated in a later theme), but they all voiced criticism of the limited 
options from treatment services, and never accepted all the policies and 
protocols. 
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005: No no, I was a bit of a stubborn prick eh. None of 
those things (treatments) seemed really like… my cup of 
tea (laughter). 
001: Yeah it was going to be a big nasty cycle again, I’d 
have to go to CADS, go back up, take-aways cut, be 
punished um.. ..go back up, only to have to come back 
down again and then was I going to feel like shit and was 
I going to be able to get take-aways?…...well it is a 
punishment (laughter) 
002:… it is something (ibogaine) I could try and it may 
work, and I was open to something that may work as 
opposed to nothing that didn’t work. 
Anti-establishment personality was a somewhat subjective perception but 
represented a captured tone during interviews; expressions such as cringing 
and rolling of eyes when discussing doctor's visits or hospital stays. It was 
grouped into this theme as the non-acceptance of standard treatments was 
felt to influence the overall discontentment with opioid substitution 
treatment. Likewise with the next code. 
Code 8) ‘Restricted achiever’ was prevalent in all the interviews. The 
described life achievements and journeys of  the interviewees were more 
notable and numerous, observed by the interviewer, when compared to 
interviews in addiction services. This code fell into the theme of 'not sitting 
comfortably on opioids' because for many respondents, going in to OST 
represented a personal failure, it contradicted their own sense of personal or 
life success. In the previous codes, respondents expressed barriers to OST 
such as the physical and mental side effects from the opioids but for this 
code, OST was like admitting something they did not like had control over 
them. It emerged clearly from the way respondents matter-of-factly 
described their life experiences, and their perception that opioid 
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dependence, even as a substitution treatment, negatively affected their 
achievement potential.  
002: I was really, really quite determined. I mean I’ve 
seen people get cancers and all sorts of stuff and die you 
know die these depressing deaths and still hooked on gear 
and just wondering what life would be like without it. And 
I was like pretty young and.. and my brain was still pretty 
active and I was still… even though my physicality was 
deteriorating I was still young enough to like well I can 
still build myself up and raise this family and do the best I 
can... Yeah and retrain and all that stuff, um.. I think I 
was quite motivated. But still couldn’t kick the fucking 
habit, Yeah. 
003: It was just you know, you’re happy doing nothing… 
you’ve failed! Next thing you know 10 years have gone 
past and you just haven’t done it, you-know? 
Code 9) ‘Anxiety of being dependent’ was only voiced by three respondents 
and appeared to relate to any substance, not just opioids. 
008: I just hated the idea of being a drug addict to be 
honest. Not the stigma but I felt it was a real lack of will 
for myself. Like I always hated the idea of being beholden 
to something like that. It's hard to explain. 
003: I didn’t want to be dependent on something you-
know? 
004: But… another motivating thing and I’ll mention this 
because I don’t think anyone else will mention this but it 
was definitely a thing for me. But the incredible 
underlying anxiety because you pick up every ten days. I 
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lived, live 30 kilometres away up a gorge… I even went to 
the point where I had a really good doctor and he is very 
understanding and I told him at one stage, I told him of 
my anxiety and I said could you prescribe some as extras 
that I could keep and give to my wife to hide away or 
something like that and so if worse was to happen or 
something were to happen I’d have a stash. Which he did 
for me so I had it…. and then I ended up using them.  
Overview of Theme One 
These nine codes were grouped together because they all demonstrated the 
mental, emotional, physical and conflicted personality ‘un-ease’ which most 
ibogaine users described when using opioids, including substitution opioids. 
These feelings were demonstrated and described before ibogaine therapy 
and for some afterwards, when they relapsed back to opioid use. The theme 
of 'not sitting comfortably on opioids' captured the participants' combined 
feeling that staying on opioids long-term was detrimental to their wellbeing. 
Respondents described this anti-opioid perspective happening in their life 
before they knew about ibogaine treatment and appeared to be the driver for 
both attempting opioid detoxification, and avoidance of substitution 
treatments. 
Motivations for using ibogaine 
Theme Two directly emerged from the interview questions regarding the 
‘motivations’ for why people chose ibogaine. It became a separate theme as 
this was when respondents became aware of ibogaine and chose it 
specifically for their opioid detoxification. The main findings were that the 
short length of time required for treatment and recovery was a strong 
motivator for respondents; along with hope, both that the treatment would 
work, and that there would be an absence of opioid withdrawal symptoms. 
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Whether or not ibogaine was legal did not seem to be a factor for 
respondents. This theme was represented by five codes. 
Code 1) ‘Hope and reports of treatment successes’ was consistent with all 
ten respondents. Hope of avoiding opioid withdrawals and hope of a 
detoxification that might work. There was a portrayed sense of despair with 
available, standard detoxification treatments. This was voiced both 
regarding the initial withdrawal effects and the indefinite recovery time 
after the detoxification. In this recovery period people described a long 
journey with ‘no light at the end of the tunnel’, and it taking a long time – 
months - to feel normal without the use of opioids. 
008:  So we went to this house and I remember this chick 
with a hat on and shades and not talking much and it was 
like, yeah you know I’m doing this thing and I met J. and 
it was all good - and then I went back a couple of days 
later and this girl was like, you know, engaged, talking, 
happy… and I was like yeah, OK I gotta., I just got to go 
for it - and I didn’t know a lot about it and I didn’t know a 
lot about the risk, I had no idea what I was getting myself 
into. 
009: …a friend of mine was an opiate user who hated the 
idea of the thought of methadone, he was one of my best 
friends. And he went onto poppy tea instead and um… he 
disappeared for about six years and we heard he was on 
the Coast and we had no idea. And then I found him in 
Lyttelton and I visited him and I thought he was going to 
die, so sick and not the person I knew and loved. And then 
I saw him two years later… and he turned up here to tell 
A. and I his experience with the ibogaine. And it was like 
he had gone... like the last time I saw him he was 10 years 
older than he was. And now he had ‘Peter Panned’ it 
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totally and looked like he was 10 years younger than he 
was. And he was actually one of T.’s first treatments. 
First-hand knowledge of ibogaine treatment success and consequently 
having 'hope' as a motivator for ibogaine treatment is separate from the 
second code, ‘how ibogaine was discovered’, as most interviewees had 
heard of, or 'discovered' ibogaine prior to meeting a success case. 
Code 2) ‘How ibogaine was discovered’ was in response to a direct 
question.  For the purpose of this study respondents were asked how they 
came to know about ibogaine.  This information was captured as it 
highlighted the method by which ibogaine users obtained knowledge, 
including with regard to the medical risks of treatment. Most respondents 
told a story of how, by chance, they had heard of ibogaine treatment. 
007: I think I’d seen a documentary about it… A while 
ago. But basically no one I knew had ever heard of it.  I 
just did a lot of research online and it sounded amazing - 
It sounded like the ultimate, you don’t want it, you know. 
003: Just looking for it on the internet. I was just looking 
for yeah, yeah, opiate withdrawal medicine. And I was on 
an internet chat site for recovering opiate addicts… And I 
saw it mentioned there by some-one really. 
005: What’s it called… detox or die I think it’s called. I’ve 
always been a drug geek, I’d read about stuff on 
‘EROWID’ and I’d heard about it on there. 
Respondents researched their own information on the treatment, mainly on 
the internet; and through chat rooms and peer discussion the initial medical 
knowledge pertaining to ibogaine was discovered as well. It did appear that 
all respondents knew of the risks of death with ibogaine, despite giving 
various incorrect reasons for those deaths occurring. 
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Code 3) ‘Quickness of treatment’ was a strongly voiced code by all 
respondents. Treatment here incorporated both the acute, opioid withdrawal 
symptom phase of detoxification, and the time for recovery from 
dependence afterwards. Clearly separated from the ‘effectiveness’ of 
ibogaine treatment, interviewees also sought a quick solution to their 
dependence. One interviewee was determined to achieve an opioid 
detoxification in 2-3 days as that was all the time he had allowed away from 
his own business. 
007: I just thought there must be something out there 
which would make it easier to come off the opiates… 
Yeah…um… more of a stopping. Because with methadone 
it’s more a solid three week hard core withdrawal and it 
is hard work and it’s easy to go back…  You’ve got to be 
so determined, so strong.… the ability to stay off as well 
yeah. 
004:… I had asked about going to a rehab centre or 
something like that. Everything took so long and I had my 
own business and family, like how could I take six months 
out. 
Code 4) ‘Previous hallucinogenic use’ was identified early as a strong 
theme, enough for it to be added as a research question (refer Methodology 
section Chapter 3). All ten respondents had used hallucinogenic drugs as 
part of their drug using career, including one respondent, 004, who was 
prescribed methadone for pain. 
003: Yup.. mushrooms and Acid…yup mostly 
mushrooms… and LSD. 
004: …and then at about in my mid 30’s um.. I smoked pot 
again for a while and then experimented with a couple of 
other things, just because of the town I was living in and 
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the people who were there and the lifestyle I was living. 
So I ended up trying magic mushrooms… Yeah. I tried a 
couple of LSD trips and I think I was given some cactus 
once. 
010: You know I first tried alcohol and stuff. And I smoked 
pot pretty regular, I really loved smoking pot. And then I 
tried the tripping, the mushrooms, LSD and.. ah.. all those 
things.. I was a bit of a tripper there for a while. 
All respondents stated they did not ever feel their hallucinogenic use was 
problematic.  It was described as recreational use and fell well under 
diagnostic criteria for DSMV (American Psychiatric Association, 2013). 
 Code 5) ‘Use unaffected by legality’, the last code for this theme emerged 
strongly, with respondents clearly prepared to use the substance whether it 
was legal or not. As per the Method section, question ten of the interview 
asked directly if people’s choice to use ibogaine was affected by its legality. 
All ten participants were indifferent to legal status, with six respondents 
having had their therapy when ibogaine was not a scheduled medicine, 
while the other four stated they would still do treatment if it were not legal. 
002: Oh ok. if, well I think… and I’ve said this to you 
before, if it was illegal I would definitely still use it. And 
that’s the difference because the options are you can try 
this once illegal or you could go back and shooting heroin 
ten thousand times which is going to be much worse for 
you and I think I tried it because… nothing conventional 
was working and .. the whole idea that there was  
something out there that could work and be successful… I 
had to explore that path. I really had to try something that 
was really going to. 
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002: … The way it's gone now and made it scheduled, it’s 
responsible and it still gives the right people an option to 
use it. 
007: Yeah if I really thought I needed it absolutely. 
Illegality has never stopped me with these things 
(laughter). 
Overview of Theme Two 
The respondents voiced three major drivers for choosing ibogaine.  Firstly, 
that this treatment offered some hope of success and alleviation or even 
elimination of opioid withdrawals.  Secondly, the potentially short length of 
time for treatment and recovery appeared to be a significant motivator for 
people. And thirdly a previous positive experience with hallucinogenic 
drugs and the way they heard about ibogaine was also significant. 
Safety conscious and support seeking 
Theme Three included seven separate codes that became apparent from the 
interviews. Information was sought to answer the study's sub-question; 
‘What safety measures and medical tests were ibogaine users aware of and 
utilised? This theme captured the lengths people went to for medical input 
before, during and after ibogaine treatment. Those who did not use a clinic 
sought medical tests, albeit incorrect medical screening, through their 
General Practitioner (GP). Those with support of an ibogaine treatment 
provider received the correct medical assessment, even if their GP had no 
prior knowledge of what screening to provide.  All respondents sought 
support before, during and after ibogaine treatment and it came in many 
forms - their GP, parents and family, friends, community nurses, and 
ibogaine experts.  
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Code 1) ‘Safety conscious and seeking medical input’ is similar to the 
theme's title except the overall theme incorporates all types of support 
ibogaine users utilised, including family and Narcotics Anonymous for 
example. The first code’s findings emerged strongly with all ten 
respondents aware, to some degree, of the cardiac risks and potential death 
risk. Nine out of ten sought some form of medical test from their General 
Practitioner (GP). Of the ten respondents: three used an Australian-based 
ibogaine provider; six used an established New Zealand clinic which 
supported medical assessment prior to ibogaine treatment; and one 
respondent used ibogaine independently, alone. The following excerpts 
demonstrated awareness of the risks and that respondents sought a GP for 
medical tests prior to ibogaine treatment. 
002: and I think other stuff I read because it was people 
that had a weak heart. So that was your first, um..first 
thing to look into. So this was where it was decided that if 
you were going to try you had to have a medical. So to get 
a medical for something illegal, you needed to see your 
doctor and then go through the medical fraternity, so shit, 
alright, it was going to come out what you're doing. If 
anything does go wrong you want to be noted that you 
were giving it your best shot that everything was wrapped 
up. And if the medical fraternity was involved they 
couldn’t say you can’t use it but they could possibly 
advise you of the best way to go about it. 
003: Right I did a... I C... An ECG or an EEG or 
something... and I did liver panel and a kidney panel and 
had all my bloods done and everything.  Yeah you had to 
get those done before they would let you do the treatment. 
010: Yeah I did. I actually did tell my GP I was going to 
be doing it and he didn’t know a lot about it but the fact 
that it was better than staying on opiates meant that it was 
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a... another… you know could only.. you know even if it 
didn’t go that well.. I was still trying to go in the right 
direction so he basically saw that as positive and gave me 
some remedial fuckin Valium… and back up help... 
through the other end… yeah my GP had been my GP 
since I was young, knew my family and knew I was a 
sensible character and he knew I wasn’t trying to pull one 
over him…. And that was basically um.. I would get my 
blood pressure read and... make sure my heart wasn’t 
thumping out of my chest too far and blood pressure was 
reasonably stable. 
Code 2) ‘Need for preparation and guidance before treatment’ illustrated the 
lengths respondents went to, to have some support before treatment.  All ten 
believed ibogaine therapy required much preparation before treatment. 
Respondents felt that having a guide and someone to explain what to expect 
was essential. This was to help with planning, the anxiety of the treatment 
and the physical preparation, such as reducing other drug use and taking 
mineral supplements. 
002: Right because this was new and I was taking it with 
the only other person in New Zealand who had used it, 
which was T... And I had been talking to K. the other 
person who had been using it as well, in incremental 
doses. The treatment, the level of support before treatment 
was... for the time… was really high I think. Because I 
think I wasn’t going into it uninformed and I had other 
users who… really wanted to give me all their knowledge 
and all their support and they helped me bring it into the 
country and everything. And they were like, they really 
backed me. And I think because their experiences were 
positive I followed their advice. 
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004: I think she did it very well, she gave me plenty of 
information.. um.. she told me as much as she could of 
other peoples’ experiences. She linked me up to a couple 
of other people who had already been through it. 
Even the respondent who used ibogaine alone in his bedroom, had 
discussed the effects of treatment with the peer he had obtained the ibogaine 
from.  He had also made preparations such as having a friend handy to 
‘come do his dishes and clear away spew buckets’. 
Code 3) ‘Need for 24/7 care during treatment’ was related to the above code 
but separate in that it strongly emerged ibogaine treatment incapacitated the 
user, and safety measures, including hydration and even toileting, appeared 
to require third party assistance for eight out of ten respondents. 
001: I definitely couldn’t walk by myself, no way… It was, 
it felt like I could take a step, and then I would take a step 
and just fall over. I guess it was no strength. I think I was 
pretty out of it for most of the first day. 
006: …yeah… I was still pretty out there. And so it kind of 
stopped… it didn’t… go any further than that. And I was 
freaking out all the next day…. Thinking it hadn’t worked 
and how was I going to get methadone. If it hadn’t been 
for J. being there supporting me, saying ‘you’ll be alright, 
you’ll be alright, I probably would have, somehow. 
008: Ah no the first day I was out, I was gone. I couldn’t 
walk for a couple of days properly... that ataxia, ataxia… 
attacks you (laughter).. yeah because they had like the test 
dose and then the flood dose at night and that was… I 
don’t remember a lot of that... I remember a lot of weird 
visuals and stuff and feeling hot and cold... not feeling like 
~ 94 ~ 
I could swallow, not feeling like I could breathe... thinking 
I was going to die… a lot. 
Code 4) ‘Need for guidance after treatment’ was voiced by all ibogaine 
users, whether because they received support after treatment and found it 
beneficial, or did not receive follow-up care and, on reflection, considered it 
might have helped. The support was mostly around having questions 
answered regarding ongoing experiences with their treatment. 
006: I went home for two nights and realised that... I think 
I had two nights at home after I got home... and it was… 
shit! I was off… my chops and I didn’t know what was 
going on... you know I didn’t actually realise I needed 
more time away. I think it was the third morning I was at 
home… yeah two nights back at home. T. came round in 
the morning because she would pop in, a lot, and she 
came in and I was lying on my daughter’s bed just crying 
and saying I’ve never felt so worse. And she said you 
going to K’s house and you need to pack a bag. And K. 
came and picked me up and I stayed there for a week. And 
I laid there on the deck and got waited on hand and foot 
and I wasn’t around  my smelly teenagers as I couldn’t 
stand the smell of them any-more. 
001: Yeah, I went and stayed with M. and C., and that 
really fucked me up because they knew I had come back 
and they knew I was clean and they would sit there and 
shoot up and having their Ritalin and stuff... 
009: Yeah totally. And afterwards she was just in my life 
here. Supporting me. The same thing like just trying to… 
like lots of really good recovery information… 
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All respondents voiced that an ideal ibogaine clinic would have aftercare 
support and be available to answer questions. Most respondents described 
post-treatment situations they had not anticipated, and questions they had 
wanted answered. 
Code 5) ‘Family/friend/General Practitioner support’. Although this support 
is described and woven through the other codes, the level of support 
respondents received from family, and even their GP, stood out as this was 
an anticipated controversial, underground treatment. 
002: Yup, and my doctor came in and did my blood 
pressure… A home visit. Yeah yeah, she is a family 
doctor, very much a family doctor (laughter). Yeah right 
in the middle of it just to check stuff. 
002: Yeah yeah. And I had another friend who was a um.. 
a …um.. community mental health nurse… and, um, he 
was kind of on board. I was actually going to pay him to 
be a nurse on standby and stay overnight at the house. But 
that in the end wasn’t really required. But he did come 
and check up and make sure my trip was going alright 
(Laughter).  It was kind of a big deal. Weirdly I likened it 
to… assembling a whole surgical team to remove a 
splinter (laughter) that’s kind of what it felt like.  
005: A... um, it just sort of… it just sort… it’s funny. Once 
the ball got rolling, backing out wasn’t an option. Mum 
and dad got it all organised and paid for and it was just 
happening, it was beyond my control sort of thing. So I 
just stepped back and let it, sort of let it go and let the day 
come you know. My parents... I mean essentially it was 
smuggled in from Australia and it was probably more 
expensive than it was on prescription, I mean I don’t know 
but… 
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Code 6) ‘AA / NA dichotomy’. This code was so labelled because some 
respondents clearly were against the nature and associated culture of 
Alcoholics Anonymous support groups. Whereas others in the group 
mentioned them positively and utilised them for peer support and something 
to focus on.   
003: Na. Nope. I haven’t done any of those things. I did 
try Narcotics Anonymous, I went to a couple of meetings 
and went, like, ‘fuck this’. I found the people really… 
didn’t seem really pro… it was more of a doom and gloom 
approach…. 
002: Yeah I did a lot of NA, for a while. Especially after 
every time I done a cold turkey or something. Met some 
people, some like-minded people and that was a whole 
part of changing your playgrounds really. 
005: Well, I actually went to NA meetings up there as 
well… And I wanted to meet people that knew drugs but 
wasn’t sort… knew where I was coming from and knew 
the world a little bit and also actually when I first went up 
there I wanted… I was drinking and smoking weed pretty 
heavily… at the three month mark. 
Information specifically about the influence of NA/AA groups on the four 
respondents who had utilised them was not especially sought, but dovetailed 
with the theme of ibogaine users being safety aware and motivated to find 
peer support. 
Code 7) ‘Anxiety around ibogaine treatment’, was placed into this theme as 
it appeared to be a motivator for people to be prepared and seek medical 
testing. It was described by eight out of the ten respondents, and was 
distinctly separate from the anxiety of being drug-free afterwards. This 
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anxiety was because of the known risks associated with ibogaine treatment 
specifically. 
006: …and I didn’t really want to know a whole lot of 
stuff about it and T. gave me a whole lot of information 
about it and i didn’t look at it. And she would tell me 
things and I would just go; ‘la la la la’, because I was 
terrified, I was absolutely terrified. I knew that is was a 
possibility that it could… it could be really dangerous. 
And I decided that I might die (laughter). 
008: Yeah it scares the crap out of me and because of 
what happened up North it scares the living crap out of 
me even more… Yeah I was cutting my mum’s hair the 
day before I left and I said to her, ‘you know if I don’t 
come back, don’t ever feel like you let me down, you 
know’ (laughter) because it was just… I thought I was 
going to die you know. But I didn’t feel like I had an 
option as I felt like I was going to die anyway.. I was just 
so….. 
One respondent, who had used ibogaine independently and one respondent 
who obtained more ibogaine after the original treatment, still sought 
medical and social support for those treatments. 
Overview of Theme Three 
Usually through their GP’s, respondents sought medical testing prior to 
ibogaine treatment. Better medical testing was achieved when an ibogaine 
treatment provider gave guidance about which tests ought to be conducted, 
as often GPs were not familiar with this treatment. All respondents sought 
social and peer support throughout their treatment and this was crucial for at 
least eight respondents who said they were ataxic during ibogaine therapy. 
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Support was also sought afterwards sometimes through other conventional 
treatment settings such as NA or their addiction (CADs) case manager. 
The best practise 
Theme Four arose from the researcher's observation during interviews and 
participants' accounts of ibogaine treatment, that a few key elements of the 
treatment process made it safer, more effective and more comfortable for 
people as a detoxification process. It captured how the experience of having 
an ibogaine support clinic and/or peer support, meant people received safer 
and more effective treatment through, for example, the medical control of 
side effects, like nausea and sleep disturbance, during and after 
detoxification. Another action which seemed to help was switching to a 
short-acting (half-life) opioid prior to detoxification as this appeared to 
allow ibogaine to capture the withdrawals within the time frame ibogaine 
was bio-active.  Other indicators for better outcomes were the use of 
ibogaine booster doses after treatment, and the use of higher flood doses, as 
opposed to multiple smaller doses.  Theme Four was represented by five 
codes. 
Code 1) ‘Negative experience of ibogaine treatment’ was voiced by two 
respondents about their own treatment and, although not available for 
interview, respondents mentioned two others who had negative ibogaine 
treatment experiences. These included not having the hallucinogenic effect 
they had hoped for, either due to low ibogaine dose or vomiting the flood 
dose up, and experiencing opiate withdrawals during treatment. One 
respondent experienced significant physical side effects of a fast heart rate 
(tachycardia) for one month after treatment, related to a previous heart 
deformity of which symptoms may have been masked by opioids. 
004: Well, I didn’t understand what an unpleasant 
experience I would actually have on the drug. I 
misinterpreted that, big time…. And also I had no idea of 
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what the ... um... couple of months following it would be 
on a spiritual physical level. Because that’s another story 
in itself really 
010: She did it through T. and got the whole thing and it 
didn’t go all that well…. We knew we had to do it away 
from each other to do it properly. Um... and so she ended 
up getting yeah... she tried though and she actually had 
CK. and um… I think T. popped in occasionally… 
(laughter) After three days J. actually jumped out of a 
window and fucking (laughter) jumped into a car in her 
pyjamas and drove down... and her dose hadn’t been 
closed off so she went down to the chemist and drank a 
dose down.  I think its methadone. I think you have to do it 
on morphine eh? 
Awareness of what can cause negative and dangerous experiences for 
people fits into this theme well as it informs improved practise. 
Code 2) ‘Sleep disruption and management’ is characterised by sleep 
disruption related to the effect of ibogaine, or related to the effects 
associated with opioid detoxification. It also captured their descriptions of 
what was effective in managing it. This code was voiced by nine out of the 
ten respondents, and was generally an expected outcome for participants. 
001: yeah basically I spent the time wandering around the 
hotel, lying down, getting up, not being able to sleep, 
lying down, lying on the couch, kind of… Um… I think it 
was the fourth day because I need to stop smoking, I have 
a very chronic cough, and every time I would lay down for 
sleep he would hear me cough and I… I have a really 
heavy cough and he would see me shaking and… like 
literally shaking… and he said you need to sleep and it 
[diazepam] would have only got me half an hour sleep it 
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wasn’t much at all…. No, it was the ibogaine that caused 
it.. 
002: Yeah I think I did. I slept quite well. And like I 
said … on the second, third or fourth night we had a short 
prescription of Valium. I’m sure it was Valium. 
004: It was a bit rough eh, because I really needed this 
help and I had none. And she would go to bed because she 
was so tired and would sleep all night long. And I would 
wander all night long. I tried to watch the Olympics on 
T.V but I couldn’t sit down for longer than five minutes, it 
was just… this terrible feeling and that just went on and 
on. 
Code 3) ‘Morphine versus methadone’. Six of the respondents had their 
detoxification off methadone and four detoxified off codeine or morphine 
sulphate. Three who withdrew off methadone stated they would have 
preferred to withdraw off morphine, as the protracted effects of a 
methadone withdrawal lasted longer than the benefits of the ibogaine 
therapy. 
002: I was on, I was only on about 60mgs [of methadone] 
and then I’d tapered down to probably about 30. I did a 
reasonable rapid count-down to 30 and before I went onto 
the ibogaine, I went, I don’t know, maybe five days, I think 
it may have been a week. There was a short period where 
I was on a reasonably high dose of DHCs… [before 
ibogaine treatment] 
009: And also I jumped off methadone and went on to um 
used DHCs for three days… yeah just made sense to me... 
um... stuff from that I had learnt from Dr G. The one who 
told me to jump off methadone and use the... back to 
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smack before the naltrexone… T. thought it was a really 
good idea.  
Code 4)  ‘High versus low ibogaine dose, use of boosters’. This code 
captured the experience of two respondents who used low doses of ibogaine 
in their treatments, and the six who used booster doses after the initial flood 
dose of ibogaine. One respondent used ibogaine independently six months 
after their initial treatment.  Of the six who used booster doses, all stated 
they helped with both further opioid withdrawal and pain management. 
Four used booster doses within 48 hours of initial treatment, which had the 
positive effect of further reduction of opioid withdrawals. Two used booster 
doses at three months after, and with good effect, for management of pain 
issues. One respondent who used incremental small doses of ibogaine had a 
negative experience with ibogaine treatment, and was disappointed 
regarding the lack of expected psychedelic effect. 
003: yup um.. and then they gave me a booster at that 
point of time. About 200mgs. I didn’t want to take it, I was 
like what is that shit you gave me, its hard core! But I 
thought ‘I trust these girls’.... at the time I thought they 
were some crazy witch doctor or something. Oh yeah, it 
was to make me feel a bit better and I was not really, I did 
not believe them. 
006: The second night I ended up needing the booster I 
started kicking the second night.. um.. and I had no 
sleep … and I didn’t want to take the booster I didn’t want 
to hear the noise I didn’t want to hear the buzzing noise 
again and even though it sounds all positive and when I 
talk about it, it sounds positive but I didn't want to do it 
again, to take the booster. Because it was really hard it 
was the hardest thing I’ve done in my life. But the booster 
didn’t take me back there... thank god… and T. told me 
that wasn’t going to happen. 
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Code 5) ‘Control the vomit’ was voiced strongly by most respondents. It is 
difficult to ascertain if all respondents experienced nausea, as the Dunedin 
ibogaine treatment provider administered and encouraged use of 
antiemetic’s to good effect. Nausea and vomiting emerged as something 
which greatly affected the effectiveness of the ibogaine treatment, as people 
sometimes lost a proportion of their orally-administered ibogaine dose. 
004: I can pretty much tell you this was all in the first 6 
hours because there was a marker when I started 
spewing… with an antiemetic on board. 
009:…I ended up puking any way and the tablets came out 
mostly whole... T. deciding that I needed to have some 
more... and me fighting it and saying; ‘no that stuff tastes 
gross’ and 'I’ll feel sick I don’t want to have any more'... 
and then her convincing me that I was having 
withdrawals... I was so disorientated the way I was feeling 
I couldn’t relate them to being withdrawals. 
010: There was a friend of mine who was a good mate 
coming up and making me drinks, doing my dishes and 
fucking cleaning up buckets of spew… 
Overview of Theme Four 
The six codes represented the combined experiences of this sub-group 
experimenting with ibogaine for opioid detoxification. They together 
highlighted some of the practises that help people have more comfortable 
experiences, such as management of sleep and nausea. Best practise derived 
from the interviews would also include a transition to short-acting opioids 
before ibogaine treatment, and obtaining the medical and social support 
identified in other themes. Use of ibogaine boosters 24-72 hours after 
treatment appeared to help with residual withdrawals; and for pain 
management, a booster three months after treatment was beneficial. 
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Ibogaine treatment effects on depression and 
anxiety 
Theme Five was originally incorporated within ‘treatment effects on 
dependence’, which represented an overall theme of ibogaine effects. It 
separated into its own theme as it was voiced strongly by the respondents, 
describing marked, observed changes to their mood and anxiety after 
ibogaine treatment. The interplay between these themes is discussed in 
Chapter Five, but this theme described the positive changes respondents 
reported relating to their mood and feelings of anxiety which could last 
from one week to three months. It was directly attributed to the effects of 
the ibogaine and not the absence of opioids. There appeared to be a mental 
processing of respondents' drug use and some resolution of emotional issues 
which occurred during, and for some time – one to two days', up to three 
months' – afterwards.  Seven codes were identified within this theme. 
Code 1) ‘Positive effects on mood after ibogaine treatment’ became 
apparent from the first interview until the last and was strongly voiced by 
all respondents. It was described as a better outlook on their future, 
incorporating some hope of living life ‘without a crutch’. Others described 
it as simply knowing their mood was improved. 
003: Oh yeah, kind of it felt like during those days, I don’t 
know, it felt like, it felt like, how do you describe it… it felt 
like all the weight on the shoulders had been lifted. It felt 
just free and elated. It felt like I was 16, brand new and 
had just woken up. 
005: Ah I spent a lot of time in bed, I was exhausted. I was 
physically and mentally, every kind of exhausted. Um but I 
wasn’t miserable um and at least I was, I was pretty 
happy. 
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009: …You know like… like I just had this.. it was like this 
antidote to depression. It was like this natural 
antidepressant that was like pervasive through my entire 
life. Everything was new and interesting and alive. And 
most of the people I know… like I’ve been there side by 
side with people who have come off methadone and 
succeeded. I have three friends now who have come off 
without ibogaine… and they have just struggled and 
struggled you know like a year of struggling and there 
was none of that, none… 
The temptation was to combine this code of mood management with the 
second code, 'anxiety management affecting abstinence', as they were both 
discussed and voiced together. However most respondents discerned a 
difference for themselves, between anxiety and mood, and were able to 
describe the separate effects of ibogaine treatment on both. 
Code 2) ‘Anxiety management affecting abstinence’. Effects on anxiety 
required a separate code because anxiety featured strongly around the 
withdrawal from opioids for this group. Most respondents voiced specific 
effects on their anxiety and ‘stresses’ due to the ibogaine, after treatment. 
This was expressed as no longer feeling anxious about maintaining a 
personal drug supply, or more generally, as accepting or conquering one's 
personal fears. 
002: And… at that stage you’re normally going oh maybe 
just one. But that was the deal-breaker at the end of it. It 
was the actual removal of the.. idea of going to score. You 
were going to think you were going to score, normally, 
and you get that bit of anxiety and you couldn’t...that 
anxiety wouldn’t go until you actually scored. That 
anxiety wasn’t there!  Oh it was like you might have 
fleeting thoughts but they were just like fleeting and there 
wasn’t that… upwelling of; ‘oh I got to go and score’. 
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And that got me through to the six month period and I’ve 
just really never looked back. It’s just been, that was it. 
You know. 
004: …one of the biggest outcomes for me was that sort of 
in the treatment I was sort of shown this fear and anxiety 
and afterwards it was gone. 
Code 3) ‘How to cope without a crutch’ came through from half the 
respondents, and was a real fear for some prior to ibogaine treatment. It 
overlapped with anxiety management somewhat, but included other reasons 
why people lean on drug use. Notably, this was voiced by some as an 
anxiety about no longer using opioids for pain management following the 
ibogaine treatment, and no longer using drugs as an emotional support. 
005: Yeah there’s the… just the whole fact that like I said 
before I kind of felt like because I’m doing this much 
drugs and I’m just miserable, maybe if I’m doing much 
less I could be more miserable, that was going on in the 
back of my mind as a possibility. I also read that’s not 
common after taking ibogaine, you know so but it still 
nags at you that if that’s your emotional sort of crutch 
then, like getting wasted all the time and that’s not going 
to be there it’s kind of scary to think how that would be 
but... 
008: Yeah and my body got a hammering. I managed to 
bend them all, well you know put stress on them, on them 
all. And because I was on methadone I’d been using my 
body in ways which wasn’t ideal. So I don’t remember 
cravings… but then I did start to freak about how to live 
with this pain... no sorry I had a top up [ibogaine] in the 
January or February the next year. About four months 
later. I had about 400mgs I think… Yeah and my doctor 
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was like let’s just give you some codeine... and I thought 
oh no this was a fucking bad idea I don’t want to do this. 
Code 4) ‘Powerful effect of hallucinogen’. This code almost had its own 
theme, except that ultimately it appeared the outcome of the psychedelic 
experience was related to mood and anxiety management. The effect of the 
hallucinogenic drug ibogaine was noticeably stronger for the eight 
respondents who took higher doses of ibogaine, and was described as much 
stronger in effect than previously-used hallucinogens such as LSD and 
magic mushrooms. 
002: Ah,. day one I remember being, I was ,about 18hrs 
into it, and the girls had gone outside for a cigarette, it 
was snowing outside and they had locked themselves 
out… and it was like, knock knock can you let us in the 
door. And I was like sure. Get up and I just found myself 
walking with jelly legs, walking through this massive 
Mechano-lego hallucinations (laughter) 
003: Yup. It wasn’t like a movie of my life or anything. It 
was like scenes from a freakin' horror movie. 
005: And it was all sort of emotionally charged and all 
sort of apocalyptic, very apocalyptic… Like literally. It 
was literally like seeing scenes of different apocalyptic 
worlds. 
006: Um… No I was being catapulted to outer space and 
then I was looking at the earth and it was breaking into 
three pieces… and I was getting this really strong 
message that if we don’t sort our shit out this is what will 
actually happen. And… then there would be jellyfish to 
make it better. Because my head was actually breaking 
because when the earth was doing it, it was my brain that 
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was doing it. The pressure was unbelievable… the 
jellyfish would make it all better. The jellyfish were 
incredible (laughter), and then I remember thinking I was 
dead. Because I could see myself and I told myself wiggle 
your toe and I couldn’t and I was like well at home they 
are going to have to cope with me dead… and I thought 
they will actually be alright if I’m dead… 
The powerful effects of ibogaine as an hallucinogenic drug tied in with the 
next four codes relating to the described mental effects of the experience. 
Code 5) ‘Mental /cognitive work after treatment’ was voiced by all the 
respondents when they described their journey after ibogaine treatment, 
both immediately afterwards and in the months following. It incorporated 
simply thinking about their life during and after treatment, to having 
‘thoughts’ and ‘visions’ that directly helped respondents to accept personal 
fears or grievances. 
001: No, and that was the one thing I noticed when I came 
home afterwards, I could sleep for 18 hours beforehand, I 
could lay down, read a book and fall asleep I could sleep 
all the time… and then I came home and I’m up at 12 
researching the Yugoslav wars because my brain was still 
active and I couldn’t turn it off... and I was up again at 
5.30 in the morning, so yeah (laughter)... 
009: … and that ibogaine had allowed me to... kind of… 
to think about really clearly… um... the things in my life I 
needed to change. So it was actually like... the reason I 
think ibogaine was so successful for me was the reflecting 
properties in it. The state, the mind state you are in for the 
next three months. It created a really unique situation 
with my mind where I would be able to calmly look at 
things and analyse things. Particularly things I felt really 
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guilty about. Like part of the whole parenting thing, like 
being an addict and being a parent, like, I was carrying a 
shit ton of guilt. And… just all the negative things I was 
carrying in my life. It enabled me to analyse those quite 
clearly as well. It’s really hard to explain. 
005: But then I'd go back to bed and… like for a good 
week or two afterwards I would go back to bed and return 
to the full-on dreaming... 
Respondents described not having read about or anticipated this post-
treatment effect. Interwoven with this code was the sixth code, ‘acceptance 
of fears, vulnerability and pain’.   
Code 6) ‘Acceptance of fears, vulnerability and pain’ emerged as a code 
when respondents described why they felt better after treatment. It seemed 
to occur more during the hallucinogenic/psychedelic phase of treatment and 
was often part of further described ‘epiphanies during treatment’. 
004: They… when I ask... it was almost as though if I 
wanted to ask a question, I’d ask it and I’d get told the 
answer. And I said why am I seeing such demonic shit? 
What is this demonic shit all about? And they told me it 
was all the stuff I’d filled myself up with over the years 
and taking the drugs, the opioids, had locked it into me, in 
the forms of emotions and stuff like that and it had me 
really negative… and they were showing me so I can let it 
go. The fear. It was all fear-based. Um... ‘they’ were 
African! 
006: .. I know I laughed for most of the day... but I was 
laughing at really awful things that had happened in my 
life. And telling T. every-thing that had ever happened in 
my life and laughing at it. I found out after that it was sort 
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of going back and attaching different feelings to negative 
experiences. 
006: Yeah but after I had the death thing and had to let go 
of all that shit, then I was OK to go away for a week. It’s 
the ultimate anxiety management really isn’t it? Accept 
death. 
Code 7) ‘Heightened senses post treatment’ captured participants' accounts 
of how long the hallucinogenic effect continued, or as one described it, ‘the 
antidote for depression for three months afterwards’. It was described in 
several ways, with some respondents stating their diet was severely affected 
- not being able to eat gluten products - and others saying it was like having 
LSD every day for three months, with their taste and visual senses 
heightened. Ultimately this after-effect appeared to benefit people’s mood 
and anxiety. 
001: So weird yeah. And I had to wear sunglasses because 
I was super sensitive to the light eh?… It’s the food thing. 
You know the food thing? You don’t talk about the gluten- 
and dairy-free thing in here? 
004: … Suddenly I could smell the sea and the sea weed 
and a seal on the beach. I could smell the leaves rotting in 
the bush behind me. My senses just came alive. I had to 
get out of this shop because it was so overwhelming, the 
plastic bags, the varnish on the tables, a woman’s 
perfume was way too overbearing. And that lasted for 
three days before it settled down. 
Respondents described these heightened senses as effects of the 
hallucinogen and not the later described (in Theme Seven) ‘spiritual 
effects’. 
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Overview of Theme Five 
Respondents described in detail the effects of ibogaine and its associated 
psychedelic nature, on their improved mood and anxiety levels. This 
appeared to last from one week to three months and was directly attributed 
to the drug ibogaine and not to being drug-free, which was occurring at the 
same time. Acceptance of one's fears, and continual mental processing and 
reflection after treatment, was associated with the reported beneficial effects 
on respondents' moods. 
Ibogaine treatment effects on dependence 
This sixth theme was constantly voiced in the interviews, and included 
changes to both opioid and other drug use.  Seven out of 10 respondents 
reported they remained opioid-free at time of interviewing. The remaining 
three described periods of abstinence lasting from three to six months. 
Effects on other drug use were also described as positive. As in Table 4, 
five participants were currently abstinent from alcohol and other non-opioid 
drugs. The abstinence appeared to be mostly maintained as a result of 
improved mood and outlook, but also through the absence of opioid 
withdrawals.  It was represented by five codes. 
Code 1) ‘Absence of opioid withdrawals’.  All respondents reported 
markedly less or no opioid withdrawal symptoms both during treatment, 
and for various lengths of time afterward. This obviously had an effect on 
the interviewees' final treatment goal of being opioid-free and thus helped 
define this theme. Effects on withdrawal symptoms did not appear dose-
related. That is, three respondents who had used low, incremental doses of 
ibogaine still had marked absence of opioid withdrawals. 
002: Yup. Despite everything else a severe absence of 
withdrawal symptoms. And this was the beginning of the 
clincher… 
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[seven weeks later]… 
Yeah pretty good.. I think the big deal was I wasn’t 
fighting withdrawal. And, I mean that’s 90 percent of the 
battle. Yes I’m tired, yes I’ve gone through a lot, yes I’ve 
done this but I don’t have that kickarse…monkey on my 
back. Not thinking about where to score, not thinking 
about who to get in contact with. It was just like you 
know... 
006: Oh I didn’t get any. None at all for the whole time. 
One week? No withdrawals, nah. No I never got any 
withdrawals. 
005: I remember Dr G. came round for a chat and I 
remember him saying ‘oh you don’t look like a chap who 
has come off methadone two days ago’ , and I was sitting 
in the kitchen talking to him like it wasn’t that big of a 
deal. 
Code 2) ‘Effects on opioid usage’ captured overall effects of ibogaine on 
respondents' opioid dependence, which is separate from just focussing on 
the withdrawals. Of the 10 respondents, seven cited continued abstinence 
from opioids, and three relapsed. One respondent utilised ibogaine again, 
after an original treatment and two-month abstinence period, but then 
further relapsed. Of the six respondents from the Dunedin clinic five cited 
continued abstinence. 
007: ...and broke my wrist last year you know little things 
like that… which in the past would have been big triggers 
or an excuse or whatever you know. 
009: No I didn’t need to... I mean I had a situation where 
my husband had an affair and my best friend died in the 
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same week and I remember just losing my mind for a little 
bit thinking what do I do, what do I do and what would I 
normally do, and being, like, well normally I would just 
get stoned. And that was as close as it ever came… I was 
going ‘well that would be a dumb idea’. So literally going 
well I’ll still be in this situation but then I’d be really 
pissed off with myself as well. Like that was it. That was 
literally… like that was a year later. There was no… I had 
absolutely, like, 100% never any desire whatsoever… 
010: Um six months [relapse]….  For me it’s… I don’t 
have any excuses apart from the fact that I ended up 
becoming my mother’s care giver, she ended up having 
cancer and I ended up looking after her. That’s what she 
finally died of...so I ended up dabbling again to help me 
with that process… 
Code 3) ‘Three-month point after treatment’ was first looked for because of 
the literature, but was clearly apparent in this study, as a time period after 
treatment where those who had maintained abstinence could struggle. 
003: [three months] Ah yes, yes, DHCs, and then started 
some morphine… 
001: Literally I would pull up and lie in my car until 5 
o’clock, and read a book, for seven hours, 3 days a 
week...and I’ll go and visit M. And it was that old 
association, it was comfortable, and he does it. I’d come 
round and he’d be wasted, and I’d do that again time 
after time, and then you know, eventually he had 
something, oh I'll have a little bit…I guess, so, I… the job 
didn’t work out and I couldn’t start Uni halfway through 
the year, the courses were all full-year… 
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005: Yeah, and then um… I was probably um smoking 
ciggys daily again by two months um… and drinking 
somewhat regularly then. No opioid use at that point and 
around about, like, three and a half months I was a bit 
lost you know. I wasn’t back at university, I still haven’t 
got the girl friend, I still was… um… a bit lost and I used 
opiates again a couple of times around the three-four 
month mark. And it freaked me out. I thought oh shit, this 
is not good. So I packed my shit and went to Auckland and 
got a job up there, in Auckland. 
Code 4) ‘Effects on other drug use’ was a surprise to some of the 
respondents, and helped some with their treatment goals. One respondent 
described his partner, who used ibogaine solely for the purpose of a 
cannabis detoxification, but which had no effect on that substance. Other 
respondents noted that they wished they'd known it could help with other 
substances, and would have planned for more out of their ibogaine 
treatment. 
001: Yeah yeah I had to force myself to start smoking, in 
Australia, after four days of no sleep and I had nothing to 
do, I wasn’t allowed to watch TV so I was pacing back 
and forward in this hotel...hotel room. The only other 
thing to do was smoke and I had my first one and I threw 
it away. It was the most revolting thing I had ever had, I 
had to force myself to. 
005: So the first two weeks there was no craving for 
absolutely anything. No alcohol, no benzos no ciggys 
even. But then after about two weeks the first craving that 
came to me was for ciggys and that was after about two 
weeks um... and um… I hadn’t... I think I went close to a 
month before I had a beer… Yeah, I guess the interesting 
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thing about that is that I had um… one beer and I felt like 
I was tripping again. 
Code 5) ‘Effects of treatment on pain and the physical body’. In this code 
all respondents reported strong physical effects during treatment such as 
tactile sensations and ‘tingling up the nerves’. Two interviewees strongly 
voiced that while subject to the effects of ibogaine they had received a form 
of physical healing. 
004: … what was happening was, as my body was starting 
to wake up, the signals coming up the nervous system... 
this is the best way I can describe it. It would start at my 
feet, so I’d be talking to you now and I’d get this electric 
type of energy in my feet and it would go up my legs and 
into my spine and go to the spot where I was injured and I 
would hear this noise like a crackle. Then it would go 
shooting down my arms and I would have to shake them. 
If I was sitting here talking to you, you would think I was 
spastic. I would be shaking my limbs, my arms and my 
feet. It was so weird, I couldn’t sit still. When I got home 
it took my wife three days to cut my hair because I 
couldn’t sit still long enough 
004: Ok three months I remember I was struggling with 
my pain a wee bit and, you know, that sort of came 
back…. just real back pain and this nerve pain and… 
um… I remember sort of thinking that was the first time I 
had this sort of doubt about future thinking, like, what am 
I going to do now? You know, how do I face this pain 
without medication?. Yeah the end of the bubble basically. 
And so… I took, like, a top up dose… [ibogaine] 
007:… and it got to that stage of, ‘oh here it comes 
rushing up my body’. It rushed up my body… it got to the 
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tumour and it was just, it was like a really loud...two 
freight trains colliding, I could physically hear it, and 
physically felt it, it was like this bang!... And everything 
stopped.…Well in hindsight it was profound, you know, 
because, because it literally… stopped the tumour… once 
we figured it out. 
The experienced physical effects fitted in well with the effects on 
dependence, when opioid dependence was viewed alongside pain 
management. 
Overview of Theme Six 
Seven respondents reported remaining opioid-free following ibogaine 
treatment, and five of this number remained abstinent from other drugs as 
well; so there was an obvious effect on drug dependence for these 
respondents. The effect appeared to last from three months to an indefinite 
number of years, and was influenced by a lack of opioid withdrawals, and 
experiences of positive physical effects on the body. 
The spiritual effect 
Theme Seven, an independent and final theme: the 'spiritual effect’.  Voiced 
by most respondents in various forms, it appeared to be more influential 
with four respondents in particular. This theme recorded the information 
that these four participants yearned for something else, another lifestyle and 
mental awakening, away from opioids, which may help understand some of 
their motivations for use. It also captured the very vivid experiences 
respondents described as ‘spiritual’. This includes the three respondents that 
mentioned being visited during their hallucinogenic experience by an 
African Shaman. 'The spiritual effect' was represented by four codes. 
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Code 1) ‘Long-term effect of hallucinogen’ was described by the four most 
affected respondents, and was described as lasting up to three months after 
initial treatment. Although similar to the already specified code of 
‘heightened senses after treatment’, this emerged as a separate code in the 
spiritual theme because respondents described it separately, distinct from 
the changes in appetite and smell. 
006: No I would say three months… I was tripping balls 
for three months. It was kind of like I’d taken a tab of 
acid… a tab of local acid... for quite some time. But I 
often say even now... the way I feel now before ibo, I 
would have to take half a tab of acid to be like I am all of 
the time now…(laughter) it just never wore 
off...happiness-wise. I used to be really quite jittery and 
anxious all the time…ask G (laughter). 
006: I spent a lot of time just being amazed. Which I still 
do actually, all I need to do is look up at the sky now and I 
can just go ‘duuh’ and switch off. Because I got to see 
like, the world and atmosphere from space. To see that 
visual layer of atmosphere just blew my mind and now I 
look up and go holly shit (laughter) 
008: People were just laughing because I was just so out 
there, I wanted to let the grass grow, and allowing the 
mouse to live in my cupboard… 
This code was definitely described as the hallucinogenic effects of ibogaine 
that lasted well after the initial treatment. Whereas the second code, ‘sense 
of epiphany during treatment’ was described and experienced during 
ibogaine treatment.  
 Code 2) ‘Sense of epiphany during treatment’ captured respondents' 
descriptions of the hallucinogenic effects during the first, active phase of 
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ibogaine treatment, but with a spiritual, or some greater significance 
attached. 
004: .. Directly after ibogaine I had this feeling, and it’s 
hard to describe, but after treatment I felt slightly magical 
in the sense I felt really positive...the music sounded 
better...lots of things seem better. There was just this neat 
feeling. And the very first pharmaceutical drugs I took 
edged that feeling away again. And I’ve read before that 
other people experience this… Yeah I came home and 
picked up a paint brush and I’ve never painted before in 
my life. And since I have done about, about 15 amazing 
paintings...and even been offered money for them. 
006: … and I was like well at home they are going to have 
to cope with me dead... and I thought they will actually be 
alright if I’m dead… And it’s really funny because at 
about....in the middle of the night which could have been 
three in the morning, possibly the same time, my daughter 
sat up in bed, she was in bed with my husband, and she 
sat up and said; ‘where’s the body?' (laughter) and she 
had never said anything like that before… Yeah yeah see 
this is a tricky one for me too because I got the very 
strong message when I was under the influence of 
ibogaine that I should be a provider now. So… I sat up the 
next day and said to T. well I have to go train to be an 
addiction practitioner now and do what you do, because I 
got told that. 
Code 3) The little brown man. Tied in very closely with the sense of 
epiphany for four respondents, were three of the four respondents who 
described in detail a visitation, during treatment, of what they described as a 
Shaman from Africa who aided both physical healing and spiritual healing 
for them. This code captured their experiences. 
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004: Right, the second phase was the sensation of an 
African person standing in front of me.  And… for want of 
a better description because you will think I’m totally 
crazy and its part of my anxiety almost, in talking tonight 
because when I recall this stuff it seems like so much out 
of the frickin box..  Right OK. So I have this African dude 
in front of me and he is talking to me in this kind of pigeon 
garbled English type of thing…“oh bugger we will have to 
use the cell-shaking method”…  And I was sitting there 
going what the fuck is the cell-shaking method and how is 
that going to work? 
006: …. and then this wee dude came and sat on my bed 
and he said... you’re really anxious as a person and we 
need to do something about that otherwise it’s not going 
to be good and he said to me ‘breathe like this’ and it was 
really like (deep breaths) and he said ‘blow your breath 
out as much as you can and blow your breath out as hard 
as you can and you will feel less anxious’ and so I did 
that. And K.… I could hear K. saying; ‘are you alright in 
there K?’ and I said I’m just exorcising some demons 
because this is what this man is telling me, he was sitting 
there, just sitting there talking to me.  He was black… this 
wee African dude. 
Code 4) ‘Search of the spiritual’. This code was originally under Theme 
One, ‘motivations to use ibogaine’, as it was represented there also. 
However it was moved to this theme as it was more strongly described 
throughout the whole treatment experience, including post-treatment 
recovery. 
005:… cos um definitely like um, like as I said pretty 
miserable, like generally a pain in the arse to be around. 
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I’d alienated friends and I was like I was...I was expecting 
some psychological, some emotional benefit as well. 
 
007: … and I was getting into a bit of… like Reiki and 
energy work and I felt it was holding me back from that 
too so yeah….Curiosity, I don’t know. Curiosity you know 
thinking maybe I’ll take this…. It was more the curiosity 
about what this may do to the tumour.  That was my 
motivation. 
Overview of Theme Seven 
The four codes in this theme demonstrated a consistent description people 
told when using ibogaine. This description could fall under psycho-social or 
emotional improvements driving better treatment outcomes. However, this 
theme represented the respondents' detailed descriptions of subjects that 
perhaps went beyond the emotional and mental level, such as Shaman 
visitations and physical healing. It also captured other less well-described 
motivations for choosing ibogaine such as wanting to do Reiki healing 
work. 
Summary - Chapter Four 
The findings of this case study on ten opioid-dependent people using 
ibogaine for their detoxification were logically grouped into common 
subjects, discussed, and then these subjects were logically grouped into 
themes. There were seven such themes.  
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'Not sitting comfortably with opioids' 
This group of respondents reported strongly a desire to be completely free 
of opioid use, including no longer using substitution opioids. They 
described it as no longer wanting the effects of the narcotic in their body 
and mind. Negative effects on mood were voiced the strongest followed by 
effects on the physical body, as related to using illicit opioids and 
substitution opioids, mostly methadone. Daily anxiety was reported by half 
the respondents and attributed to the effects of opioids. Also a sense of 
frustration was reported that being on substitution therapy held them back 
from goals they wanted to achieve. Goals ranging from energy healing 
work, to raising a family and running a business. These effects caused some 
to keep substitution doses at a sub-therapeutic level. In general, the group 
had an anti-establishment view of standard addiction treatments but most 
utilised methadone treatment (OST). 
The study group reported severe low moods associated with opioid 
withdrawals and did not tolerate these well. However most respondents had 
many multiple and desperate unsuccessful attempts at opioid detoxification. 
Prolonged withdrawal symptoms, including that of depression, and ‘an 
anxiety’ about life without drugs were key features identified for their lack 
of success. 
'Motivations for using ibogaine’ 
This second theme described respondents’ strong motivations to use 
ibogaine as an alternative treatment option for opioid detoxification. Mostly 
the respondents described a sense of hope that this form of treatment would 
have long term success and alleviate opioid withdrawals during the 
detoxification stage. The reported quickness of treatment time with ibogaine 
was also described as attractive, reducing an expected six months recovery 
time to sometimes less than two weeks. Legality of the treatment did not 
affect respondents' choice to use ibogaine but did affect the level of medical 
input achieved before, during and after treatment. This group of respondents 
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had previous positive experiences with recreational hallucinogenic drugs 
(LSD, mushrooms) and a strong relationship with cannabis use was 
described by most. A self-described attraction to ‘psycho-stimulating drugs’ 
appeared to be part of the motivation for choosing ibogaine. Four 
respondents described searching for a spiritual healing or profound 
psychological meaning and resolution, which they felt would be required to 
maintain opioid abstinence, and which hallucinogenic ibogaine treatment 
was believed to assist with. The strongest reported motivator was knowing 
someone who had been opioid-dependent, who had experienced ibogaine 
treatment and made changes the respondents themselves wished to achieve. 
'Safety conscious and support-seeking' 
All ten respondents sought medical testing from their General practitioner 
(GP), prior to ibogaine treatment, even the independent user of ibogaine. 
When respondents had the guidance of an ibogaine treatment provider they 
obtained the safest, recommended, pre-treatment medical tests and 
screenings. New Zealand and Australian treatment providers used by 
respondents in this study provided a list of the recommended medical tests 
and screens and these were achieved before ibogaine treatment could 
continue. Respondents who did not use a treatment provider obtained non-
recommended, perhaps irrelevant, pre-treatment medical screening. When 
ibogaine became legal to prescribe as an off-licence medicine in New 
Zealand, respondents described having access to medical support during 
and after ibogaine treatment, such as nausea control and sleep 
augmentation. Legality also legitimised the ibogaine treatment providers in 
New Zealand, and some respondents even described taking their treatment 
provider along to their GP with a complete list of what was required. This 
theme of ‘support-seeking’ clearly identified the type of support and 
preparation people who use ibogaine required for successful treatment 
outcomes, as evidenced by those who did not have support or after-care 
plans and relapsed into opioid use. More successful cases utilised supports 
including peers who had used ibogaine, internet chat sites, a knowledgeable 
‘clinic’ or ibogaine peer group, and family members. Some utilised GPs and 
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community psychiatric nurses during ibogaine treatment. Physical care was 
often required for the first two days of ibogaine treatment, and rest and 
recovery for a further one to two weeks was described as required and with 
much emotional support, and often medical support where sleep was 
affected. Half the respondents stated they required information, support and 
even booster doses of ibogaine from their treatment providers. The AA 
(Alcohol Anonymous) treatment model was utilised by half the respondents 
after treatment, somewhat at odds with identified respondent traits of being 
anti-establishment and critical of standard treatments. 
'Best practise' 
The theme of ‘best practise’ emerged when respondents described 
variations in ibogaine treatments and what they would have done 
differently. This included utilising a therapeutic dose of ibogaine, and being 
able to use booster doses during treatment and in the months afterwards.  
Other more pragmatic considerations were hydration, nausea management 
and sleep concerns as related to ibogaine treatment. It was emphasised that 
switching to shorter-acting opioids before ibogaine treatment allowed for 
greater effectiveness in managing opioid withdrawals, than when 
detoxifying off longer-acting methadone. Perhaps most intriguing was that 
respondents who experienced a ‘spiritual effect' during the psychedelic 
phase of ibogaine treatment described major positive effects on their mood, 
and resolution of their anxiety, both of which positively affected opioid 
abstinence. Although this spiritual-type healing was sought by other 
respondents it was not always achieved, mostly because of poor nausea 
control or lower ibogaine dosing. It appeared the knowledge and 
reassurance of an ibogaine treatment provider facilitated this experience, 
perhaps as part of best practise. 
'Effects of treatment on depression and anxiety' 
This theme represented the way respondents described ibogaine treatment's 
ability to improve mood and anxiety, even at low doses of ibogaine. This 
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was strongly emphasised by the respondents as the main reason they felt 
they no longer needed other drugs or further opioid use. Improved mood 
also included feeling less anxiety and in some cases complete removal of 
anxiety was achieved. This effects were described as being due to the 
hallucinogenic effects of ibogaine and not just the removal of opioids from 
the body. The mood improvements and less feelings of anxiety were 
reported to last for one to three months. During this same time period 
respondents described little or no opioid withdrawal symptoms which they 
reported also helped with anxieties and mood. 
'The effects of treatment on dependence' 
With seven respondents reporting having remained opioid-free, and five of 
this number abstinent from other drugs as well, there was an obvious effect 
on drug dependence after ibogaine treatment for this group of respondents. 
The effect of ibogaine treatment was described as eliminating withdrawal 
symptoms during detoxification phase, and improving mood and anxiety in 
the recovery period after treatment. The improved mood was attributed to 
ibogaine, not the absence of other drug use. The effect appears to last from 
3 months (for three respondents who relapsed into opioid use), to years and 
into recovery (for seven respondents who remained abstinent at time of 
writing). Other effects of ibogaine treatment, described during abstinence, 
included a reported positive effect on the physical body with two 
respondents using booster doses of ibogaine three months after initial 
treatment to successfully manage pain. The three participants who relapsed 
still achieved significant periods of abstinence (3 – 6 months), regardless of 
negative experiences or poorer ibogaine treatment practises.    
'The spiritual effect' 
A consistent attraction described by the respondents for the use of ibogaine 
was labelled as 'the spiritual effect'. Participants often detailed they were 
searching for some mental or emotional resolution to the cause of their drug 
use and felt ibogaine or hallucinogenic treatments could facilitate this. 
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Some respondents went further, and described the effects of treatment as 
going beyond mental and emotional, to a spiritual type of change. 
Respondents who stated their experience with ibogaine was negative were 
mainly disappointed that they did not receive the spiritual effect they had 
hoped for, however they still achieved opioid abstinence. The ‘spiritual 
effect’ theme captured some respondents’ reason for wanting off opioids 
altogether, even a stable substitution treatment service. Opioids themselves 
were described by two respondents as a ‘block’ to their individual 
spirituality; one respondent said opioid use prevented her from attaining her 
goal of energy healing work. This theme also captured the two respondents 
who described 'spiritual epiphanies' during the active phase of ibogaine 
treatment, and described being visited by an African shaman. They 
attributed their subsequent physical and emotional healing and removal of 
‘all’ anxiety, to this hallucinogenic encounter. 
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CHAPTER FIVE: 
DISCUSSION 
Overview of chapter 
This study's main research question was: ‘what were the experiences and 
motivations of opioid-dependent people using ibogaine in New Zealand?’, 
with the sub-question, ‘What safety measures and medical tests were 
ibogaine users aware of and utilised?’  
To explore these questions a multiple case study method was chosen, as 
described by Yin (2009), to allow illumination of why decisions were made 
and how they were implemented (p 20). Ten respondents were recruited, 
mainly through relationships built with the Dunedin ibogaine treatment 
provider and contacting people who had used their service, and through 
previous contact with an opioid substitution service in Christchurch. 
As per Chapter Four, 38 codes, or different subjects, discussed by various 
respondents, were grouped into seven logical themes. These were identified 
by the researcher with consultation with the researcher's supervisors. The 
seven codes were: ‘Not sitting comfortably with opioids’; ‘Motivations for 
using ibogaine’; ‘Safety conscious and support-seeking’; ‘The best 
practise’, ‘Ibogaine treatment effects on depression and anxiety’; ‘Ibogaine 
treatment effects on dependence’; and ‘The spiritual effect’ 
An ibogaine user's experience in New Zealand is described via three 
separate discussions.  These discussions illuminate the relationships and 
complexities between six of the most significant themes. Discussions 
highlight important findings that emerged, how findings are connected and 
the consistencies and inconsistencies with current literature. The discussions 
note areas for further exploration, which lead to later sections covering 
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further research. The sub-question as to what medical and safety tests were 
achieved before ibogaine treatment are also highlighted in the discussion. 
The relationships between these themes are represented in Graph 1. 
Strengths and limitations of this research is also discussed at the end of this 
chapter. 
Overview of discussions 
Discussion 1) The relationship between ‘Not sitting comfortably on opioids’ 
and ‘Motivations to use ibogaine’, concludes most ibogaine users in this 
case study experienced adverse side effects when using opioid drugs, 
including substitution opioids. These were described as low mood, feeling 
anxious, physical side effects, and a feeling of being stuck. This interplayed 
with the main method of dissemination of ibogaine information, which was 
through internet, non-medical peer forums. Most promised hope of much-
reduced withdrawal symptoms, a quick detoxification from opioids, and 
reported that ibogaine detoxification was successful in the majority of cases. 
Discussion 2) The relationship between ‘Safety conscious and support-
seeking’ and 'The best practise’ concludes that all respondents sought 
medical testing before their ibogaine treatment. Those who had the 
guidance of an ibogaine treatment provider achieved correct pre-treatment 
medical tests. Those who sought medical tests independently achieved non-
recommended and irrelevant pre-treatment tests. Additional medical support 
such as managing ibogaine treatment symptoms, heart ECG monitoring, 
sleep disruption and nausea during treatment allowed respondents to 
achieve better ibogaine treatment outcomes. The ibogaine treatment 
providers were more effective when the drug was legal. People achieved 
positive outcomes when using ibogaine booster doses anywhere up to three 
months after initial treatment. 
Discussion 3) The relationship between ‘Ibogaine treatment effects on 
depression and anxiety’ and ‘Ibogaine treatment effects on dependence’, 
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concludes that detoxification with ibogaine positively affected users mood 
and feelings of anxiety during, and up to three months after treatment. Most 
respondents stated this was a large factor in managing the withdrawals and 
recovery from dependence after detoxification. The theme of 'The spiritual 
effect’ also appeared to play a part in reasons why people chose ibogaine 
treatment, and for some, the reasons why their mood and anxiety issues 
were resolved post-treatment. 
Discussion One  
The relationship between: ‘Not sitting comfortably on opioids’ and 
‘Motivations to use ibogaine’ 
'Not sitting comfortably on opioids' emerged as the first theme and was 
described with much emphasis by all the respondents. It was a new point of 
view for the researcher and not widely read about in the literature, although 
one New Zealand study discussed lower health status comments, including 
that of life satisfaction scores, compared to that of the general population 
(Deering et al., 2004).  In a European qualitative study focussing on quality 
of life indicators for people in OST, De Mayer et al (2011) described one 
theme of the opioid-dependent sample was that opioids had a paralysing 
effect on their emotions. This dissatisfaction with the pharmacological 
effects of opioids was openly voiced by the respondents of this study. The 
reasons people stated they were not at ease with opioids was not the 
anticipated restrictions of substitution programmes, but the mental and 
physical side effects people described of both illicit and substitution 
opioids. The effects were described and attributed to the actual drug, in this 
case methadone, not because of other life factors. This was harder to 
describe for illicit opioid users because of the nature and demands of an 
illegal drug dependence which can create its own stresses and anxieties 
(Adamson, Sellman, Deering, Robertson, & de Zwart, 2005). Respondents 
in this study mostly stated that opioid substitution gave stability compared 
to their illicit use periods, and that periods of illicit use were harder times 
physically and mentally. However, two respondents clearly outlined the low 
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mood and physical lethargy they felt when using a stable amount of illicit 
opioids and whilst in a stable life period. This dis-ease with the 
pharmacological effects of opioids was the same for substitution opioids: 
nine respondents stated low mood, anxiety and physical side effects were a 
strong motivator for wanting to change from, albeit a successful, 
substitution treatment, to something away from opioids completely. 
The physical side-effects of substitution therapy were well-reported in the 
literature, ranging from effects on sexual dysfunction (Trajanovska, 
Vujovic, Ignjatova, Janicevic-Ivanovska, & Cibisev, 2013), to prolongation 
of the interval of the cardiac QTc wave (Mohamad et al., 2013). However, 
there was much less direct literature on depression scores of methadone 
users compared to non-methadone counterparts. One study estimated there 
was a 10-30% prevalence (across five studies) of major depression in a 
cohort of methadone maintenance populations but did not correlate this with 
the pharmacological effects of the drug, rather it cited the lifestyle and other 
co-morbidities of the population studied (Peles, Schreiber, Naumovsky, & 
Adelson, 2007). 
Another finding from this theme of  'not sitting comfortably on opioids', 
was the many attempts at quitting or previous unsuccessful detoxification 
attempts: eight out of ten respondents had attempted to ‘detox’ prior to 
ibogaine treatment. This was re-emphasised by the respondents when they 
described their journeys towards ibogaine treatment. Some respondents felt 
it was characteristic of people who chose ibogaine treatment, to have had 
numerous unsuccessful attempts at detoxification using other means, such 
as gradual withdrawal of methadone dose. However, for two respondents 
ibogaine therapy was their first attempt at opioid detoxification, stating fear 
of opioid withdrawals and the associated low mood had previously 
prevented any attempts of withdrawing off a substitution programme. It was 
unclear from the literature if people who use ibogaine had more quitting 
attempts than the general opioid population. Most articles found stated this 
population had ‘unsuccessful attempts at reducing or stopping and may exit 
and enter an opioid substitution service multiple times’ and appeared not to 
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explore, for the purposes of those studies, the number of quit times 
attempted (Adamson & Sellman, 1998; Deering, Sellman, & Adamson, 
2014).    
Another interesting finding from the case study was the code ‘opioid 
withdrawals and associated low mood were not tolerated very well’. This 
group described being particularly vulnerable to low moods associated with 
opioid withdrawals. This was not overly described in the literature explored 
except that low mood was a known feature of opioid withdrawal (Kamlet & 
Alper, 2010). It would be worthy of further exploration to ascertain if there 
are groups whose main barrier to reducing substitution treatment was 
managing this low mood. Again, two respondents who did not attempt any 
previous detoxifications stated they hadn’t because of fear of withdrawal 
symptoms and low moods. Ibogaine specifically attracted these respondents 
because of the hope of less withdrawal symptoms. 
Other topics related to this theme were expected and well-reported in the 
literature, such as the self-stigma of being an addict (Koester, Anderson, & 
Hoffer, 1999). Opioid-dependent populations are a marginalised vulnerable 
hard-to-reach group (Deering et al., 2004), and not well-tolerated in the 
medical world or society generally, largely due the tactics and methods 
deployed by some of this group to obtain narcotics, including deceit, 
manipulation and crime (Butler & Sheridan, 2010; Degenhardt & Hall, 
2012). Respondents in this case study described not only seeing these 
behaviours in their peers but acknowledged that is how they would be 
perceived as well. Four respondents especially felt this to be a reason for 
‘not sitting comfortably’ on opioid substitution therapy or even illicit use. 
Two respondents described not liking being ‘beholden’ to something; or 
where living remotely required regular pharmacy pick-ups which caused a 
constant anxiety of being dependent ‘on anything’. Anxiety around being 
dependent was noted in the literature reviewed, but described by De Maeyer 
et al (2011) as ‘wishing to be independent.  
~ 130 ~ 
The second theme, ‘Motivations for using ibogaine’ was clearly separated 
from the first ('Not sitting comfortably on opioids'), as the first theme 
presented for respondents before they had any knowledge of ibogaine 
treatment. Motivations for ibogaine use were significant for this study as 
they helped answer the second part of the main research question. The 
significant codes within this theme were the respondents’ described sense of 
hope that a detoxification may work. Not only were there genuine reports of 
success on the internet but also from people, face-to-face, who had been 
successfully treated. Reported treatment success also brought hope of less 
withdrawal symptoms during treatment and afterwards. The whole process 
appeared to give hope of quick treatment and recovery.  The collective case 
study highlighted a feeling of desperation the respondents felt on opioid 
substitution therapy because of low mood and physical side effects as 
already mentioned. The physical side effects associated with methadone and 
buprenorphine were well captured in an Australian sample of 500+ OST 
clients (Winstock, Lea, & Sheridan, 2008). Sheridan et al (2008) illustrated 
OST populations' main listed physical side effects by asking ‘what they 
sought treatment for’, related to physical effects of substitution treatment. 
These were dental concerns, constipation, sweating and 12% reported 
chronic headaches they sought treatment for. Sedation was also listed as a 
concern but more for the methadone sample than the smaller buprenorphine 
sample. Mood and anxiety were not listed or the focus of that study. It did 
mention this could be a possible cause for poor retention rates, and this was 
eventually directly measured (Winstock et al., 2008). 
The method by which the case study cohort discovered ibogaine therapy, 
the internet, is largely uncensored and many addiction forums report 
treatment success with ibogaine. Nine respondents out of ten placed 
emphasis on the hope they felt and desperation that some treatment had to 
work for them. Seven respondents specifically stated the reported absence 
of withdrawal symptoms was a key part of their hope. Five respondents 
stated they hoped ibogaine could deliver a form of mental or psychological 
treatment, which they felt they needed to accomplish opioid abstinence. 
Motivations for ibogaine use, as stated in the literature review, had no direct 
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literature or data. When searching the literature for possible motivations for 
ibogaine treatment (Chapter 2) the quickness of treatment was found 
mentioned in international ibogaine cases but as an outcome or side effect, 
not as an initial motivator for people seeking this treatment (Lotsof & 
Alexander, 2001). All respondents mentioned the ‘quickness’ of treatment 
when describing why they chose ibogaine treatment. Respondents stated it 
was also the faster recovery time after detoxification that was attractive. 
Two respondents stated it was relatively easy for them to detoxify off 
methadone, but the six month recovery period afterwards was often 
described as the ‘last hurdle’ that always tripped them up (referring to 
relapse). When examining the interplay with theme one, especially around 
opioid withdrawal and the ensuing long detox being intolerable to 
respondents, compared to ibogaine's brevity of treatment and alleviation of 
opioid withdrawal, it was clear this illustrated a significant connection for 
the case study respondents. Six of the respondents also participated in 
Noller et al (2017) study and motivations for choosing ibogaine treatment or 
previous barriers to OST were not measured and so cannot be compared 
with this study. Most of the research explored for possible motivations for 
ibogaine use found wider hallucinogenic treatment studies that mentioned 
the ‘spiritual type redemption’ people seek from their drug treatments (de 
Rios, Grob, & Baker, 2002). There emerged within this theme, for one 
respondent, a search for the spiritual effect.  She stated she wished to do 
energy healing work and believed energy blocks, caused by her opiate use, 
had prevented her from doing so, but that ibogaine treatment could remove 
those blocks. 
Another obvious motivator the study found for ibogaine use was an 
attraction to hallucinogenic drugs. This was found for all ten respondents 
who had used various forms of other hallucinogens in their drug use career, 
including the one pain-related client. This strong code was placed within 
this theme, as being attracted to the effects of hallucinogenic drugs affected 
a person’s desire to use hallucinogenic alternative treatments. Although 
attraction to the type of drug and its effects was a possible motivator for 
ibogaine therapy, previous use of hallucinogens was also described as a 
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personality type of ‘some’ opioid users by one respondent. He described in 
his experience that some opioid users wanted ‘psycho-active’ drugs such as 
cannabis and hallucinogens, whilst other ‘types’ of opioid users don’t wish 
for any extra thoughts but to ‘numb’ all thoughts and feelings. He believed 
this same group would not use cannabis for this reason. Previous 
hallucinogenic drug use was not noted in any literature related to ibogaine 
studies. Most respondents who took higher doses of ibogaine said it was a 
much stronger hallucinogenic agent than that of magic mushrooms or LSD. 
Two respondents stated they were glad of the experience of having mentally 
navigated through previous ‘bad trips’ to cope with the experience of 
ibogaine. This is of significance when considering what positively affected 
people's experience with ibogaine treatment. Especially in light of best 
possible future practise.  The findings of this case study regarding 
characteristics also captured that all ten respondents had previously used 
cannabis, and most had a strong relationship with it. 
The effects of the first theme, including low mood and sickness on 
methadone and not tolerating opioid withdrawals, appeared necessary for 
the motivations in the second theme to be significant. Information about 
ibogaine is widely available on the internet and, as reported by one 
respondent, was talked about among certain opioid-using peers and 
networks but not commonly in New Zealand OST services. An opioid 
detoxification that promoted absence of withdrawals and a 3-5 day 
treatment period appeared very seductive when length of treatment and 
opiate withdrawal were major barriers to getting off an undesired 
substitution therapy. Therefore theme two (motivations for ibogaine) 
appeared for the participants in this case study to need the strong presence 
of theme one. 
Another relationship between these two themes was the multiple failed 
detoxification attempts the respondents in this case study endured. They 
often recounted opioid detoxifications as being fraught with low mood and 
feelings of hopelessness; a feeling of not being able to see ‘the light at the 
end of the tunnel’. These previous detoxifications, discovered in theme one, 
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were mainly self-directed, even on substitution programmes, and for four 
out of ten respondents, were attempted faster than recommended. Another 
three stated they had long, protracted opioid withdrawals and still struggled 
severely with low mood. No specific mood treatments occurred with any of 
the previous detoxification attempts. If these physical and mood symptoms 
associated with opioid withdrawals were not a feature for the person, or if 
they were successfully treated/managed, perhaps this would lessen the 
effect of theme two, the motivations to seek and use ibogaine therapy. This 
was also the conclusion of Winstock et al (2008) in a study that suggested 
effective treatment of methadone’s physical side effects could translate to 
better retention rates in OST. 
Discussion Two  
The relationship between; ‘safety conscious and support seeking’ and ‘best 
practise’. 
Alongside ascertaining people's experiences of ibogaine treatment in New 
Zealand, this study sought information on what medical knowledge 
ibogaine users obtained about ibogaine and what, if any, pre-treatment 
health screening did they achieve or not achieve. There was little in the 
literature to answer this question especially when ibogaine was used 
independently, peer-to-peer initiated. It appeared most ibogaine treatment 
providers used a standardised treatment model, which included pre-
treatment medical screening, ECG and blood tests (Alper, Lotsof, & 
Kaplan, 2008). However as the literature suggested, ibogaine therapy was 
first used as a peer-to-peer treatment in the 1970s, whereas clinics and more 
official ibogaine providers occurred later in countries that accepted this 
alternative addiction treatment, for example Netherlands, Mexico and New 
Zealand (Harrison & Mojeiko, 2010). Therefore, it was not expected that all 
respondents, including independent users, were fully aware of cardiac risks 
and links to cases of death with ibogaine use. Although the degree of 
accuracy with medical information varied between respondents, all ten had 
sought some form of medical testing through their GP or other known 
~ 134 ~ 
medical provider, prior to their use of ibogaine. The tests conducted and 
knowledge of the drug ibogaine itself, was reported to vary widely between 
health professionals. Some tests conducted were not screening for possible 
risk factors such as co-current drug use. What was clear however was that 
all eight respondents who used ibogaine treatment providers, obtained the 
recommended pre-treatment tests (ECG and blood tests) through clinic 
guidance, even if their GP had no knowledge of the drug or treatment risks. 
Information about other drug use was also obtained. This correct health 
screening was achieved when ibogaine was legally prescribed (post-2013) 
and when it was not. However, it was described as being much easier, and 
open to further support, when it was legally prescribed. The two 
respondents who used ibogaine in New Zealand without the support of this 
clinic, obtained very limited pre-treatment screening such as a simple blood 
pressure check. The two respondents who used an Australian-based 
independent ibogaine provider were also advised of necessary pre-treatment 
screening and both obtained an ECG and blood tests, again in spite of their 
GP not knowing about ibogaine treatment.  In these cases, the GP was 
prepared to follow patient/treatment provider recommendations.   
Alongside this strong code of medical awareness and screening, was the 
strongly voiced need for support, before, during and after ibogaine 
treatment. This was an expected discovery as the need for support was 
discussed widely in the literature (Schenberg et al, 2014: Bastiaans, 2004; 
Kamlet & Alper, 2010). Of note was the respondent who obtained ibogaine 
from a friend and used it independently in his house and had arranged for a 
friend to visit him. Fortunately for this one case, the dose of ibogaine was 
sufficiently low that he did not experience the ataxia and immobilisation felt 
by other respondents using higher doses. Eight other respondents stated they 
needed assistance to walk to the toilet during the first phase of ibogaine 
treatment. Two respondents felt it would be gross neglect to leave someone 
unattended because of the need for reassurance and reminding patients to 
drink water.  Also voiced strongly, including by the person who used 
ibogaine independently, was the need for pre-treatment guidance, questions 
to be answered and encouragement prior to treatment. Respondents also 
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talked about the need for reassurance from their provider; even though they 
had sought and asked for this, there was still considerable anxiety about the 
ibogaine treatment expressed by half the respondents. This anxiety 
regarding ibogaine treatment was managed in most cases by seeking and 
obtaining reassurance from previous ibogaine users and this was part of the 
largely unseen work of support providers. This was not observed widely in 
the literature, however Kamlet & Alper (2010) advised that there was often 
patient anxiety about going into opioid withdrawals and the treatment not 
working to alleviate these withdrawals. However, this was during the actual 
clinical treatment phase and did not mention the months’ lead-up. 
Family members, including parents in four cases, were utilised as main 
supports during ibogaine treatments, support which included payment and 
organising of accommodation. Other supports utilised were GPs, a 
community psychiatric nurse and ibogaine treatment volunteers. 
Respondents had a range of two weeks' to one year's lead-up, or pre-
treatment period before using ibogaine, and it was during this time they 
sought medical screening and tests through their medical practitioners. Post- 
treatment support sought included four respondents utilising Narcotics and 
Alcoholic Anonymous (NA/AA) support groups. All respondents felt they 
needed some form of support for a period after treatment, ranging from 
answering questions, to requiring booster doses of ibogaine when 
experiencing pain or drug-use after the original ibogaine treatment. The use 
of booster doses and after-treatment support was not widely discussed in the 
literature. However there were cases of international ibogaine users having 
described changing cities and making new friends as part of the planning 
needed for afterwards (Bastiaans, 2004; Lotsof & Alexander, 2001). The 
seven respondents who remain opioid-abstinent appeared to have made 
significant changes after treatment, including their partners having ibogaine 
treatment, and moving cities. The three who relapsed described making no 
changes to their using peer networks and advised the need for people to plan 
for this period before treatment. More generally planning for after 
treatment, including moving away from drug-using peers, was a frequent 
~ 136 ~ 
strategy employed by those seeking abstinence (Toumbourou, Hamilton, & 
Fallon, 1998). 
The fourth theme, ‘The best practise’, was (and will continue to be) 
significant to an ibogaine user’s experience. Less knowledgeable, poorer 
quality practises resulted in more negative experiences, and less effect on 
mood changes and subsequent drug abstinence. The literature clearly 
outlined safe medical practise, including ECG monitoring and nausea 
control (Alper, Stajić, & Gill, 2012; Kamlet & Alper, 2010; Lotsof & 
Wachtel, 2002). However the ten respondents had ‘hit-and-miss’ results 
regarding the safety of their treatments. The six participants who used the 
support of the Dunedin clinic had a journey of discovery about what made 
for safest and most effective treatment.  Respondents who had used the 
clinic after ibogaine became a registered medicine in New Zealand in 2013 
received therapeutic doses of ibogaine, antiemetic’s prior to treatment for 
nausea control, and had switched (changed) from methadone to a short-
acting opioid (codeine). They also had available (though not always 
required) booster doses of ibogaine, anywhere from 24 hours to three 
months after the initial dose. Respondents who did not have an experienced 
ibogaine treatment provider and when ibogaine was not legal had  sub-
therapeutic ibogaine amounts, poor nausea control and poor ibogaine dose 
control, and this was while they were still on long-acting (chemical half-
life) opioids, (i.e. methadone). 
'Controlling the sickness' during the active phase of ibogaine treatment was 
voiced by nine respondents, with one stating that due to vomiting she had 
not received an adequate dose of ibogaine and had a poor treatment 
experience (though overall positive treatment results). Nausea control in 
relation to dosing issues was well-covered in literature pertaining to 
international clinic practice (Kamlet & Alper, 2010). Not observed in the 
literature was the frequently described need for sleep management during 
and after ibogaine treatment. All respondents reported poor sleep after 
treatment, with three respondents saying it severely affected their level of 
functioning. Management strategies suggested by the respondents included 
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use of benzodiazepines for a reprieve, and natural sleep remedy such as 'tart 
cherry juice' for its reported melatonin release benefits (Howatson et al., 
2012). 
This theme of ‘best practise’ became  significant for the research question 
because so much of the outcome, both in terms of managing treatment risks, 
reduced drug use and affected mood, appeared connected to the knowledge 
and experience of the ibogaine treatment provider and whether simple steps 
were followed or not followed during treatment. Whether a patient received 
best practise or not, appeared based on fortune and luck, despite best 
intentions by providers, who were still learning about the treatment. Of note 
though is that two respondents who had negative ibogaine experiences were 
among the seven who remained opioid abstinent. The respondent who used 
ibogaine independently in his house relapsed after six months, but had a 
positive experience with the treatment despite vomiting and having sleep 
disruption. 
The use of booster doses of ibogaine after initial treatment was interesting 
from a prescriber's point of view. With this not discussed widely in the 
literature or even mentioned by some international clinics, it would be 
difficult for a prescriber of ibogaine to know if prescribing additional doses 
was a warranted practise. Schenberg et al (2014) report statistically 
significant differences in abstinent rates between ibogaine users who used 
single does compared to multiple doses of ibogaine, but this was for a study 
cohort which included poly-drug use, alcohol and cannabis users. For this 
study on people with opioid dependence, it appears reassurance was 
required from the ibogaine treatment provider, as reported by the 
respondents, for booster doses to be administered. It appeared from this case 
study, the use of booster doses two days after initial ibogaine treatment had 
the positive effect of further reduction of opioid withdrawals. Booster doses 
were specifically sought for management or return of pain symptoms for 
two respondents. It was prescribed and used at three months after the initial 
treatment, with pain alleviating effects. There were no reported cravings to 
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use opioids at this stage but a specific described return of pain which 
ibogaine was used for. 
Attached and overlapping the theme of 'best practise' is theme seven, ‘the 
spiritual effect’. This was an independent theme, in which all respondents 
described in their own ways, searching for something else, something with 
meaning, away from opioid use.  It is represented in Diagram 1 as an 
overlapping circle with the theme of 'best practise'.  The overlapping codes 
here represented the sense of epiphany during treatment noted by four 
respondents, which had positive effects on their subsequent mood and drug 
abstinence. It also overlaps best practise because with guided experienced 
practise, the hallucinogenic effect of the treatment appeared to be embraced 
and utilised for treatment effect. This occurred at well-measured (per 
kilogram of body weight) therapeutic doses between 1500 and 2000mg total 
(Alper, Lotsof, Frenken, Luciano, & Bastiaans, 1999; Kamlet & Alper, 
2010). Most literature however avoided reference to the potentially 
enhanced anti-addictive effects or cognitive work that a hallucinogenic 
experience could offer. Wider literature suggested people seeking 
treatments specifically for depression were searching for hallucinogenic, 
enhanced, spiritual and cognitive therapies. (Oram, 2012; Strassman, 1995). 
Human ibogaine trials that attempted to gain legitimacy for potential 
treatment using randomised controlled trials (RCT), focused primarily on 
drug abstinence and pharmacological effects of treatment. RCT trials 
struggled by their numerical nature to capture the effects of the psychedelic 
experience and/or how this related to more measurable / observable 
abstinence periods (Yin, 2004). For one respondent her ‘negative’ 
experience with the ibogaine treatment was not having the intense 
hallucinogenic experience and hoped for ‘spiritual awakening’. She related 
this to the ibogaine provider’s inexperience, at this stage, and not having 
adequate ‘flood dosing’ (taking ibogaine in a single dose). Despite not 
having an ‘epiphany’ the same respondent believed the noises she heard 
‘collided’ at a point in her body later to be diagnosed with a tumour. The 
meaning she attributed to this was ‘being guided’ to a medical discovery.  
She did also obtain desired opioid abstinence.  Two further respondents 
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stated that the ‘epiphany’ and shaman visitation they experienced resolved 
long-standing anxiety issues, and they directly related this to having 
obtained opioid abstinence. The other respondents who experienced 
hallucinogenic effects up to three months after treatment believed this 
‘mind state’ or noticeable difference in sensations helped with the 
acceptance of no longer using. Most respondents had significant 
psychedelic experiences during ibogaine treatment but did not necessarily 
connect the visions and experience with something that could assist them in 
post-opioid life. They connected them more to unrelated horror or science 
fiction visual effects. It appeared therefore that guidance and planning for 
altered states of consciousness should form part of ‘best practise’ to prepare 
and educate people that experiences are significant but not necessarily 
related to spiritual meaning. Best practise would also include providing 
therapeutic doses, and all the safety measures required for optimal and 
safest administration of the larger ibogaine doses. This would afford 
ibogaine patients the best opportunity to experience the desired 
mental/psychedelic effects. 'The spiritual effect' theme also overlapped with 
theme five, 'effects on depression and anxiety' as outlined in the next 
discussion. 
The relationship between the themes, ‘safety conscious and support-
seeking’ and ‘best practise’ and the overlapping third theme of  'the spiritual 
effect' was clearly demonstrated with this New Zealand case example. Prior 
to ibogaine being legally available in New Zealand medical experts were 
consulted about the treatment but had limited information on what medical 
screening and tests were required or important. Most testing achieved was 
irrelevant to ibogaine treatment. Respondents who used an ibogaine 
treatment provider once ibogaine was legal, were better able to openly 
discuss the medical screening involved with their GP, and even to offer a 
list of required tests. These respondents had access to and achieved 
recommended pre-treatment medical screening, such as ECGs and blood 
tests, and they also had full, recommended (Lotsof & Wachtel, 2002) 
mineral supplement regimes prior to treatment, Magnesium especially was 
important, considering the cardiac risks associated with ibogaine use were 
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potentiated by hypomagnesaemia or low magnesium levels (Maas & 
Strubelt, 2006). The group using legally prescribed ibogaine in this period 
had access to antiemetics and benzodiazepines for sleep management, 
which assisted in the overall experience. Respondents who used ibogaine 
before it was a registered medicine accessed less appropriate pre-treatment 
tests and felt they could not discuss additional medical support with their 
GP. The respondents who used ibogaine in Australia accessed correct pre-
treatment tests but did not have access to after treatment medical support. 
The respondent who accessed ibogaine independently (when it was legal), 
went to his GP but obtained irrelevant pre-treatment screening perhaps due 
to lack of specialist clinic support and also no easily obtainable prescriber's 
guide to ibogaine in New Zealand (i.e.: a list of required tests). This 
highlighted the need for ibogaine treatment to be supported through 
knowledgeable support services.  Correct pre-treatment testing appeared to 
produce the safest treatment outcomes. When ibogaine became legal it 
further made ibogaine a legitimate treatment and a medical person, vital to 
safer treatment and improved treatment outcomes, was shown to become 
involved throughout treatment, without fear of colluding in an illegal 
practise. 
Discussion Three  
The relationship between; 'ibogaine treatment effects on depression and 
anxiety' and 'ibogaine treatment effects on dependence'. 
Theme six, 'ibogaine effects on depression and anxiety', was strongly 
described by seven respondents, six of whom were part of the seven who 
remained abstinent.  The theme was captured in seven different codes 
described in the results chapter. The significant codes in this theme were 
due to the detailed emphasised and distinct descriptions respondents gave 
regarding the differences they felt in relation to both their mood and their 
ability to manage anxiety post ibogaine treatment. These unexpected 
changes to mood and outlook on life were notable enough for respondents' 
friends to tell them they appeared happier. All respondents stated their 
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improved mood helped with feelings of needing to use drugs. Two 
respondents stated they experienced a complete absence of all anxiety after 
treatment. These same two respondents had described spiritual epiphanies, 
where they had been visited by an African shaman or spiritual guide in 
visions, during treatment. Interestingly both these respondents described 
coming to terms with their anxieties during the psychedelic phase of 
treatment, both through the guidance of the shaman and visual experiences. 
Other respondents described mental processing or just thinking about their 
personal fears and anxieties. This formed a code within the sixth theme, 
'acceptance of fears, vulnerabilities and pain'. For this reason and because of 
the intertwined complexities of 'the spiritual effect', it was represented in 
Diagram 1 as overlapping the effects on depression and anxiety. 
The ways in which mood and anxiety were affected were discussed in more 
detail through a recorded conversation with treating medical doctors 
discussing experiences at the West Indies ibogaine clinic. Here the effects 
of ibogaine after treatment were described as a ‘sticky anti-depressant’ with 
lasting effect for 6 to 12 weeks (Kamlet & Alper, 2010). This statement 
appears to be partially supported by Mash et al (1999) low dose ibogaine 
dosing trial where they recorded BDI scores pre and post treatment and 
concluded there were notable positive effects on mood with ibogaine. Also 
Noller et al (2017) study with a sample number of 14 participants with eight 
completing a 12 month follow up in which regular BDI scores were taken, 
concluded there is significance with mood changes even at the 12 month 
mark, but a significant change at one month post treatment. Few other 
studies where interested in mood changes, more focussed on abstinent 
periods. Reports of mood changes was consistent with interviews in this 
case study. Respondents described clear differences to their mood as ‘light 
at the end of the tunnel at last’. The respondents believed their moods and 
anxiety were affected by the pharmacological properties of ibogaine, rather 
than the removal of opioids from their body. Due to multiple attempts at 
detoxification many participants could compare states of sobriety without 
the use of ibogaine to their experience with ibogaine. Glick et al (1998) on 
their studies on rats brains  note that serotonin reuptake was 25 times 
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greater in the Nuclease Accumbens (NA) region with ibogaine ingestion. It 
is clear in pharmacological literature that ibogaine and noribogaine inhibit 
the action of the 5-hydroxytryptamine (5-HT or Serotonin) transporter 
(SERT) but in a different mechanism than that of selective serotonin 
reuptake inhibitors (SSRI) or that of cocaine (Jacobs, Zhang, Campbell & 
Rudnick 2007). The same authors conclude that the actions of ibogaine on 
the serotonin transporters are novel and not yet understood. Whatever the 
pharmacological effects are, the reported effects on mood would be an area 
worthy of further exploration among both ibogaine users and comparing 
with people withdrawing from opioids using other methods. Are 
respondents correct in reporting ibogaine enhances mood above that of no 
longer experiencing the effects of opioid use? Described improvements and 
benefits to mood and anxiety appeared to last the same length of time as 
other codes found in this theme, including lasting effects of the 
hallucinogen, and heightened senses (both described as lasting for three 
months). 
The respondents' comments contributed to another interesting code labelled, 
‘mental cognitive-work after treatment’. Four respondents described 
continued mental processing and thinking about their life. It was grouped 
under the theme ‘ibogaine treatment effects on depression and anxiety’, 
because the effects of that processing and eventual acceptance of self and 
situations, affected moods and fears after ibogaine treatment. Some 
overseas case studies described positive effects on mood as more of a side 
effect of ibogaine   treatment (Lotsof & Alexander, 2001). However, the 
focus of these studies has been on length and periods of abstinence, and not 
the relationship between mood changes and corresponding drug abstinence. 
The final theme that emerged was ‘ibogaine treatment effects on 
dependence’. This is a significant theme because it was the desired outcome 
of ibogaine participants’ journey and experience. All ten respondents had 
substantial periods of abstinence from opioids including seven who still 
reported being opioid-abstinent at time of writing. The shortest reported 
period was three months and was in response to the respondent's frustration 
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and dissatisfaction with the return to her previous life situation. The two 
others who relapsed appeared to do so around the six-month point, one in 
response to their mother’s death, and one because of using an old 
acquaintance's supply of codeine. These were still considerable periods of 
abstinence following a 3-14 day detoxification and consistent with literature 
which focused heavily on periods of achieved opioid abstinence as a 
quantifiable outcome of the therapy (Harrison & Mojeiko, 2010; Lotsof & 
Alexander, 2001; Mash et al., 2001). The reasons for drug abstinence 
ranged from spiritual epiphanies and acceptance of fears and physical pain, 
to control over anxieties and positive changes in mood and outlook on life. 
 A significant code in this theme was the absence or lessening of opioid 
withdrawals, physically and in relation to mental health for the recovery 
period afterwards. This was emphasised and clearly described as being 
experienced physically (less restlessness, cravings, hot and cold sweats and 
cramps), and mentally, in terms of absence of low mood associated with 
opioid withdrawals (hopelessness, frustration, low motivation and 
anhedonia). This was described as the turning point for all seven 
respondents who did not relapse: not having to battle and endure the long-
lasting effects of opioid withdrawals. Even for those that reported the 
presence of some withdrawal symptoms they were said to be easily 
manageable compared to experiences of previous methadone reductions. 
This too is widely supported in literature and purported to be the main anti-
addictive quality of ibogaine (Glick, Maisonneuve, & Szumlinski, 2000; 
Lotsof, 1992; Mash et al., 2001). Of interest in this theme and not expected 
or ascertained in literature were the described effects on pain management. 
Two respondents went so far as to describe direct benefits to physical health 
during the active psychedelic phase of ibogaine treatment, including the 
diagnosis of a cancer. Two further respondents stated it helped with pain 
management. One of these respondents believed the period of reduced pain 
achieved with ibogaine was around three months. Interestingly he received 
a booster dose of ibogaine at this point specifically for pain management 
with good further effect, without using any opioids. Current medical 
practise obviously manages pain using medicine and arguably the most 
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effective drugs used for treatment are opioids (Savage, Kirsh, & Passik, 
2008; Sheridan & Butler, 2008). Thus the effects of ibogaine on pain 
management logically group into this theme of effects on dependence (or 
further opioid use). There was no discussion in the literature about pain 
management with ibogaine except the clinical trials where ibogaine 
enhanced pain management in ‘heated rat tail’ experiments (Bagal, Hough, 
Nalwalk, & Glick, 1996). One respondent stated ibogaine and the 
subsequent removal of methadone un-masked severe shoulder pain from an 
over-use syndrome and this pain required surgery. Ibogaine did not appear 
to manage this reported pain. All respondents described strong physical 
sensations and tactile hallucinations during ibogaine therapy. 
Effects on other drug use were noteworthy, and were a surprise to half the 
respondents. Smoking cessation (cigarettes/tobacco) and changes to alcohol 
use were the most common. One respondent stated it helped with cravings 
and use of methylphenidate (Ritalin), a stimulant drug. Early human trials 
concluded ibogaine achieved marked abstinent periods with alcohol 
dependence disorders but appeared far less effective with stimulant 
dependence (Mash et al., 1998; Mash et al., 2000). The same studies 
concluded there was little significance or abstinent period with a cocaine 
(stimulant drug) group when using ibogaine for detoxification, and it had 
little effect on managing cocaine cravings after detoxification. Although 
this one respondent described no cravings to use methylphenidate, he had 
also significantly changed his social network and opioid and 
benzodiazepine use as well, perhaps assisting with triggers to use stimulant 
drugs. Smoking cessation was mentioned in the Mash et al., (2001) and 
Mash et al., 2000) studies and others, where ibogaine users described, to 
their surprise, they no longer wanted to smoke tobacco (Lotsof & 
Alexander, 2001). Likewise earlier pharmacological experiments concluded 
ibogaine had an effect on nicotine reward pathways within the Nucleus 
Accumbens (Carnicella, Kharazia, Jeanblanc, Janak, & Ron, 2008). 
Interestingly, respondents reported cigarette and alcohol use resumed 
around three months after treatment. Marijuana use appeared the least 
changed as described by the respondents. No studies or ibogaine treatment 
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providers appeared to have reported much on ibogaine treatment for 
cannabis dependence.  
Exploring participants' experiences three months after ibogaine treatment 
highlighted the relationship between the two themes of ‘ibogaine effects on 
mood and anxiety' and 'ibogaine effects on dependence’. Respondents 
reported significant changes to mood and anxiety for around an average of 
three months, consistent with the literature (Harrison & Mojeiko, 2010). 
This coincided with other reported experiences, which 'wore off' or changed 
at three months, such as pain management, heightened senses, lingering 
effects of the hallucinogen and a return to alcohol/nicotine use. Mood 
changes were described most emphatically by respondents, as the main 
driver or reported cause of their achieved opioid abstinence. The sense of 
hope felt by respondents, in relation to having reduced or no opioid 
withdrawals, was described as both a strong motivator for treatment, and a 
factor in remaining abstinent. It was illustrated not just by absence of 
physical withdrawals, but by absence of emotional and mental low mood 
usually associated with drug withdrawals. Positive mood changes and 
acceptance of fears during treatment were also described by one respondent 
as beneficial for pain management in terms of accepting the pain and not 
fearing its worsening. These themes became interconnected, especially 
when exploring comments of those who had relapsed  and the pictures they 
painted of a return to hopelessness. This could be described as mood change 
affecting relapse. There was much literature on post-acute opioid 
withdrawal syndrome (PAWS), a syndrome which occurred after 
detoxification, described as protracted withdrawals which lasted for six 
months and featured depression symptoms (Kamlet & Alper, 2010). 
Effective management of PAWS, in that case study, was achieved through 
the use of ibogaine, which also had positive effects on periods of 
abstinence. 
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Limitations and strengths 
The first limitations to the study are related to the already addressed 
methodology and method of case study research. Although selected and 
argued that this is the most appropriate method to answer the question of a 
person’s ibogaine experience in New Zealand, all research methods have 
their limitations. Case selection can be ‘targeted’ by the researcher for 
desired information and respondents can flavour the answers in a 
subconscious attempt to please the researcher or promote their own interests 
(Gillham, 2000; Yin, 2004). This study used information obtained from 
respondents’ self- reports. The validity of self-reported data has been 
explored in a comprehensive review by Harrison (1997) in her critique of 
research methods using self-reported data. Her review concludes people 
who use drugs and are involved with the criminal justice system tend to 
under report their drug use.  People involved with studies that do not have 
perceived implications to their treatment or legal proceedings, that is a 
study conducted by a researcher with no power influence, were found to be 
mostly accurate. For this study, the researcher declared he was no longer 
employed by an OST service and met participants at public or home 
addresses. These limitations were consciously addressed by the researcher 
through transparent supervision with research supervisors and by 
interviewing all potential respondents who met the very limited inclusion 
criteria. Further research rigor is discussed in the methodology chapter.  
Perhaps the obvious strength with case study research is this method allows 
deeper understanding of a person’s experience and what can assist in this 
journey than statistical numbers alone can provide. Numbers alone may lose 
the ability to explain the connection and significance between events and 
decisions (Yin, 2004). 
The second limitation for this study was the number of participants who 
were located via one group/clinic based in Dunedin. Six out of ten in total 
were recruited via establishing contact with a key person at the clinic. A 
further two respondents, who used an Australian ibogaine treatment 
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provider, remain connected and even established the same group. Therefore 
only two respondents had no connections to the Dunedin clinic or network. 
Despite contacting five North Island (New Zealand) OST services, local 
drug support agencies and messages on open social media platforms, there 
were no respondents from other New Zealand ibogaine clinics. One 
respondent resides in the North Island but utilised the Dunedin clinic.  
The third limitation of this study is potential for recall bias of respondents. 
This study did not exclude for ibogaine treatments that occurred many years 
ago and had an open time limit for when ibogaine treatment occurred. 
Recalling detailed medical information becomes somewhat more difficult 
especially around times and sequence of events. This is demonstrated by 
some respondents in the interviews mixing up terminology of medical tests 
achieved and more vague responses on specific medical questions.  
The forth limitation is the ethnic representation of participants.  All 
respondents who comprised the case study identified as New Zealand 
Pakeha (European descent). Consultation was sought with the University of 
Otago, Christchurch Kaitakawaenga Rangahau Māori (Facilitator Research 
Māori) and with local mental health and addiction Maori health workers; 
however no Maori who had experienced ibogaine treatment were available 
to be contacted. No Asian or people with other Polynesian backgrounds 
responded, missing representing experiences and possible variations in 
experience of individuals of other ethnic populations.  
The strengths of the study however, are also based on the sample size. The 
expected sample size was five and at periods in the study this target 
appeared unlikely to be achieved, as the first two sought for respondents 
were uncontactable. The sample size of 10 afforded the researcher the 
opportunity to gain a comprehensive range of experiences and outcomes, 
including an independent user and a pain-related opioid dependent 
respondent. 
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Perhaps, a final strength of the study would be the experience of the 
researcher and academic supervisors. Interviewing people about personal 
experiences requires empathy and sensitivity (Gillham, 2000). Experience 
in working in opioid substitution services and an understanding of what this 
experience can mean for people with opioid dependence were found to be 
crucial in gaining rapport and credibility with the respondents. Experience 
in building a relationship with mutuality and reciprocity was essential to 
gain such personal, often not shared, experiences of their treatment (Stein-
Parbury, 2013). The researcher remains truly grateful for respondents’ 
willingness to trust the researcher and share their experiences. Experienced 
academic supervisors afforded and ensured least burden and impact for 
respondents through careful consideration of interview process development 
and care of identifiers. The importance and rigour of confidentiality was 
acknowledged and carefully maintained 
Summary of discussion 
The question of 'what were the experiences and motivations of an ibogaine 
user in New Zealand?' has been answered through three discussions on the 
relationships between six of the seven themes found in the case study. The 
relationships between the themes helped illuminate the journey of an 
opioid-dependent person using ibogaine for opioid detoxification. The case 
study described physical and mental side effects of long-term opioid use, 
related specifically to the pharmacological properties of opioids. This study 
group made multiple attempts at quitting and self-detoxification and cited 
prolonged withdrawal symptoms, which included low mood as key factors 
in those detoxification attempts being unsuccessful. This interplayed with 
the allure of ibogaine treatment, where individuals had hope promoted by 
reports of quick opioid detoxifications and less withdrawal symptoms. Most 
information about ibogaine was discovered on internet chat sites and 
forums, and then through known peers who had used ibogaine. New 
Zealand provides a unique landscape to test the effects of ibogaine, which, 
at time of writing, was an off-license registered medicine. Case study 
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respondents obtained safer, appropriate pre-treatment medical screening and 
correct tests when ibogaine was legal, and especially when they and their 
GP were supported and advised by an ibogaine treatment provider. 
Respondents also had better after-treatment medical support when it was a 
registered medicine. All respondents sought medical screening before 
treatment, even when ibogaine wasn’t legal and/or without the support of a 
treatment provider. In the cases where it was not legal or there was no 
treatment provider supplying test requirements, correlated with incorrect 
pre-treatment medical screening and testing.  So a lucky few were afforded 
what was described as 'the best practise' in terms of ibogaine treatment. For 
example, they had the associated nausea and vomiting managed with 
antiemetic’s, and the after-treatment sleep disruption was managed with 
benzodiazepines, or even ‘tart cherry juice’ for natural melatonin release. 
The use of booster doses of ibogaine two to four days after initial treatment 
afforded people further reduced opioid withdrawals, and some used booster 
doses for pain management three months afterward to good effect. 'Best 
practise' was reflected in better outcomes in terms of effects on depression, 
anxiety and opioid abstinence. The majority of respondents reported 
positive changes in mood and anxiety management for three months after 
ibogaine treatment. This had not been anticipated by the respondents as an 
effect of treatment. These positive changes in mood and anxiety appeared to 
correlate to a positive effect on periods of abstinence. Reported absence of 
withdrawal features, including associated low mood, again for a period of 
three months and longer, was another major factor affecting periods of 
abstinence for this case study group. Seven out of ten respondents remained 
abstinent of opioids at time of writing. The remaining three still achieved 
significant periods of abstinence (3 – 6 months) regardless of negative 
experiences or poorer ibogaine treatment practises. The experience of an 
ibogaine user in New Zealand is summarised in Diagram 1. 
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It appears if ibogaine is legal 
greater medical testing/support is 
achieved 
It appears there is greater 
treatment potency with ibogaine if 
treatment is with a specialist clinic. 
Better practise meant better 
effects on mood and anxiety. 
The spiritual 
effect 
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CHAPTER SIX: 
CONCLUSION 
Overview of chapter 
The final chapter reiterates the origin of the research question, what the 
question was and what the study's aims and objectives were. This chapter 
outlines the extent to which the research question has been answered, and 
the implications for practice and policy, as well as potential further 
research. It will end with a concluding statement highlighting the findings 
of the study, which were in support of the argument that the safest, most 
effective ibogaine treatment outcomes were achieved when it was a 
legitimate, medically-supported treatment option. 
The research question 
This research was initiated following observations by the researcher 
working in an OST service. An opioid-dependent person on OST chose an 
alternative treatment for methadone detoxification. The treatment was 
ibogaine through a New Zealand organisation. The OST service declined 
the patient's request for support during treatment, and they later withdrew 
that person from their OST program for non-collection of methadone doses. 
As discussed in the introduction, this decision not to support was based on 
reports of death from ibogaine use (Dettmer, Cohn, & Schwarz, 2013). 
Further reports demonstrating other factors involved with reported deaths 
(Alper et al., 2012) was not explored perhaps because of ‘stereotyping’ 
alternative treatments. Clearly, a greater understanding of ibogaine 
treatment by addiction treatment services, especially its risks and safety 
measures, was required, along with a greater understanding of the 
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experiences and motivations of those who chose it for opioid detoxification. 
The research question therefore became: 
 ‘What are the experiences and motivations of opioid-dependent people 
using ibogaine?’ With the secondary question: ‘what safety measures and 
medical screening were ibogaine users aware of and utilised?’ 
To what extent have the research questions 
been answered? 
The extent to which the research questions have been answered was 
addressed in the literature review and the findings. The participant 
interviews revealed ten different experiences ranging from those who 
sought the support of an ibogaine treatment provider, utilised their 
knowledge and obtained recommended pre-treatment medical screening, to 
the minority who obtained ibogaine independently, sought help from their 
GP, but lacking the input of an ibogaine treatment provider, obtained non-
recommended screening tests. It appeared positive treatment experiences, 
and desired treatment results of opioid abstinence were greatly affected by 
the individual’s preparation and planning for the treatment, both before and 
after. This need for planning, especially for the recovery time, was voiced 
by all respondents, including the three who had relapsed into opioid use. 
Having an ibogaine treatment provider appeared to positively affect both 
access to appropriate medical support and appropriate post-treatment 
support. These ten varied experiences were captured in seven identified 
common themes. When analysed together they represented an overall 
experience of ibogaine treatment. 
The seven themes are: ‘not sitting comfortably on opioids’, where 
respondents reported depression, anxiety and physical side-effects of long-
term opioid use, and could not tolerate the mental depression effects of 
opioid withdrawal. Some reported being blocked or stunted either in terms 
of desired lifestyle and family, or a described spiritual, emotional block 
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from being on opioids. 'Motivations for using ibogaine’ captured the hope 
of less opioid withdrawal symptoms during detoxification with ibogaine, 
and also the hope of a quick recovery time afterwards. 'Safety conscious 
and support-seeking’ captured all respondents seeking medical support.  All 
respondents stated they needed physical, emotional and expert support 
during and after treatment. 'The best practise’ described respondents' varied 
ibogaine treatment experiences and what afforded best practise. This 
included the use of therapeutic ibogaine doses, the use of booster doses of 
ibogaine after treatment, and management of nausea and sleep deprivation. 
'Ibogaine treatment effects of depression and anxiety’ was the surprise 
strong theme which detailed the emphasised reports of improved mood and 
reduced anxiety attributed to ibogaine use. This in turn appeared to have the 
most effect on the next theme, ‘ibogaine treatment effects on dependence’ 
which captured seven respondents' successful opioid detoxification 
treatment, and three respondents who relapsed to opioid use between three 
and six months after ibogaine treatment. The spiritual effect’, the last 
theme, forged itself through the interviews with two respondents who 
described spiritual-type epiphanies during ibogaine treatment, and four who 
described a search for some spiritual change which they believed was 
required to remain abstinent. 
Therefore, the research question was answered through the findings and 
discussion that emerged from ten different ibogaine treatment experiences. 
The seven themes supported findings from the literature review and 
revealed experiences and motivations for use of ibogaine less reported in 
the literature. The findings lead to recommendations for practice, policy and 
procedure, and exposed potential areas for future research. 
Implications for practice/policy 
From the findings of this research emerged five implications for ibogaine 
practise and support, relevant to current legislation and policy on legitimate 
ibogaine prescribing in New Zealand. A number of these findings were also 
consistent with other research. 
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1. More effective management of opioid withdrawal symptoms and 
treatment of associated low moods could potentiate an individual's 
success of opioid detoxification. Greater emphasis on opioid 
withdrawal management during gradual opioid reduction and 
current methods of exiting OST services, could help individuals 
achieve and maintain their abstinence goals. This case study 
described low tolerance for opioid withdrawal symptoms as a 
barrier to successful detoxification, and highlighted how better 
mood and less anxiety assisted individuals in remaining abstinent 
from opioids. 
2. An experienced ibogaine clinic provided individuals with safe and 
superior ibogaine treatment outcomes.  Respondents who obtained 
pre-treatment medical screening without the guidance of an 
experienced ibogaine provider, received inadequate 
physical/medical assessments. Respondents who obtained pre-
treatment medical screening through their GP said their doctor did 
not know about the risks associated with ibogaine or what to ‘test’ 
for.  Where available, all GPs in this study followed ibogaine 
treatment provider’s recommendations. Respondents sought and 
stated they required support before, during and long after ibogaine 
treatment. This was obtained through ibogaine treatment providers, 
families and GPs, or in their absence, internet chat forums and 
ibogaine internet support sites. This education and support role will 
be an important one for any future ibogaine service providers in 
New Zealand, as this study clearly showed that greater support 
before, and long-term support after treatment, resulted in better and 
safer treatment outcomes. 
3. Alongside the need for an ibogaine support service was a clear 
indication that safer ibogaine treatment practises were achieved 
when ibogaine was legal in New Zealand. Respondents said they 
had greater support and could be more open with their GP when 
ibogaine was a legal, prescribed medicine. This supported current 
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New Zealand legislation and policy, with ibogaine being an off-
label registered (able to be prescribed prescribed) medicine for the 
treatment of opioid detoxification. When ibogaine was legal and 
able to be openly discussed, respondents received the correct 
medical screening, more supportive medical care, and screening 
for alcohol and other drug use. This last, as co-morbid use of 
stimulant drugs increases the risk of cardiac arrhythmia with 
ibogaine treatment (Alper et al., 2012). Respondents felt they could 
be more honest about ibogaine treatment with their AOD treatment 
services when it was a legal treatment, and some utilised these 
services for support after ibogaine treatment. 
4. The hallucinogenic experience was embraced. Respondents sought 
and stated they felt it was beneficial for their desired treatment 
goals, to have psychedelic experiences during ibogaine treatment; 
to feel the drug's mental and cognitive effects. The hallucinogenic 
properties appeared to have positive effects on respondents' 
reported moods and management of anxiety, which is consistent 
with the literature on hallucinogenic treatments for other 
psychiatric disorders such as depression (Strassman, 1995). It is a 
significant consideration for future ibogaine treatment providers.    
5. The benefits of multiple ibogaine doses. The use of ibogaine 
booster doses, 24 hours to three months after initial ibogaine 
treatment, had beneficial treatment effects on all respondents that 
utilised them. They further reduced opioid withdrawal symptoms 
and helped with pain management issues. The boosters were all 
described as ‘sub-therapeutic’ doses, amounts around 200-400mg, 
and did not produce further psychedelic effects. Prescribers 
currently have little guidance or literature to support the 
prescribing and use of booster doses, so this was a significant 
implication in terms of continued practise, and the prescribing of 
ibogaine as a medicine for opioid detoxification. 
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Further research 
Areas this study highlighted for potential further research included the 
relationship in discussion 3, chapter five: the effects of ibogaine use on 
depression and anxiety.  Research with ibogaine has largely focused on the 
absence or reduction of withdrawal symptoms during opioid detoxification, 
and the related abstinence periods. Conducting studies specifically designed 
to capture ibogaines’ effect on the mood and anxiety of users, before and 
after ibogaine treatment, could further illuminate its true effect on 
depression and anxiety.   
The use of booster doses of ibogaine, following initial treatment, is less 
reported in the literature. Future ibogaine treatment groups could be 
randomly assigned one of two treatment plans - one in which patients are 
given booster doses, and another in which they are not. This could 
determine the effectiveness of ibogaine booster doses in relation to periods 
of abstinence, and alleviation of opioid withdrawal symptoms. 
To measure the psychedelic effects of ibogaine on treatment outcomes, 
future ibogaine treatment groups could potentially receive non-psychedelic 
ibogaine metabolites such as noribogaine. The impact on mood, and effects 
of treatment, could be compared with those who experienced psychedelic 
effects using ‘normal’ ibogaine. 
Ongoing medical monitoring of future ibogaine groups such as continual 
ECG recordings during ibogaine treatment, could provide further medical 
data on the effects of ibogaine treatment and how it affects cardiac function. 
Ideally, an ibogaine treatment cohort might undergo magnetic resonance 
imaging (MRI) or a positron emission tomography (PET) brain scan during 
ibogaine treatment, to record what areas of the brain, especially within the 
dopamine reward pathways and ventral tegmental area (VTA), were 
activated. This would provide further data to measure the neurobiological 
effects of ibogaine. 
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Concluding comment  
The contribution of this research is in identifying factors and influences that 
could benefit future ibogaine treatment experiences for opioid-dependent 
people. The influence of individual histories and socio-political effects 
contributed to motivations and reasons for ibogaine use. Crucial factors, 
such as managing anxiety of ibogaine treatment, are described by 
participants that can make it a possible successful treatment. 
008: Yeah I was cutting my mum’s hair the day before I 
left [ibogaine treatment] and I said to her; ‘you know if I 
don’t come back, don’t ever feel like you let me down’, 
you know  (laughter) because it was just… I thought I was 
going to die! But I didn’t feel like I had an option, as I felt 
like I was going to die anyway… I was just so… so 
‘chemical-ised’… I was just so… depressed and 
traumatised.  
Respondents shared information difficult to obtain from the current 
ibogaine literature.  Their described benefits of the psychedelic effect 
during treatment, included an 'epiphany' or deep-rooted 'understanding' that 
they no longer needed opioids. It was also described as beneficial for 
increased positive mood, and reduced or absence of anxiety after 
detoxification with ibogaine treatment. The benefits of having an ibogaine 
treatment provider were also invaluable as described by the respondents of 
this study. Recommended pre-treatment screening was achieved and much-
needed support during, and long after treatment, was obtained by 
respondents who utilised an ibogaine treatment provider. Respondents 
described a desire for more GP/expert input throughout both treatment and 
recovery phases. The minority of respondents who did not use an ibogaine 
treatment provider obtained non-recommended, pre-treatment screening, 
and they also had perhaps poorer support and treatment outcomes. Seven 
out of the ten respondents in this study reported still remaining opioid-
abstinent from their ibogaine treatment, in accordance with wider literature 
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reporting a 70% success rate for opioid abstinence after ibogaine treatment 
(Lotsof & Alexander, 2001; Mash et al., 2001). The respondents – the ten 
people who participated in this study - described the effects of ibogaine 
treatment which helped most in their shared goal to become opioid-free. 
These effects were, the great reduction in opioid withdrawal symptoms 
during the detoxification phase, and improved mood and reduced levels of 
anxiety for three months after treatment. All ten respondents in this case 
study said they would use ibogaine whether it was legal or not, but 
preferred it to be legal for the advantages of better medical support. 
Much gratitude and appreciation is expressed to the participants of this 
study and notably, Tanea Paterson who helped make the connections. 
Through interviewing these ten people, who generously, if tentatively 
shared some of their most vulnerable experiences, much valuable 
information regarding ibogaine treatment was revealed. Information that 
could help people obtain safer, more supportive, effective treatment 
experiences with ibogaine in the future. 
Foremost this study was about people. People who had a shared drug 
dependence and a shared experience of choosing ibogaine treatment for 
their opioid detoxification.  
“There will be some open minded people that will go; 
yeah this (ibogaine treatment) suits my personality, my 
situation, my frame of mind, my ability to deal with it. I 
can rationalise hallucinations for what they are, I’m not 
going to flip out. Yes, it is a big spider web made out of 
mechano or origami, that’s dropping out of the ceiling 
looking at me,.. I can deal with that (respondent 002). 
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11 May 2015 
Dr D Deering 
Department of Psychological 
Medicine (ChCh) Terrace House,  
4 Oxford Terrace 
University of Otago, Christchurch 
 
 
Dear Dr Deering, 
I am again writing to you concerning your proposal entitled “Experiences of opoid 
detoxification using Ibogaine in various settings: Exploring Ibogaine users’ 
motivations, understanding of risks and effect of Ibogaine treatment.”, Ethics 
Committee reference number H15/042. 
Thank you for your letter of 6th May 2015 addressing the issues raised by the 
Committee. 
The Committee thanks you for providing clarification in respect of the recruitment 
process and for the detailed comment relating to the interview settings. 
On the basis of this response, I am pleased to confirm that the proposal now has 
full ethical approval to proceed. 
The standard conditions of approval for all human research projects reviewed and 
approved by the Committee are the following: 
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Conduct the research project strictly in accordance with the research proposal submitted 
and granted ethics approval, including any amendments required to be made to the 
proposal by the Human Research Ethics Committee. 
Inform the Human Research Ethics Committee immediately of anything which may 
warrant review of ethics approval of the research project, including: serious or 
unexpected adverse effects on participants; unforeseen events that might affect 
continued ethical acceptability of the project; and a written report about these 
matters must be submitted to the Academic Committees Office by no later than the 
next working day after recognition of an adverse occurrence/event. Please note 
that in cases of adverse events an incident report should also be made to the 
Health and Safety Office: 
http://www.otago.ac.nz/healthandsafety/index.html 
Advise the Committee in writing as soon as practicable if the research project is 
discontinued. Make no change to the project as approved in its entirety by the 
Committee, including any wording in any document approved as part of the project, 
without prior written approval of the Committee for any change. If you are applying 
for an amendment to your approved research, please email your request to the 
Academic Committees Office: 
gary.witte@otago.ac.nz jo.farrondediaz@otago.ac.nz 
Approval is for up to three years from the date of this letter. If this project has not 
been completed within three years from the date of this letter, re-approval or an 
extension of approval must be requested. If the nature, consent, location, 







Mr Gary Witte 
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APPENDIX THREE: 
 MAORI CONSULTATION 
 
8 May 2015 
 
 
Dr Daryle Deering 
National Addiction Centre, Department of Psychological Medicine, 
University of Otago, Christchurch 
 
 
Ma te rangahau Hauora e tautoko te whakapiki ake te Hauora Maori. 
All health research in Aotearoa New Zealand benefits the Hauora (health and 
wellbeing) of tangata whenua. 
 
 
Tena koe Daryle, 
 
Thank you for taking the time to meet with me at my office at the University of 
Otago, Christchurch on the 8th May 2015, to discuss your research study titled: 
 
Experiences of Opioid Detoxification Using /bogaine in Various 
Settings: Exploring lbogaine Users' Motivations, Understanding of 
Risks, and Effects of /bogaine Treatment 
 
I note that you are the Principal Investigator for this research project and that Mr 
Jamie Walker, a Master's student within your department will be completing his 
research thesis from this study. 
 
Commentary on Proposed Research Projects 
From my discussion with you I have ascertained that the main objective of this 
study is to explore the experiences of taking lbogaine for the purpose of alleviating 
opioid withdrawal symptoms and cravings for opioid drugs and the settings in which 
this occurred. This study looks more specifically at: 1). Individual's motivations for 
using lbogaine, 2). Their understanding of lbogaine and risks associated with its 
use, 3). Health checks undertaken, 4). The lbogaine experience and effects, the 
settings and services provided and, 5). Impact on subsequent opioid drug use. 
 
This study aims to recruit between 5-10 participants by advertising at the Needle 
Exchange and more informally, through community based opioid peer support 
groups.  It is intended that participants for this study will be recruited from three 
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regions including Dunedin, Christchurch and the West Coast. 
 
Maori Health Gain 
While this research project does not specifically target Maori, you have indicated that 
it is possible Maori will have a presence within the recruitment population. Ideally, 
this presence should be reflective of the Maori population nationally around 15%. As 
you have noted, nationally 13% of clients receiving opioid substitution treatment 
have been reported to be Maori. Interestingly, people identifying as European  or 
Other  ethnicity  are two to four times more likely to be prescribed the use of strong 
opioids compared to Maori, Pacific or Asian ethnicities. You also acknowledge that 
some Maori may not identify as Maori within treatment services for opioid 
dependence, due to the stigma associated with opioid dependence. 
 
In terms of Maori health gain, your research application should highlight the direct 
benefits for Maori participants who participate in the studies documenting the direct 
health benefits/gains for those individual Maori who consent to be part of this 
research. I note that you will be advocating for study participant's to have a health 
assessment including blood and ECG tests. Where study participants may find 
health assessments costly, you will provide information to them so that health 
assessments are undertaken at minimal or no cost. 
 
Partnership 
With regard to Maori involvement in your study, I have suggested that you consult 
with Viola Anderson, Maori Health Worker for the Methadone Clinic at the Specialist 
Mental Health Service, Canterbury District Health Board, Christchurch, to discuss 
her capacity to provide cultural oversight and support for this project. This would 
ensure that Tikanga Maori frameworks are considered and integrated where/when 
necessary, particularly during the engagement process with Maori. Alternatively if 
this is not possible it will be necessary to consider in part, funding for Hauora Maori 
involvement in this project. 
 
I note that Maori study participants will be offered the opportunity to be interviewed 
by a Maori interviewer (Ms Irene Whittaker), should they so wish. 
 
Ethnicity 
As your study may involve Maori participants, there is a need to acknowledge the 
issues pertaining to ethnicity and to consider how ethnicity data will be collected 
for this study. It is recommended that ethnicity data is collected from each 
participant in accordance with the Ministry of Health guidelines, which involves the 
use of the Census 2013 question. 
 
Consent 
Issues regarding informed consent for Maori participants who are recruited into this 
study were discussed. With this in mind, you must ensure that Maori participants 
are explicitly aware that consent is for this research project only. 
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Potential Further Support Resources 
Further resources that you might want to access to strengthen your 
responsiveness to Maori within your research are: 1. HRC's Nga Pou Rangahau 
Hauora Kia Whakapiki Ake Te Hauora Maori 2004-2008, 2. The Health Research 
Strategy to Improve Maori Health and Well Being 2004-2008. The other reference 
that is available is 3. Hauora Maori Standards of Health IV: A Study of the Years 
2000-2005 by Bridget Robson and Ricci Harris, Maori Health Research Unit, 
Wellington School of Medicine, University of Otago, Wellington. All provide Maori 
specific information on a range of health issues. 
 
The recent publication Tatau Kahukura: Maori Health Chart Book 2010, Ministry of 
Health, 2010 (2nd edition), is an update relating to the socio economic determinants 
of health, health status and service utilisation of the Maori population. Further 
references are available from the HRC's Guidelines for Researchers on Health 
Research Involving Maori (page 22), www.hrc.govt.nz.  
 
Dissemination of Results 
The HRC's Guidelines for Researchers on Health Research Involving Maori, is 
important in terms of how your research results may contribute to Maori health gain. 
Therefore, it is important that appropriate Maori organisations and researchers are 
aware of your findings. This should occur not only in an academic forum, but also 
within the community from where data is drawn. The findings from this study should 
be further discussed with relevant Maori stakeholders. I would recommend that you 
utilise your relationships with Hauora Maori advisors involved in your study, to assist 
you in with the dissemination of your research back to local Maori forums such as 
Te Korowai Atawhai (Maori Mental Health Team, Specialist Mental Health Services, 
Canterbury District Health Board, Christchurch). You also advise that a whanau 
friendly newsletter will be sent to Maori participants in the study. As such these 
forums will allow an opportunity for the consideration of Maori community feedback 
into any discussion going forward. 
 
 
Ka nui tonu nga mihi, 
 
Karen Keelan 
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